Heart Failure

• 

  Subject Areas on Research

  • "Not the 'grim reaper service'": an assessment of provider knowledge, attitudes, and perceptions regarding palliative care referral barriers in heart failure. 
  • "Targeting the Heart" in Heart Failure: Myocardial Recovery in Heart Failure With Reduced Ejection Fraction. 
  • "Time Is Muscle" in Acute Heart Failure: Critical Concept or Fake News? 
  • 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: a joint report of the American College of Radiology Appropriateness Criteria Committee and the American College of Cardiology Foundation Appropriate Use Criteria Task Force. 
  • 2013 ACCF/ACR/ASE/ASNC/SCCT/SCMR appropriate utilization of cardiovascular imaging in heart failure: an executive summary: a joint report of the ACR Appropriateness Criteria ® Committee and the ACCF Appropriate Use Criteria Task Force. 
  • 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 
  • 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 
  • 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 
  • 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. 
  • 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. 
  • 2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A Report of the ACC Competency Management Committee. 
  • 2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A Report of the ACC Competency Management Committee. 
  • 2017 ACC/AHA/HFSA/ISHLT/ACP Advanced Training Statement on Advanced Heart Failure and Transplant Cardiology (Revision of the ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant): A Report of the ACC Competency Management Committee. 
  • 2017 Comprehensive Update of the Canadian Cardiovascular Society Guidelines for the Management of Heart Failure. 
  • 21st Century Cures: A Step Forward for Patients With Heart Failure. 
  • 59-Year-Old Woman With Fatigue, Dyspnea, and Lower Extremity Edema. 
  • A "Trapped Heart" in an Octopus Pot: Takotsubo Cardiomyopathy; Review of a Rare Clinical Syndrome Following Solid-Organ Transplant. 
  • A Bayesian Model to Predict Survival After Left Ventricular Assist Device Implantation. 
  • A Canadian context for the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF) trial. 
  • A Critical Appraisal of Short-Term End Points in Acute Heart Failure Clinical Trials. 
  • A Critical Evaluation of the Representation of Black Patients With Heart Failure and Preserved Ejection Fraction in Clinical Trials: A Literature Review. 
  • A Decade With Editorial Mentors: The Day They Dropped the Mic. 
  • A Fully Magnetically Levitated Circulatory Pump for Advanced Heart Failure. 
  • A Fully Magnetically Levitated Left Ventricular Assist Device - Final Report. 
  • A Gordian knot: disentangling comorbidities in heart failure. 
  • A Hospital Level Analysis of 30-Day Readmission Performance for Heart Failure Patients and Long-Term Survival: Findings from Get With The Guidelines-Heart Failure. 
  • A Machine Without an Owner's Manual. 
  • A Multicenter Trial of a Shared Decision Support Intervention for Patients and Their Caregivers Offered Destination Therapy for Advanced Heart Failure: DECIDE-LVAD: Rationale, Design, and Pilot Data. 
  • A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial. 
  • A Novel Paradigm for Sacubitril/Valsartan: Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload. 
  • A Novel Rehabilitation Intervention for Older Patients With Acute Decompensated Heart Failure: The REHAB-HF Pilot Study. 
  • A Test in Context: Critical Evaluation of Natriuretic Peptide Testing in Heart Failure. 
  • A Young Woman With Heart Failure and Altered Mental Status--The Answer in the Electrocardiogram. 
  • A balanced assessment of the STICH trial. 
  • A bridge for the 21st century in heart transplantation? 
  • A call for collaboration: the evolving heart failure apprenticeship network. 
  • A caravanning cardiomyopathy. 
  • A clinical and biochemical score for mortality prediction in patients with acute dyspnoea: derivation, validation and incorporation into a bedside programme. 
  • A combined clinical and biomarker approach to predict diuretic response in acute heart failure. 
  • A comparative evaluation of hemodynamic and neurohumoral effects of nitroglycerin and nifedipine in congestive heart failure. 
  • A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). 
  • A comparison of two spirituality instruments and their relationship with depression and quality of life in chronic heart failure. 
  • A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial. 
  • A contemporary review of mechanical circulatory support. 
  • A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. 
  • A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research. 
  • A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. 
  • A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. 
  • A global rank end point for clinical trials in acute heart failure. 
  • A global ranking approach to end points in trials of mechanical circulatory support devices. 
  • A longitudinal, collaborative, practice-based learning and improvement model to improve post-discharge heart failure outcomes. 
  • A meta-analysis of the effect of exercise training on left ventricular remodeling in heart failure patients: the benefit depends on the type of training performed. 
  • A moment-adjusted imputation method for measurement error models. 
  • A multicenter analysis of clinical hemolysis in patients supported with durable, long-term left ventricular assist device therapy. 
  • A multicenter analysis of the ED diagnosis of pneumonia. 
  • A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. 
  • A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. 
  • A novel approach for measuring residential socioeconomic factors associated with cardiovascular and metabolic health. 
  • A novel link between G6PD deficiency and hemolysis in patients with continuous-flow left ventricular assist devices. 
  • A pharmacogenetic investigation of intravenous furosemide in decompensated heart failure: a meta-analysis of three clinical trials. 
  • A pilot study examining activity monitor use in older adults with heart failure during and after hospitalization. 
  • A practical use of theory to study adherence. 
  • A qualitative descriptive study of the work of adherence to a chronic heart failure regimen: patient and physician perspectives. 
  • A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). 
  • A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. 
  • A reappraisal of loop diuretic choice in heart failure patients. 
  • A reevaluation of the costs of heart failure and its implications for allocation of health resources in the United States. 
  • A review of dyspnea in acute heart failure syndromes. 
  • A secondary analysis of the CHOIR trial shows that comorbid conditions differentially affect outcomes during anemia treatment. 
  • A smoker's paradox in patients hospitalized for heart failure: findings from OPTIMIZE-HF. 
  • A standardized definition of ischemic cardiomyopathy for use in clinical research. 
  • A systematic meta-analysis of the efficacy and heterogeneity of disease management programs in congestive heart failure. 
  • A systematic review of randomized trials of disease management programs in heart failure. 
  • A taxonomy for disease management: a scientific statement from the American Heart Association Disease Management Taxonomy Writing Group. 
  • A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Acute Heart Failure Score. 
  • A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association get with the guidelines program. 
  • ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with chronic heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Heart Failure Clinical Data Standards): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Failure Society of America. 
  • ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). 
  • ACC/AHA/HRS 2008 Guidelines for device-based therapy of cardiac rhythm abnormalities. 
  • ACCF/AHA/AMA-PCPI 2011 performance measures for adults with heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures and the American Medical Association-Physician Consortium for Performance Improvement. 
  • ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 multimodality appropriate use criteria for the detection and risk assessment of stable ischemic heart disease: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons. 
  • ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 Appropriate Use Criteria for Echocardiography. A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance Endorsed by the American College of Chest Physicians. 
  • ACCF/HRS/AHA/ASE/HFSA/SCAI/SCCT/SCMR 2013 appropriate use criteria for implantable cardioverter-defibrillators and cardiac resynchronization therapy: a report of the American College of Cardiology Foundation appropriate use criteria task force, Heart Rhythm Society, American Heart Association, American Society of Echocardiography, Heart Failure Society of America, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. 
  • ACP Journal Club. Review: in patients with heart failure, β-blockers reduce mortality but do not differ from each other. 
  • ACP Journal Club: pooled RCTs: β-blockers reduce mortality in heart failure patients with sinus rhythm but not in those with AF. 
  • ACR Appropriateness Criteria® Dyspnea-Suspected Cardiac Origin. 
  • ACR Appropriateness Criteria® Suspected New-Onset and Known Nonacute Heart Failure. 
  • Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure. 
  • Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the PROTECT study. 
  • Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by [123I]metaiodobenzylguanidine scintigraphy. 
  • Absence of effect of cardiac denervation and induced right ventricular failure on canine myocardial norepinephrine binding sites. 
  • Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices. 
  • Accessory atrioventricular pathway in an infant: prediction of location with body surface maps and ablation with cryosurgery. 
  • Accuracy of Seattle Heart Failure Model and HeartMate II Risk Score in Non-Inotrope-Dependent Advanced Heart Failure Patients: Insights From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients). 
  • Accuracy of physician prognosis in heart failure and lung cancer: Comparison between physician estimates and model predicted survival. 
  • Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement? 
  • Activation delay-induced mechanical dyssynchrony in single-ventricle heart disease. 
  • Acute Coronary Syndromes and Heart Failure Critical Care Units Utilization and Outcomes in Teaching and Community Hospitals: A National Population-Based Analysis. 
  • Acute Heart Failure and Atrial Fibrillation: Insights From the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) Trial. 
  • Acute Heart Failure: Alternatives to Hospitalization. 
  • Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study. 
  • Acute aortic dissection presenting with congestive heart failure: results from the International Registry of Acute Aortic Dissection. 
  • Acute decompensated heart failure patients admitted to critical care units: insights from ASCEND-HF. 
  • Acute decompensated heart failure: update on new and emerging evidence and directions for future research. 
  • Acute decompensation after removing a central line: practical approaches to increasing safety in the intensive care unit. 
  • Acute effect of percutaneous MitraClip therapy in patients with haemodynamic decompensation. 
  • Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. 
  • Acute heart failure associated with high admission blood pressure--a distinct vascular disorder? 
  • Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the PROTECT trial. 
  • Acute heart failure in the elderly: differences in clinical characteristics, outcomes, and prognostic factors in the VERITAS Study. 
  • Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure. 
  • Acute heart failure in the young: Clinical characteristics and biomarker profiles. 
  • Acute heart failure syndromes: assessment and reconstructing the heart. 
  • Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy. 
  • Acute heart failure: perspectives from a randomized trial and a simultaneous registry. 
  • Acute kidney injury and 1-year mortality after left ventricular assist device implantation. 
  • Acute myocardial beta-adrenergic receptor dysfunction after cardiopulmonary bypass in patients with cardiac valve disease. Duke Heart Center Perioperative Desensitization Group. 
  • Adaptive mechanisms that preserve cardiac function in mice without myoglobin. 
  • Adding Troponin to the Puzzle of Heart Failure With Preserved Ejection Fraction: Marker or Mediator? 
  • Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. 
  • Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients. 
  • Adequate health literacy is associated with higher heart failure knowledge and self-care confidence in hospitalized patients. 
  • Adherence and persistence in the use of warfarin after hospital discharge among patients with heart failure and atrial fibrillation. 
  • Adherence to guideline-recommended adjunctive heart failure therapies among outpatient cardiology practices (findings from IMPROVE HF). 
  • Adherence to medication according to sex and age in the CHARM programme. 
  • Adjudicated Heart Failure in HIV-Infected and Uninfected Men and Women. 
  • Adjunctive agents in systemic chemotherapy. 
  • Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. 
  • Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. 
  • Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). 
  • Admission to the intensive care unit and well-being in patients with advanced chronic illness. 
  • Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims. 
  • Adrenomedullin, endothelin, neuropeptide Y, atrial, brain, and C-natriuretic prohormone peptides compared as early heart failure indicators. 
  • Advanced (stage D) heart failure: a statement from the Heart Failure Society of America Guidelines Committee. 
  • Advanced Practice Provider Versus Physician-Only Outpatient Follow-Up After Acute Myocardial Infarction. 
  • Advanced congestive heart failure: What do patients want? 
  • Advanced heart failure treated with continuous-flow left ventricular assist device. 
  • Advanced heart failure. 
  • Advanced heart failure: a call to action. 
  • Advanced therapies for end-stage heart failure. 
  • Advances in Heart Failure Management: Improving Outcomes With Innovation. 
  • Advances in heart failure: natriuretic peptide testing. 
  • Advances in the surgical treatment of heart failure. 
  • Advancing care for acute heart failure--no time to relax. 
  • Adverse Remodeling and Reverse Remodeling After Myocardial Infarction. 
  • Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. 
  • Adverse events in children implanted with ventricular assist devices in the United States: Data from the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS). 
  • Aerobic exercise training and general health status in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION)trial. 
  • Aetiology, timing and clinical predictors of early vs. late readmission following index hospitalization for acute heart failure: insights from ASCEND-HF. 
  • After-hour ventricular assist device coverage: what level of expertise is required? 
  • Age differences in the use of implantable cardioverter-defibrillators among older patients hospitalized with heart failure. 
  • Age, functional capacity, and health-related quality of life in patients with heart failure. 
  • Age- and gender-related differences in quality of care and outcomes of patients hospitalized with heart failure (from OPTIMIZE-HF). 
  • Age-dependent augmentation of cardiac endothelial NOS in a genetic rat model of heart failure. 
  • Air Pollution in Patients With Heart Failure: Lessons From a Mechanistic Pilot Study of a Filter Intervention. 
  • Albuminuria in chronic heart failure: prevalence and prognostic importance. 
  • Aldosterone antagonists--last man standing? 
  • All that glitters is not gold. 
  • Alpha 1-adrenoceptor activity in arterial smooth muscle following congestive heart failure. 
  • Alpha-1 adrenoceptor-angiotensin II type 1 receptor cross-talk and its relevance in clinical medicine. 
  • Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. 
  • Alterations in serum sodium in relation to atrial natriuretic factor and other neuroendocrine variables in experimental pacing-induced heart failure. 
  • Altered expression of myosin heavy chain in human skeletal muscle in chronic heart failure. 
  • Alternative pay-for-performance scoring methods: implications for quality improvement and patient outcomes. 
  • America and Apple Pie: How Do We Change the American Health Care System? 
  • Amino-terminal pro-B-type natriuretic peptide testing and prognosis in patients with acute dyspnea, including those with acute heart failure. 
  • Amino-terminal pro-B-type natriuretic peptide testing for inpatient monitoring and treatment guidance of acute destabilized heart failure. 
  • Amino-terminal pro-B-type natriuretic peptide testing for the diagnosis or exclusion of heart failure in patients with acute symptoms. 
  • Amino-terminal pro-brain natriuretic peptide for the diagnosis of acute heart failure in patients with previous obstructive airway disease. 
  • Amino-terminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin T for prediction of mortality in acute heart failure. 
  • Amino-terminal pro-brain natriuretic peptide: a biomarker for diagnosis, prognosis and management of heart failure. 
  • Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. 
  • Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality. 
  • Amlodipine in chronic heart failure. 
  • Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug. 
  • Amrinone therapy for congestive heart failure in outpatients with idiopathic dilated cardiomyopathy. 
  • Amrinone: its effect on vascular resistance and capacitance in human subjects. 
  • An ECG index of myocardial scar enhances prediction of defibrillator shocks: an analysis of the Sudden Cardiac Death in Heart Failure Trial. 
  • An N-ethyl-N-nitrosourea mutagenesis recessive screen identifies two candidate regions for murine cardiomyopathy that map to chromosomes 1 and 15. 
  • An interesting finding during transesophageal echocardiographic assessment of the mitral valve. 
  • An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALIANT registry. 
  • Anaemia and coronary artery disease severity in patients with heart failure. 
  • Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. 
  • Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure. 
  • Analysis of ventricular activation using surface electrocardiography to predict left ventricular reverse volumetric remodeling during cardiac resynchronization therapy. 
  • Anatomy of the obesity paradox in heart failure. 
  • Anemia and associated clinical outcomes in patients with heart failure due to reduced left ventricular systolic function. 
  • Anemia and mortality in heart failure patients a systematic review and meta-analysis. 
  • Anemia as a risk factor and therapeutic target in heart failure. 
  • Anemia in patients with heart failure and preserved systolic function. 
  • Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. 
  • Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. 
  • Angiographic and clinical outcomes associated with direct versus conventional stenting among patients treated with fibrinolytic therapy for ST-elevation acute myocardial infarction. 
  • Angiotensin II antagonism is associated with reduced risk for gastrointestinal bleeding caused by arteriovenous malformations in patients with left ventricular assist devices. 
  • Angiotensin II type 1 receptor-associated protein is an endogenous inhibitor of angiotensin II type 1 receptor action in cardiac hypertrophy: role in check and balance. 
  • Angiotensin as local modulating factor in ventricular dysfunction and failure due to coronary artery disease. 
  • Angiotensin converting enzyme inhibitors and the cardiovascular system. 
  • Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. 
  • Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure. 
  • Angiotensin-converting enzyme inhibitor dosing in heart failure: what is optimal? 
  • Animal models of heart failure: a scientific statement from the American Heart Association. 
  • Anti-beta(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. 
  • Anti-inflammatory effect of physical training in heart failure: role of TNF-alpha and IL-10. 
  • Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: Insights from the APixaban for PRevention of Acute ISchemic Events 2 trial. 
  • Anticoagulation in heart failure: current status and future direction. 
  • Antidepressant use, depression, and survival in patients with heart failure. 
  • Antihyperglycemic Medication Use Among Medicare Beneficiaries With Heart Failure, Diabetes Mellitus, and Chronic Kidney Disease. 
  • Antihyperglycemic Therapies to Treat Patients With Heart Failure and Diabetes Mellitus. 
  • Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. 
  • Antithrombotic Strategies and Device Thrombosis. 
  • Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients. 
  • Aortic Insufficiency During Contemporary Left Ventricular Assist Device Support: Analysis of the INTERMACS Registry. 
  • Apoptosis and heart failure. 
  • Application of the Seattle Heart Failure Model in ambulatory patients presented to an advanced heart failure therapeutics committee. 
  • Approaches to decongestion in patients with acute decompensated heart failure. 
  • Appropriate baseline laboratory testing following ACEI or ARB initiation by Medicare FFS beneficiaries. 
  • Appropriateness of therapy with angiotensin-converting-enzyme inhibitors in elderly outpatients. 
  • Are We Approaching Chronotropy (In)competently? 
  • Are models better than cardiologists?: An analysis of risk prediction in heart failure. 
  • Are racial/ethnic gaps in the use of cardiac resynchronization therapy narrowing?: an analysis of 107,096 patients from the National Cardiovascular Data Registry's ICD Registry. 
  • Are serial BNP measurements useful in heart failure management? Serial natriuretic peptide measurements are useful in heart failure management. 
  • Are there negative responders to exercise training among heart failure patients? 
  • Are we targeting the right metric for heart failure? Comparison of hospital 30-day readmission rates and total episode of care inpatient days. 
  • Arrival by ambulance in acute heart failure: insights into the mode of presentation from Acute Studies of Nesiritide in Decompensated Heart Failure (ASCEND-HF). 
  • Arterial stiffness and cardiovascular events: the Framingham Heart Study. 
  • Arterial-venous nitroglycerin gradient during intravenous infusion in man. 
  • Ascending aorta to main pulmonary artery fistula following orthotopic heart transplantation: successful percutaneous closure employing an Amplatzer Duct Occluder. 
  • Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. 
  • Assessing Frailty in Patients Undergoing Destination Therapy Left Ventricular Assist Device: Observations from Interagency Registry for Mechanically Assisted Circulatory Support. 
  • Assessing prognosis in heart failure: is hepatocyte growth factor the next B-type natriuretic peptide? 
  • Assessing the Quality and Comparative Effectiveness of Team-Based Care for Heart Failure: Who, What, Where, When, and How. 
  • Assessing the appropriateness of ICD use "appropriately". 
  • Assessment of Heart Transplant Waitlist Time and Pre- and Post-transplant Failure: A Mixed Methods Approach. 
  • Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. 
  • Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. 
  • Assessment of left ventricular function in older Medicare beneficiaries with newly diagnosed heart failure. 
  • Assessment of left ventricular mechanical dyssynchrony by phase analysis of ECG-gated SPECT myocardial perfusion imaging. 
  • Assessment of regional wall motion abnormalities with real-time 3-dimensional echocardiography. 
  • Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. 
  • Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure. 
  • Association Between Regional Adipose Tissue Distribution and Risk of Heart Failure Among Blacks. 
  • Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. 
  • Association Between a Prolonged PR Interval and Outcomes of Cardiac Resynchronization Therapy: A Report From the National Cardiovascular Data Registry. 
  • Association between adrenergic receptor genotypes and beta-blocker dose in heart failure patients: analysis from the HF-ACTION DNA substudy. 
  • Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. 
  • Association between frequency of atrial and ventricular ectopic beats and biventricular pacing percentage and outcomes in patients with cardiac resynchronization therapy. 
  • Association between hemoglobin level and cardiopulmonary performance in heart failure: insights from the HF-ACTION study. 
  • Association between left ventricular ejection fraction post-cardiac resynchronization treatment and subsequent implantable cardioverter defibrillator therapy for sustained ventricular tachyarrhythmias. 
  • Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. 
  • Association between natriuretic peptides and mortality among patients admitted with myocardial infarction: a report from the ACTION Registry(R)-GWTG™. 
  • Association between performance measures and clinical outcomes for patients hospitalized with heart failure. 
  • Association between prophylactic implantable cardioverter-defibrillators and survival in patients with left ventricular ejection fraction between 30% and 35%. 
  • Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial. 
  • Association between the timing of surgery for complicated, left-sided infective endocarditis and survival. 
  • Association between troponin T and impaired left ventricular relaxation in patients with acute decompensated heart failure with preserved systolic function. 
  • Association between valvular surgery and mortality among patients with infective endocarditis complicated by heart failure. 
  • Association of 30-Day Readmission Metric for Heart Failure Under the Hospital Readmissions Reduction Program With Quality of Care and Outcomes. 
  • Association of Anemia With Outcomes Among ST-Segment-Elevation Myocardial Infarction Patients Receiving Primary Percutaneous Coronary Intervention. 
  • Association of Arterial Pulse Pressure With Long-Term Clinical Outcomes in Patients With Heart Failure. 
  • Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. 
  • Association of Electronic Health Record Use With Quality of Care and Outcomes in Heart Failure: An Analysis of Get With The Guidelines-Heart Failure. 
  • Association of Hospital Performance Based on 30-Day Risk-Standardized Mortality Rate With Long-term Survival After Heart Failure Hospitalization: An Analysis of the Get With The Guidelines-Heart Failure Registry. 
  • Association of Renin-Angiotensin Inhibitor Treatment With Mortality and Heart Failure Readmission in Patients With Transcatheter Aortic Valve Replacement. 
  • Association of Tricuspid Regurgitation With Transcatheter Aortic Valve Replacement Outcomes: A Report From The Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. 
  • Association of a 4-Tiered Classification of LV Hypertrophy With Adverse CV Outcomes in the General Population. 
  • Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. 
  • Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. 
  • Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). 
  • Association of chronic congestive heart failure in humans with an intrinsic upregulation in skeletal muscle sarcoplasmic reticulum calcium ion adenosine triphosphatase activity. 
  • Association of depression and survival in patients with chronic heart failure over 12 Years. 
  • Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. 
  • Association of parental heart failure with risk of heart failure in offspring. 
  • Association of prolonged QRS duration with death in a clinical trial of pacemaker therapy for sinus node dysfunction. 
  • Association of race/ethnicity with clinical risk factors, quality of care, and acute outcomes in patients hospitalized with heart failure. 
  • Association of the Affordable Care Act's Medicaid Expansion With Care Quality and Outcomes for Low-Income Patients Hospitalized With Heart Failure. 
  • Association of the Hospital Readmissions Reduction Program Implementation With Readmission and Mortality Outcomes in Heart Failure. 
  • Association of weight change with subsequent outcomes in patients hospitalized with acute decompensated heart failure. 
  • Associations Between Blood Pressure and Outcomes Among Blacks in the Jackson Heart Study. 
  • Associations between Seattle Heart Failure Model scores and health utilities: findings from HF-ACTION. 
  • Associations between aldosterone antagonist therapy and risks of mortality and readmission among patients with heart failure and reduced ejection fraction. 
  • Associations between anticoagulation therapy and risks of mortality and readmission among patients with heart failure and atrial fibrillation. 
  • Associations between atrial fibrillation and early outcomes of patients with heart failure and reduced or preserved ejection fraction. 
  • Associations between hemoglobin level, resource use, and medical costs in patients with heart failure: findings from HF-ACTION. 
  • Associations between outpatient heart failure process-of-care measures and mortality. 
  • Associations between published quality ratings of skilled nursing facilities and outcomes of medicare beneficiaries with heart failure. 
  • Associations between seattle heart failure model scores and medical resource use and costs: findings from HF-ACTION. 
  • Associations between understanding of current treatment intent, communication with healthcare providers, preferences for invasive life-sustaining interventions and decisional conflict: results from a survey of patients with advanced heart failure in Singapore. 
  • Associations between use of the hospitalist model and quality of care and outcomes of older patients hospitalized for heart failure. 
  • Associations between worsening renal function and 30-day outcomes among Medicare beneficiaries hospitalized with heart failure. 
  • Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. 
  • Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials. 
  • Associations of patient demographic characteristics and regional physician density with early physician follow-up among medicare beneficiaries hospitalized with heart failure. 
  • Atherosclerotic cardiovascular disease and heart failure: Determinants of risk and outcomes in patients with diabetes. 
  • Atrial Fibrillation and Heart Failure: In This Challenge Lies Opportunity. 
  • Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Atrial fibrillation and sudden cardiac death: is heart failure the middleman? 
  • Atrial fibrillation in heart failure: what should we do? 
  • Atrial fibrillation management strategies and early mortality after myocardial infarction: results from the Valsartan in Acute Myocardial Infarction (VALIANT) Trial. 
  • Atrial fibrillation or flutter on initial electrocardiogram is associated with worse outcomes in patients admitted for worsening heart failure with reduced ejection fraction: findings from the EVEREST Trial. 
  • Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. 
  • Atrial natriuretic factor: pharmacokinetics and cyclic GMP response in relation to biologic effects in severe heart failure. 
  • Atrioventricular and ventricular-to-ventricular programming in patients with cardiac resynchronization therapy: results from ALTITUDE. 
  • Augmenting outcomes in patients with advanced heart failure. 
  • Authorship in a multicenter clinical trial: The Heart Failure-A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) Authorship and Publication (HAP) scoring system results. 
  • Autocrine and paracrine mechanisms in the pathophysiology of heart failure. 
  • Autonomic Modulation for the Treatment of Ventricular Arrhythmias: Therapeutic Use of Percutaneous Stellate Ganglion Blocks. 
  • Aviation Emergencies for Heart Failure Cardiologists: A New Twist to the Heart Team. 
  • B-Type Natriuretic Peptide Testing in the Era of Neprilysin Inhibition: Are the Winds of Change Blowing? 
  • B-type natriuretic peptide - a biomarker for all seasons? 
  • B-type natriuretic peptide assessment in ambulatory heart failure patients: insights from IMPROVE HF. 
  • B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: insights from the Acute Decompensated Heart Failure National Registry. 
  • BAG3 protein in advanced-stage heart failure. 
  • BIN1 is reduced and Cav1.2 trafficking is impaired in human failing cardiomyocytes. 
  • BNP-guided heart failure therapy in older patients. 
  • BNP-guided therapy for heart failure. 
  • BRG1 and BRM SWI/SNF ATPases redundantly maintain cardiomyocyte homeostasis by regulating cardiomyocyte mitophagy and mitochondrial dynamics in vivo. 
  • Back to the Future With Intravenous Diuretics: Reinvigorating an Old Treatment Through New Care Settings. 
  • Baroreceptor function in congestive heart failure: effect on neurohumoral activation and regional vascular resistance. 
  • Baroreflex regulation of regional blood flow in congestive heart failure. 
  • Barriers to enrollment in a randomized controlled trial of hydrocortisone for cardiovascular insufficiency in term and late preterm newborn infants. 
  • Baseline Characteristics Predict the Presence of Amyloid on Endomyocardial Biopsy. 
  • Baseline Hemodynamics and Response to Contrast Media During Diagnostic Cardiac Catheterization Predict Adverse Events in Heart Failure Patients. 
  • Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. 
  • Baseline characteristics of patients in the Reduction of Events with Darbepoetin alfa in Heart Failure trial (RED-HF). 
  • Baseline clinical characteristics of patients recruited into the assessment of treatment with lisinopril and survival study. 
  • Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) study. 
  • Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. 
  • Benefits of a novel percutaneous ventricular assist device for right heart failure: The prospective RECOVER RIGHT study of the Impella RP device. 
  • Beta adrenoceptor recovery after heart failure in the dog. 
  • Beta-adrenergic axis and heart disease. 
  • Beta-adrenergic receptor desensitization in cardiac hypertrophy and heart failure. 
  • Beta-arrestin-mediated signaling in the heart. 
  • Beta-blocker therapy for heart failure: the evidence is in, now the work begins. 
  • Beta-blocker therapy in advanced heart failure: clinical characteristics and long-term outcomes. 
  • Beta-blocker use and outcomes among hospitalized heart failure patients. 
  • Better late than never: a welcome publication of tardy clinical trial results. 
  • Between Scylla and Charybdis: The choice of inotropic agent for decompensated heart failure. 
  • Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure. 
  • Beyond drug therapy: nonpharmacologic care of the patient with advanced heart failure. 
  • Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. 
  • Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). 
  • Biatrial appendage hypertrophy but not ventricular hypertrophy: a unique feature of canine pacing-induced heart failure. 
  • Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. 
  • Biomarker guided therapy for heart failure: focus on natriuretic peptides. 
  • Biomarker-based risk prediction in the community. 
  • Biomarker-guided therapies in heart failure: a forum for unified strategies. 
  • Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. 
  • Biomarkers as surrogate end points in heart failure trials. 
  • Biomarkers for the Prevention of Heart Failure: Are We There Yet? 
  • Biomarkers in acute heart failure. 
  • Biomarkers in acutely decompensated heart failure with preserved or reduced ejection fraction. 
  • Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling. 
  • Biventricular Berlin Heart EXCOR pediatric use across the united states. 
  • Bleeding and thrombosis associated with ventricular assist device therapy. 
  • Bleeding complications and blood product utilization with left ventricular assist device implantation. 
  • Blinded Patient Preference for Morphine Compared to Placebo in the Setting of Chronic Refractory Breathlessness--An Exploratory Study. 
  • Blood Pressure Response during Cardiopulmonary Exercise Testing in Heart Failure. 
  • Blood pressure reactivity to psychological stress is associated with clinical outcomes in patients with heart failure. 
  • Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. 
  • Blood-gas and hemodynamic responses to oxygen in acute myocardial infarction. 
  • Bloodstream Amyloid-beta (1-40) Peptide, Cognition, and Outcomes in Heart Failure. 
  • Blunted cyclic variation of heart rate predicts mortality risk in post-myocardial infarction, end-stage renal disease, and chronic heart failure patients. 
  • Body Weight Change During and After Hospitalization for Acute Heart Failure: Patient Characteristics, Markers of Congestion, and Outcomes: Findings From ASCEND-HF. 
  • Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. 
  • Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Boosting cardiac contractility with genes. 
  • Brain Natriuretic Peptide Treatment and Heart Failure Prevention: Reliving the Mistakes of the Past or Charting a New Course for the Future? 
  • Breaking Bad: The Heartbreak of Drug Abuse. 
  • Breaking the vicious circle of fatigue in patients with chronic heart failure. 
  • Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes. 
  • Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting. 
  • Bronchodilators in heart failure patients with COPD: is it time for a clinical trial? 
  • Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure. 
  • Bucindolol: new hopes from reviewing past data. 
  • Building the case for aerobic exercise in ambulatory patients with heart failure and a reduced ejection fraction. 
  • Bundle Up for Value-Based Heart Failure Care. 
  • Burden of medical co-morbidities and benefit from surgical revascularization in patients with ischaemic cardiomyopathy. 
  • COAPTing Heart Failure Physicians, Interventional Cardiologists, and CardioThoracic Surgeons: A New Opportunity for Patients. 
  • COPD in heart failure: are there long-term implications following acute heart failure hospitalization? 
  • CT angiography in the detection of carotid body enlargement in patients with hypertension and heart failure. 
  • CYP3A4 genotype is associated with sildenafil concentrations in patients with heart failure with preserved ejection fraction. 
  • Ca2+/calmodulin-dependent protein kinase II (CaMKII) regulates cardiac sodium channel NaV1.5 gating by multiple phosphorylation sites. 
  • Calcineurin signaling in human cardiac hypertrophy. 
  • Calcium antagonists: new therapy for congestive heart failure? 
  • Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. 
  • Can 2 Pills a Day Keep Readmission Away?: Sacubitril/Valsartan to Reduce 30-Day Heart Failure Readmissions. 
  • Can Vaccinations Improve Heart Failure Outcomes?: Contemporary Data and Future Directions. 
  • Can walking patients with heart failure and preserved ejection fraction tell us who should walk also to the catheterization laboratory or just walk home? 
  • Can we prevent heart failure with exercise? 
  • Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. 
  • Capillary density of skeletal muscle: a contributing mechanism for exercise intolerance in class II-III chronic heart failure independent of other peripheral alterations. 
  • Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. 
  • Cardiac Dysfunction and Heart Failure in Hematopoietic Cell Transplantation Survivors: Emerging Paradigms in Pathophysiology, Screening, and Prevention. 
  • Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. 
  • Cardiac Index Declines During Long-Term Left Ventricular Device Support. 
  • Cardiac Rehabilitation After Ventricular Assist Device Implantation: A Worthwhile Exercise? 
  • Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. 
  • Cardiac arrest complicating acute myocardial infarction: predictability and prognosis. 
  • Cardiac contractility modulation: the next cardiac resynchronization therapy or another renal sympathetic denervation? 
  • Cardiac evaluation of mitoxantrone. 
  • Cardiac fibroblasts in pressure overload hypertrophy: the enemy within? 
  • Cardiac function in genetically engineered mice with altered adrenergic receptor signaling. 
  • Cardiac imaging to identify patients at risk for developing heart failure after myocardial infarction. 
  • Cardiac pacing strategies and post-implantation risk of atrial fibrillation and heart failure events in sinus node dysfunction patients: a collaborative analysis of over 6000 patients. 
  • Cardiac potentials on body surface of infants with anomalous left coronary artery (myocardial infarction). 
  • Cardiac protection: evolving role of angiotensin receptor blockers. 
  • Cardiac resynchronization therapy in chronic heart failure with moderately reduced left ventricular ejection fraction: Lessons from the Multicenter InSync Randomized Clinical Evaluation MIRACLE EF study. 
  • Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction. 
  • Cardiac resynchronization therapy in heart failure patients: an update. 
  • Cardiac resynchronization therapy in patients with renal dysfunction: keep calm and carry on. 
  • Cardiac resynchronization therapy reduces the risk of hospitalizations in patients with advanced heart failure: results from the Comparison of Medical Therapy, Pacing and Defibrillation in Heart Failure (COMPANION) trial. 
  • Cardiac resynchronization therapy utilization for heart failure: findings from IMPROVE HF. 
  • Cardiac rhabdomyosarcoma presenting as hypereosinophilic syndrome. 
  • Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer. 
  • Cardiac tamponade. 
  • Cardiac transplantation following ACORN CorCap device implantation. 
  • Cardiac troponins in congestive heart failure. 
  • Cardiac troponins in congestive heart failure. 
  • Cardiac-resynchronization therapy for the prevention of heart-failure events. 
  • Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. 
  • Cardiogenic shock and heart failure post-percutaneous coronary intervention in ST-elevation myocardial infarction: observations from "Assessment of Pexelizumab in Acute Myocardial Infarction". 
  • Cardiohepatic interactions in heart failure: an overview and clinical implications. 
  • Cardiomyocyte-Specific Human Bcl2-Associated Anthanogene 3 P209L Expression Induces Mitochondrial Fragmentation, Bcl2-Associated Anthanogene 3 Haploinsufficiency, and Activates p38 Signaling. 
  • Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. 
  • Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. 
  • Cardiopulmonary exercise and 6-min walk tests as predictors of quality of life and long-term mortality among patients with heart failure due to Chagas disease. 
  • Cardiorenal Interactions. 
  • Cardiorenal interactions: insights from the ESCAPE trial. 
  • Cardiorenal rescue study in acute decompensated heart failure: rationale and design of CARRESS-HF, for the Heart Failure Clinical Research Network. 
  • Cardiovascular Complications of HIV in Endemic Countries. 
  • Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. 
  • Cardiovascular Outcomes With Minute Ventilation-Targeted Adaptive Servo-Ventilation Therapy in Heart Failure: The CAT-HF Trial. 
  • Cardiovascular biology: heart fails without pump partner. 
  • Cardiovascular critical event pathways for the progression of heart failure; a report from the ATLAS study. 
  • Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). 
  • Cardiovascular imaging utilization: boom or bust? 
  • Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. 
  • Cardiovascular toxicity of epoetin-alfa in patients with chronic kidney disease. 
  • Care and outcomes of Hispanic patients admitted with heart failure with preserved or reduced ejection fraction: findings from get with the guidelines-heart failure. 
  • Care of the patient with cardiovascular disease undergoing general surgery. 
  • Caregivers of Patients Considering a Destination Therapy Left Ventricular Assist Device and a Shared Decision-Making Intervention: The DECIDE-LVAD Trial. 
  • Caring for patients with chronic heart failure: The trajectory model. 
  • Carvedilol use at discharge in patients hospitalized for heart failure is associated with improved survival: an analysis from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Case reports of heart failure after therapy with a tumor necrosis factor antagonist. 
  • Case study: heart transplantation--increased incidence of acute rejection in female recipients. 
  • Catabolic Defect of Branched-Chain Amino Acids Promotes Heart Failure. 
  • Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. 
  • Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. 
  • Cell therapy for heart failure: the need for a new therapeutic strategy. 
  • Cellular and functional defects in a mouse model of heart failure. 
  • Challenges with Percent Predicted Maximal V˙O2 in Patients with Heart Failure. 
  • Change Is Not Always Good. 
  • Change in intrathoracic impedance measures during acute decompensated heart failure admission: results from the Diagnostic Data for Discharge in Heart Failure Patients (3D-HF) Pilot Study. 
  • Change the management of patients with heart failure: Rationale and design of the CHAMP-HF registry. 
  • Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. 
  • Changes in pulmonary artery pressure before and after left ventricular assist device implantation in patients utilizing remote haemodynamic monitoring. 
  • Changing preferences for survival after hospitalization with advanced heart failure. 
  • Changing the Carburetor Without Changing the Plugs: The Intersection of Stock Car Racing With Mechanically Assisted Circulation. 
  • Changing the Research Culture in the United States. 
  • Channeling a new focus for heart failure: insights into ion channels. 
  • Characteristics and Treatments of Patients Enrolled in the CHAMP-HF Registry Compared With Patients Enrolled in the PARADIGM-HF Trial. 
  • Characteristics and in-hospital outcomes for nonadherent patients with heart failure: findings from Get With The Guidelines-Heart Failure (GWTG-HF). 
  • Characteristics and outcomes of patients with heart failure and discordant findings by right-sided heart catheterization and cardiopulmonary exercise testing. 
  • Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. 
  • Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). 
  • Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. 
  • Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. 
  • Characteristics, quality of care, and in-hospital outcomes of Asian-American heart failure patients: Findings from the American Heart Association Get With The Guidelines-Heart Failure Program. 
  • Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. 
  • Characterization and prediction of adverse events from intensive chronic heart failure management and effect on quality of life: results from the pro-B-type natriuretic peptide outpatient-tailored chronic heart failure therapy (PROTECT) study. 
  • Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. 
  • Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. 
  • Characterization of Mineralocorticoid Receptor Antagonist Therapy Initiation in High-Risk Patients With Heart Failure. 
  • Characterization of cardiovascular clinical events and impact of event adjudication on the treatment effect of darapladib versus placebo in patients with stable coronary heart disease: Insights from the STABILITY trial. 
  • Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. 
  • Characterization of heart failure patients with preserved ejection fraction: a comparison between ADHERE-US registry and ADHERE-International registry. 
  • Characterization of hemodynamically stable acute heart failure patients requiring a critical care unit admission: Derivation, validation, and refinement of a risk score. 
  • Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. 
  • Characterizing functional stem cell-cardiomyocyte interactions. 
  • Charting a roadmap for heart failure biomarker studies. 
  • Chemical and metabolomic screens identify novel biomarkers and antidotes for cyanide exposure. 
  • Chest pain in patients with heart failure: why history may matter. 
  • Cheyne-Stokes respiration: poor prognostic sign in a patient with heart failure. 
  • Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. 
  • Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. 
  • Chronic counterpulsation devices for heart failure. 
  • Chronic mechanical circulatory support for inotrope-dependent heart failure patients who are not transplant candidates: results of the INTrEPID Trial. 
  • Chronic oral amrinone therapy in congestive heart failure: a double-blind placebo-controlled withdrawal study. 
  • Chronic refractory dyspnoea--evidence based management. 
  • Cigarette Smoking and Incident Heart Failure: Insights From the Jackson Heart Study. 
  • Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. 
  • Circadian rhythm and sudden death in heart failure: results from Prospective Randomized Amlodipine Survival Trial. 
  • Circulating Cardiac Troponin I Levels Measured by a Novel Highly Sensitive Assay in Acute Decompensated Heart Failure: Insights From the ASCEND-HF Trial. 
  • Circulating Concentrations of Orexin A Predict Left Ventricular Myocardial Remodeling. 
  • Circulating Kidney Injury Molecule-1 Levels in Acute Heart Failure: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. 
  • Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate Therapy in Patients With Heart Failure and Reduced Ejection Fraction: Findings From the Get With The Guidelines-Heart Failure Registry. 
  • Clinical Experience of HeartMate II to HeartWare Left Ventricular Assist Device Exchange: A Multicenter Experience. 
  • Clinical Implications of Cluster Analysis-Based Classification of Acute Decompensated Heart Failure and Correlation with Bedside Hemodynamic Profiles. 
  • Clinical Implications of Serum Albumin Levels in Acute Heart Failure: Insights From DOSE-AHF and ROSE-AHF. 
  • Clinical Outcomes of Metformin Use in Populations With Chronic Kidney Disease, Congestive Heart Failure, or Chronic Liver Disease: A Systematic Review. 
  • Clinical Significance of Early Fluid and Weight Change During Acute Heart Failure Hospitalization. 
  • Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society for Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. 
  • Clinical and Research Considerations for Patients With Hypertensive Acute Heart Failure: A Consensus Statement from the Society of Academic Emergency Medicine and the Heart Failure Society of America Acute Heart Failure Working Group. 
  • Clinical and angiographic correlates of short- and long-term mortality in patients undergoing coronary artery bypass grafting. 
  • Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. 
  • Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. 
  • Clinical characteristics and long-term outcomes of patients with heart failure and preserved systolic function. 
  • Clinical characteristics and outcomes of patients with and without diabetes in the Surgical Treatment for Ischemic Heart Failure (STICH) trial. 
  • Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. 
  • Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). 
  • Clinical characteristics associated with poor long-term survival among patients with diabetes mellitus undergoing saphenous vein graft interventions. 
  • Clinical characteristics of patients undergoing surgical ventricular reconstruction by choice and by randomization. 
  • Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION). 
  • Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. 
  • Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. 
  • Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial. 
  • Clinical course of atrial fibrillation in older adults: the importance of cardiovascular events beyond stroke. 
  • Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase. 
  • Clinical effectiveness of CRT and ICD therapy in heart failure patients by racial/ethnic classification: insights from the IMPROVE HF registry. 
  • Clinical effectiveness of anticoagulation therapy among older patients with heart failure and without atrial fibrillation: findings from the ADHERE registry linked to Medicare claims. 
  • Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. 
  • Clinical effectiveness of cardiac resynchronization and implantable cardioverter-defibrillator therapy in men and women with heart failure: findings from IMPROVE HF. 
  • Clinical effectiveness of cardiac resynchronization therapy versus medical therapy alone among patients with heart failure: analysis of the ICD Registry and ADHERE. 
  • Clinical effectiveness of implantable cardioverter-defibrillators among medicare beneficiaries with heart failure. 
  • Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease. 
  • Clinical lessons learned from experimental heart failure. 
  • Clinical management of continuous-flow left ventricular assist devices in advanced heart failure. 
  • Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. 
  • Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. 
  • Clinical outcomes after implantation of a centrifugal flow left ventricular assist device and concurrent cardiac valve procedures. 
  • Clinical outcomes at 1 year following transcatheter aortic valve replacement. 
  • Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure. 
  • Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. 
  • Clinical pathway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. 
  • Clinical pharmacology considerations for children supported with ventricular assist devices. 
  • Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. 
  • Clinical problem-solving. A key miscommunication--an 81-year-old woman presented to the emergency department with increasing abdominal distention, nausea, and vomiting. 
  • Clinical problem-solving. Undercover and overlooked. 
  • Clinical profile and prognostic significance of natriuretic peptide trajectory following hospitalization for worsening chronic heart failure: findings from the ASTRONAUT trial. 
  • Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial. 
  • Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial. 
  • Clinical profiles in acute heart failure: an urgent need for a new approach. 
  • Clinical response to angiotensin-converting enzyme inhibition in cardiac failure. 
  • Clinical study of the cardiac findings in patients on chronic maintenance hemodialysis: the relationship to coronary risk factors. 
  • Clinical trial evidence for treatment of depression in heart failure. 
  • Clinical trials in Japan and the United States. 
  • Clinical trials in acute decompensated heart failure--over 50 years of research. 
  • Clinical trials in hospitalized heart failure patients: targeting interventions to optimal phenotypic subpopulations. 
  • Clinical trials in mechanical circulatory support. 
  • Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. 
  • Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. 
  • Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial). 
  • Clonidine in congestive heart failure: a vasodilator with negative inotropic effects. 
  • Cluster-Randomized Trial of Personalized Site Performance Feedback in Get With The Guidelines-Heart Failure. 
  • Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. 
  • Coenzyme Q10 and Heart Failure: A State-of-the-Art Review. 
  • Coenzyme Q10 and statins in heart failure: the dog that didn't bark. 
  • Combating Acute Heart Failure in the Arena: Lessons From the ROPA-DOP Trial. 
  • Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists. 
  • Combination of loop diuretics with thiazide-type diuretics in heart failure. 
  • Combinatorial pharmacogenetic interactions of bucindolol and β1, α2C adrenergic receptor polymorphisms. 
  • Combined heart failure device diagnostics identify patients at higher risk of subsequent heart failure hospitalizations: results from PARTNERS HF (Program to Access and Review Trending Information and Evaluate Correlation to Symptoms in Patients With Heart Failure) study. 
  • Combined modality therapy for advanced, diffuse lymphocytic and histiocytic lymphomas. 
  • Combined neprilysin and renin-angiotensin system inhibition in heart failure with reduced ejection fraction: a meta-analysis. 
  • Combined treatment with vessel dilator and kaliuretic hormone in persons with congestive heart failure. 
  • Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. 
  • Combining SERCA2a activation and Na-K ATPase inhibition: a promising new approach to managing acute heart failure syndromes with low cardiac output. 
  • Combining baseline clinical descriptors and real-time response to therapy: the incremental prognostic value of continuous ST-segment monitoring in acute myocardial infarction. 
  • Comorbidities in Heart Failure: Are There Gender Differences? 
  • Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. 
  • Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. 
  • Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. 
  • Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. 
  • Comparative cardiovascular safety of dementia medications: a cross-national study. 
  • Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace? 
  • Comparative effectiveness of beta-blockers in elderly patients with heart failure. 
  • Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study. 
  • Comparative effectiveness of torsemide versus furosemide in heart failure patients: insights from the PROTECT trial. 
  • Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group. 
  • Comparative prognostic significance of simultaneous versus independent resolution of ST segment depression relative to ST segment elevation during acute myocardial infarction. 
  • Comparing the Palliative Care Needs of Those With Cancer to Those With Common Non-Cancer Serious Illness. 
  • Comparing three life-limiting diseases: does diagnosis matter or is sick, sick? 
  • Comparing unmet needs between community-based palliative care patients with heart failure and patients with cancer. 
  • Comparing willingness to pay for telemedicine across a chronic heart failure and hypertension population. 
  • Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure. 
  • Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow. 
  • Comparison of Frequency of Frailty and Severely Impaired Physical Function in Patients ≥60 Years Hospitalized With Acute Decompensated Heart Failure Versus Chronic Stable Heart Failure With Reduced and Preserved Left Ventricular Ejection Fraction. 
  • Comparison of cardiac marker concentrations in healthy blood donors and hospital patients without acute coronary syndrome. 
  • Comparison of coronary artery bypass grafting versus medical therapy on long-term outcome in patients with ischemic cardiomyopathy (a 25-year experience from the Duke Cardiovascular Disease Databank). 
  • Comparison of dyssynchrony parameters for VV-optimization in CRT patients. 
  • Comparison of hand-carried ultrasound assessment of the inferior vena cava and N-terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure. 
  • Comparison of heart failure in children with enterovirus 71 rhombencephalitis and cats with norepinephrine cardiotoxicity. 
  • Comparison of hospital costing methods in an economic evaluation of a multinational clinical trial. 
  • Comparison of impedance cardiography with invasive hemodynamic measurements in patients with heart failure secondary to ischemic or nonischemic cardiomyopathy. 
  • Comparison of major and minor depression in older medical inpatients with chronic heart and pulmonary disease. 
  • Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. 
  • Comparison of myocardial reperfusion in patients undergoing percutaneous coronary intervention in ST-segment elevation acute myocardial infarction with versus without diabetes mellitus (from the EMERALD Trial). 
  • Comparison of older depressed hospitalized patients with and without heart failure/pulmonary disease. 
  • Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). 
  • Comparison of risk prediction with the CKD-EPI and MDRD equations in acute decompensated heart failure. 
  • Comparison of survival after mitral valve replacement with biologic and mechanical valves in 1139 patients. 
  • Comparison of vessel dilator and long-acting natriuretic peptide in the treatment of congestive heart failure. 
  • Complete LVOT obstruction following aortic valve replacement after HeartMate II implantation. 
  • Composite End Points in Acute Heart Failure Research: Data Simulations Illustrate the Limitations. 
  • Concealed mechanical bradycardia: an indication for permanent pacemaker implantation. 
  • Concentrations of highly sensitive cardiac troponin-I predict poor cardiovascular outcomes and adverse remodeling in chronic heart failure. 
  • Concomitant Thoracic Aortobifemoral Bypass With Left Ventricular Assist Device Implantation. 
  • Concomitant tricuspid valve surgery during implantation of continuous-flow left ventricular assist devices: a Society of Thoracic Surgeons database analysis. 
  • Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial. 
  • Conduct of clinical trials in acute heart failure: regional differences in heart failure clinical trials. 
  • Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. 
  • Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. 
  • Congestive heart failure patients' perceptions of quality of life: the integration of physical and psychosocial factors. 
  • Congestive heart failure. 
  • Congestive heart failure: Dx and Rx in the elderly. 
  • Connecting the pieces of the cardiovascular care puzzle in Canada. 
  • Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. 
  • Consideration of ICD-9 code-derived disease-specific safety indicators in CKD. 
  • Considering the duration of heart failure: using the past to predict the future. 
  • Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. 
  • Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. 
  • Continuous flow left ventricular assist device improves functional capacity and quality of life of advanced heart failure patients. 
  • Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). 
  • Continuous versus bolus dosing of Furosemide for patients hospitalized for heart failure. 
  • Contrast nephrotoxicity: a randomized controlled trial of a nonionic and an ionic radiographic contrast agent. 
  • Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. 
  • Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. 
  • Contributions of hemodynamic monitoring to the treatment of chronic congestive heart failure. 
  • Contributions of neuroendocrine and local autocrine-paracrine mechanisms to the pathophysiology and pharmacology of congestive heart failure. 
  • Control beliefs and risk for 4-year mortality in older adults: a prospective cohort study. 
  • Controlling axillary intra-aortic balloon pump inflation is a viable option for turning an acute heart failure patient into a chronic one. 
  • Controversies and Challenges of Ventricular Assist Device Therapy. 
  • Convergences of Life Sciences and Engineering in Understanding and Treating Heart Failure. 
  • Coping effectively with heart failure (COPE-HF): design and rationale of a telephone-based coping skills intervention. 
  • Coping styles in heart failure patients with depressive symptoms. 
  • Coronary Artery Calcification and Risk of Cardiovascular Disease and Death Among Patients With Chronic Kidney Disease. 
  • Coronary artery disease in patients with heart failure: incidental, coincidental, or a target for therapy? 
  • Coronary bypass surgery with or without surgical ventricular reconstruction. 
  • Coronary cyclic flow variations following primary angioplasty is associated with poor short-term prognosis. 
  • Coronary intervention for persistent occlusion after myocardial infarction. 
  • Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. 
  • Coronary-Artery Bypass Surgery in Patients with Ischemic Cardiomyopathy. 
  • Coronary-artery bypass surgery in patients with left ventricular dysfunction. 
  • Correction of anemia with epoetin alfa in chronic kidney disease. 
  • Corrections needed to 2016 ESC and AHA guidelines on heart failure. 
  • Correlates and impact on outcomes of worsening renal function in patients > or =65 years of age with heart failure. 
  • Correlation between peak expiratory flow rate and NT-proBNP in patients with acute heart failure. An analysis from ASCEND-HF trial. 
  • Correlation of impedance cardiography with invasive hemodynamic measurements in patients with advanced heart failure: the BioImpedance CardioGraphy (BIG) substudy of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) Trial. 
  • Correlations between physician-perceived functional status, patient-perceived health status, and cardiopulmonary exercise results in hypertrophic cardiomyopathy. 
  • Cost Implications of Anticoagulation Strategies After Percutaneous Coronary Intervention Among Patients With Atrial Fibrillation (A PIONEER-AF PCI Analysis). 
  • Cost effectiveness of natriuretic peptide measurement in the primary care setting: have we found the gatekeeper for the evaluation of dyspneic outpatients? 
  • Cost of ventricular assist devices: can we afford the progress? 
  • Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. 
  • Cost-effectiveness of a disease management programme for secondary prevention of coronary heart disease and heart failure in primary care. 
  • Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Cost-effectiveness of implantable cardioverter defibrillators in patients >or=65 years of age. 
  • Cost-effectiveness of screening for asymptomatic left ventricular dysfunction in childhood cancer survivors. 
  • Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. 
  • Costs for heart failure with normal vs reduced ejection fraction. 
  • Costs of inpatient care among Medicare beneficiaries with heart failure, 2001 to 2004. 
  • Covariate adjustment in heart failure randomized controlled clinical trials: a case analysis of the HF-ACTION trial. 
  • Creation of a quantitative recipient risk index for mortality prediction after cardiac transplantation (IMPACT). 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Current and novel pharmacologic approaches in advanced heart failure. 
  • Current best practices and guidelines. Assessment and management of complications in infective endocarditis. 
  • Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. 
  • Current trends in the management of heart failure. 
  • Cystatin C-based CKD-EPI equations and N-terminal pro-B-type natriuretic peptide for predicting outcomes in acutely decompensated heart failure. 
  • Cytoskeletal regulation of TRPC channels in the cardiorenal system. 
  • DUCCS and SWANS: when U.S. site-based research was highly successful. 
  • Dangerous diuretics or death defying drugs? 
  • Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. 
  • Data Sharing From the Editors' Perspective: Our Hope With Limitations. 
  • Data sources for heart failure comparative effectiveness research. 
  • Day of admission and clinical outcomes for patients hospitalized for heart failure: findings from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). 
  • Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. 
  • Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. 
  • De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. 
  • Dead letter office. 
  • Death during coronary angiography in a woman with cardiac amyloidosis. 
  • Death of the Heart Failure Clinical Investigator: Molecules and Receptors Win Nobel Prizes, Clinical Investigation Improves Survival. 
  • Death: The Simple Clinical Trial Endpoint. 
  • Decision making in advanced heart failure: a scientific statement from the American Heart Association. 
  • Decision-Making of Patients With Implantable Cardioverter-Defibrillators at End of Life: Family Members' Experiences. 
  • Declining Risk of Sudden Death in Heart Failure. 
  • Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction. 
  • Declining in-hospital mortality in patients undergoing coronary bypass surgery in the United States irrespective of presence of type 2 diabetes or congestive heart failure. 
  • Deconditioning fails to explain peripheral skeletal muscle alterations in men with chronic heart failure. 
  • Decongestion in acute heart failure. 
  • Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. 
  • Defects in cardiomyocyte function: role of beta-adrenergic receptor dysfunction. 
  • Defibrillators: Selecting the Right Device for the Right Patient. 
  • Defining and refining heart failure risk stratification to optimize patient selection for cardiac transplantation. 
  • Defining heart failure end points in ST-segment elevation myocardial infarction trials: integrating past experiences to chart a path forward. 
  • Delivering heart failure disease management in 3 tertiary care centers: key clinical components and venues of care. 
  • Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. 
  • Depression and clinical outcomes in heart failure: an OPTIMIZE-HF analysis. 
  • Depression and heart failure in patients with a new myocardial infarction. 
  • Depression and major outcomes in older patients with heart failure. 
  • Depression in Heart Failure: Beyond a SADHART. 
  • Depression in hospitalized older patients with congestive heart failure. 
  • Depression in male and female patients undergoing cardiac surgery. 
  • Depression outcome in inpatients with congestive heart failure. 
  • Depression: are we ignoring an important comorbidity in heart failure? 
  • Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. 
  • Design and baseline data from the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized controlled trial. 
  • Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. 
  • Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure. 
  • Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. 
  • Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure. 
  • Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b). 
  • Design of design papers. 
  • Design of the RELAXin in acute heart failure study. 
  • Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. 
  • Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. 
  • Detection of tricuspid regurgitation with two-dimensional echocardiography and peripheral vein injections. 
  • Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. 
  • Determinants of variable exercise performance among patients with severe left ventricular dysfunction. 
  • Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (β-Blocker Evaluation of Survival Trial [BEST]). 
  • Determination of optimal duration of mechanical unloading for failing hearts to achieve bridge to recovery in a rat heterotopic heart transplantation model. 
  • Developing Breakthrough Drugs for Heart Failure: Lessons Learned From the Cystic Fibrosis Experience. 
  • Developing New Treatments for Heart Failure: Focus on the Heart. 
  • Developing therapies for heart failure with preserved ejection fraction: current state and future directions. 
  • Development and validation of a risk model for in-hospital worsening heart failure from the Acute Decompensated Heart Failure National Registry (ADHERE). 
  • Development of Acute Decompensated Heart Failure Therapies: Is the Journey Over? 
  • Development of a Metastatic Spinal Tumor Frailty Index (MSTFI) Using a Nationwide Database and Its Association with Inpatient Morbidity, Mortality, and Length of Stay After Spine Surgery. 
  • Development of a Pediatric Cardiac Mechanical Support Program. 
  • Development of a method to risk stratify patients with heart failure for 30-day readmission using implantable device diagnostics. 
  • Device therapy in heart failure patients with chronic kidney disease. 
  • Device therapy in the management of congestive heart failure. 
  • Diabetes and heart failure in the crosshairs: where is the target? 
  • Diabetes, quality of care, and in-hospital outcomes in patients hospitalized with heart failure. 
  • Diabetic retinopathy and risk of heart failure. 
  • Diagnostic and Prognostic Utility of Procalcitonin in Patients Presenting to the Emergency Department with Dyspnea. 
  • Diagnostic characteristics of combining phonocardiographic third heart sound and systolic time intervals for the prediction of left ventricular dysfunction. 
  • Diagnostic monitoring strategies in heart failure management. 
  • Diagnostic usefulness and prognostic implications of the mitral E/E' ratio in patients with heart failure and severe secondary mitral regurgitation. 
  • Diastolic dysfunction: old dog, new tricks. 
  • Diastolic heart failure and continuous hemodynamic monitoring. 
  • Dichotomous Relationship Between Age and 30-Day Death or Rehospitalization in Heart Failure Patients Admitted With Acute Decompensated Heart Failure: Results From the ASCEND-HF Trial. 
  • Diet and Exercise for Obese Patients With Heart Failure--Reply. 
  • Differences Between Patients Enrolled Early and Late During Clinical Trial Recruitment: Insights From the HF-ACTION Trial. 
  • Differences between depressed patients with heart failure and those with pulmonary disease. 
  • Differences in health care use and outcomes by the timing of in-hospital worsening heart failure. 
  • Differences in treatment, outcomes, and quality of life among patients with heart failure in Canada and the United States. 
  • Differential Response to Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Reduced or Preserved Ejection Fraction: Results From the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). 
  • Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure. 
  • Differential effects of exercise training in men and women with chronic heart failure. 
  • Differential gene expression and genomic patient stratification following left ventricular assist device support. 
  • Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. 
  • Digoxin and Mortality in Patients With Atrial Fibrillation. 
  • Digoxin measurements following plasma ultrafiltration in two patients with digoxin toxicity treated with specific Fab fragments. 
  • Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). 
  • Diminishment of respiratory sinus arrhythmia foreshadows doxorubicin-induced cardiomyopathy. 
  • Discharge heart rate and β-blocker dose in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF registry. 
  • Discharge to a skilled nursing facility and subsequent clinical outcomes among older patients hospitalized for heart failure. 
  • Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. 
  • Discordant Perceptions of Prognosis and Treatment Options Between Physicians and Patients With Advanced Heart Failure. 
  • Discovery of Genetic Variation on Chromosome 5q22 Associated with Mortality in Heart Failure. 
  • Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community. 
  • Disease management interventions to improve outcomes in congestive heart failure. 
  • Disease management of congestive heart failure. 
  • Disease management produces limited quality-of-life improvements in patients with congestive heart failure: evidence from a randomized trial in community-dwelling patients. 
  • Disparities in access to left ventricular assist device therapy. 
  • Disparity Between Indications for and Utilization of Implantable Cardioverter Defibrillators in Asian Patients With Heart Failure. 
  • Disrupted junctional membrane complexes and hyperactive ryanodine receptors after acute junctophilin knockdown in mice. 
  • Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure. 
  • Dissociation of the prostaglandin and renin angiotensin systems during captopril therapy for chronic congestive heart failure secondary to coronary artery disease. 
  • Distinct roles of resident and nonresident macrophages in nonischemic cardiomyopathy. 
  • Diuretic Treatment in Heart Failure. 
  • Diuretic Treatment in Heart Failure. 
  • Diuretic management in heart failure. 
  • Diuretic resistance predicts mortality in patients with advanced heart failure. 
  • Diuretic response in acute heart failure-an analysis from ASCEND-HF. 
  • Diuretic response in acute heart failure: clinical characteristics and prognostic significance. 
  • Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcome--an analysis from RELAX-AHF. 
  • Diuretic strategies in patients with acute decompensated heart failure. 
  • Diuretics and ultrafiltration in acute decompensated heart failure. 
  • Do cardiac troponins provide prognostic insight in hemodialysis patients? 
  • Do countries or hospitals with longer hospital stays for acute heart failure have lower readmission rates?: Findings from ASCEND-HF. 
  • Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. 
  • Do heart failure disease management programs make financial sense under a bundled payment system? 
  • Do physicians' attitudes toward implantable cardioverter defibrillator therapy vary by patient age, gender, or race? 
  • Do we really need more biomarkers? 
  • Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? 
  • Does Favorable Selection Among Medicare Advantage Enrollees Affect Measurement of Hospital Readmission Rates? 
  • Does Institutional Memory Matter? 
  • Does Survival on the Heart Transplant Waiting List Depend on the Underlying Heart Disease? 
  • Does a hypertonic saline load predict fluid retention in pacing induced heart failure? 
  • Does a pre-left ventricular assist device screening score predict long-term transplantation success? A 2-center analysis. 
  • Does aspirin use adversely influence intermediate-term postdischarge outcomes for hospitalized patients who are treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers? Findings from Organized Program to Facilitate Life-Saving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Does heart failure etiology, New York Heart Association class, or ejection fraction affect the ability of clopidogrel to inhibit heightened platelet activity? 
  • Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. 
  • Does low bone mineral density cause a broken heart? 
  • Does method of sternal repair influence long-term outcome of postoperative mediastinitis? 
  • Does palliative home oxygen improve dyspnoea? A consecutive cohort study. 
  • Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? 
  • Does the relationship between natriuretic hormones and diastolic function differ by race? 
  • Domain Management Approach to Heart Failure in the Geriatric Patient: Present and Future. 
  • Door-to-Furosemide Therapy in the ED: New Quality Metric or Just a Piece of the Puzzle? 
  • Doppler-detected valve movement in aortic stenosis: a predictor of adverse outcome. 
  • Dose Response of β-Blockers in Adrenergic Receptor Polymorphism Genotypes. 
  • Dose of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers and Outcomes in Heart Failure: A Meta-Analysis. 
  • Dosing of beta-blocker therapy before, during, and after hospitalization for heart failure (from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). 
  • Dosing recommendations and prescribing patterns for depressed medically ill hospitalized older patients. 
  • Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). 
  • Dronedarone in high-risk permanent atrial fibrillation. 
  • Drug Development for Heart Failure With Preserved Ejection Fraction: What Pieces Are Missing From the Puzzle? 
  • Dual natriuretic peptide system in experimental heart failure. 
  • Dual renin-angiotensin system blockade in heart failure. 
  • Durability and clinical impact of tricuspid valve procedures in patients receiving a continuous-flow left ventricular assist device. 
  • Durable mechanical circulatory support devices. 
  • Dynamic regulation of phosphoinositide 3-kinase-gamma activity and beta-adrenergic receptor trafficking in end-stage human heart failure. 
  • Dysautonomia due to reduced cholinergic neurotransmission causes cardiac remodeling and heart failure. 
  • Dysphagia in the setting of left ventricular assist device hemolysis. 
  • Dyspnea and pain frequently co-occur among Medicare managed care recipients. 
  • Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. 
  • Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study. 
  • ECG quantification of myocardial scar and risk stratification in MADIT-II. 
  • ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. 
  • Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF). 
  • Early Ambulation Among Hospitalized Heart Failure Patients Is Associated With Reduced Length of Stay and 30-Day Readmissions. 
  • Early and long-term outcomes of heart failure in elderly persons, 2001-2005. 
  • Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. 
  • Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. 
  • Early fetal hypoxia leads to growth restriction and myocardial thinning. 
  • Early impact of guideline publication on angiotensin-receptor neprilysin inhibitor use among patients hospitalized for heart failure. 
  • Early intravenous heart failure therapy and outcomes among older patients hospitalized for acute decompensated heart failure: findings from the Acute Decompensated Heart Failure Registry Emergency Module (ADHERE-EM). 
  • Early management of patients with acute heart failure: state of the art and future directions--a consensus document from the SAEM/HFSA acute heart failure working group. 
  • Early management of patients with acute heart failure: state of the art and future directions. A consensus document from the society for academic emergency medicine/heart failure society of America acute heart failure working group. 
  • Early planned institution of biventricular mechanical circulatory support results in improved outcomes compared with delayed conversion of a left ventricular assist device to a biventricular assist device. 
  • Early recovery from heart failure: insights into the pathogenesis of experimental chronic pacing-induced heart failure. 
  • Early versus late readmission during the vulnerable phase following hospitalization for heart failure: reply. 
  • Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. 
  • Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis? 
  • Easy to Predict, Difficult to Prevent. 
  • Echocardiographic documentation of vegetative lesions in infective endocarditis: clinical implications. 
  • Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography. 
  • Economic and Quality-of-Life Outcomes of Natriuretic Peptide-Guided Therapy for Heart Failure. 
  • Economic burden of heart failure in the elderly. 
  • Economic effects of beta-blocker therapy in patients with heart failure. 
  • Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure. 
  • Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. ACE inhibitors in the management of congestive heart failure: comparative economic data. 
  • Economics of treating heart failure. 
  • Editorial Commentary: Determining the cost-effectiveness of mechanical circulatory support. 
  • Educational attainment has a limited impact on disease management outcomes in heart failure. 
  • Educational videos to reduce racial disparities in ICD therapy via innovative designs (VIVID): a randomized clinical trial. 
  • Effect of Age and Renal Function on Survival After Left Ventricular Assist Device Implantation. 
  • Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). 
  • Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. 
  • Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: The INDIE-HFpEF Randomized Clinical Trial. 
  • Effect of Natriuretic Peptide-Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. 
  • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. 
  • Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. 
  • Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial. 
  • Effect of admission oral diuretic dose on response to continuous versus bolus intravenous diuretics in acute heart failure: an analysis from diuretic optimization strategies in acute heart failure. 
  • Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. 
  • Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. 
  • Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlodipine Survival Evaluation. 
  • Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. 
  • Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRAISE-2 study (prospective randomized amlodipine survival evaluation 2). 
  • Effect of angiotensin-converting enzyme inhibitors, beta blockers, statins, and aspirin on C-reactive protein levels in outpatients with heart failure. 
  • Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction. 
  • Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. 
  • Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. 
  • Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. 
  • Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis. 
  • Effect of defibrillation threshold testing on heart failure hospitalization or death in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). 
  • Effect of exercise training on ventricular function, dyssynchrony, resting myocardial perfusion, and clinical outcomes in patients with heart failure: a nuclear ancillary study of Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION); design and rationale. 
  • Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuous-flow left ventricular assist device. A double-blind randomized study. 
  • Effect of minor liver function test abnormalities and values within the normal range on survival in heart failure. 
  • Effect of nesiritide in patients with acute decompensated heart failure. 
  • Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. 
  • Effect of penicillin resistance of Streptococcus pneumoniae on the presentation, prognosis, and treatment of pneumococcal endocarditis in adults. 
  • Effect of peripheral arterial disease on functional and clinical outcomes in patients with heart failure (from HF-ACTION). 
  • Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. 
  • Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort. 
  • Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. 
  • Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study. 
  • Effectiveness and Safety of Aldosterone Antagonist Therapy Use Among Older Patients With Reduced Ejection Fraction After Acute Myocardial Infarction. 
  • Effectiveness of Cardiac Resynchronization Therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). 
  • Effectiveness of an Intervention Supporting Shared Decision Making for Destination Therapy Left Ventricular Assist Device: The DECIDE-LVAD Randomized Clinical Trial. 
  • Effectiveness of percutaneous balloon mitral valvotomy during pregnancy. 
  • Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. 
  • Effects of BG9928, an adenosine A₁ receptor antagonist, in patients with congestive heart failure. 
  • Effects of Coping Skills Training on Quality of Life, Disease Biomarkers, and Clinical Outcomes in Patients With Heart Failure: A Randomized Clinical Trial. 
  • Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. 
  • Effects of Serelaxin in Patients with Acute Heart Failure. 
  • Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. 
  • Effects of a structured heart failure program on quality of life and frequency of hospital admission in Saudi Arabia. 
  • Effects of admission to a teaching hospital on the cost and quality of care for Medicare beneficiaries. 
  • Effects of amino acid supplementation on left ventricular remodeling in patients with chronic heart failure with decreased systolic function and diabetes mellitus: rationale and design of a magnetic resonance imaging study. 
  • Effects of biventricular pacing on left heart twist and strain in a porcine model of right heart failure. 
  • Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. 
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. 
  • Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. 
  • Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. 
  • Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. 
  • Effects of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. 
  • Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. 
  • Effects of exercise training on health status in patients with chronic heart failure: HF-ACTION randomized controlled trial. 
  • Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure. 
  • Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. 
  • Effects of mindfulness training programmes delivered by a self-directed mobile app and by telephone compared with an education programme for survivors of critical illness: a pilot randomised clinical trial. 
  • Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (acute study of clinical effectiveness of nesiritide and decompensated heart failure). 
  • Effects of nitric oxide after cardiac transplantation in the setting of recipient pulmonary hypertension. 
  • Effects of propranolol treatment on left ventricular function and intracellular calcium regulation in rats with postinfarction heart failure. 
  • Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. 
  • Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. 
  • Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. 
  • Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. 
  • Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction. 
  • Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). 
  • Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes. 
  • Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. 
  • Efficacy and Safety of Spironolactone in Acute Heart Failure: The ATHENA-HF Randomized Clinical Trial. 
  • Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure. 
  • Efficacy and durability of central oversewing for treatment of aortic insufficiency in patients with continuous-flow left ventricular assist devices. 
  • Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. 
  • Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus. Results from the ATLAS trial. 
  • Efficacy and safety of nesiritide in patients with acute decompensated heart failure. 
  • Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. 
  • Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. 
  • Efficacy of Intravenous Furosemide Versus a Novel, pH-Neutral Furosemide Formulation Administered Subcutaneously in Outpatients With Worsening Heart Failure. 
  • Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. 
  • Efficacy of signal-averaged electrocardiography in the young orthotopic heart transplant patient to detect allograft rejection. 
  • Efficacy of zoniporide, an Na/H exchange ion inhibitor, for reducing perioperative cardiovascular events in vascular surgery patients. 
  • Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Ejection fraction, B-type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure. 
  • Electrocardiographic QRS duration and the risk of congestive heart failure: the Framingham Heart Study. 
  • Electromechanical associations. 
  • Electronic health records and quality of care for heart failure. 
  • Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure. 
  • Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. 
  • Elevated preoperative heart rate is associated with cardiopulmonary and autonomic impairment in high-risk surgical patients. 
  • Eliminating racial and ethnic disparities in cardiac care. 
  • Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. 
  • Emerging Therapies for Congestive Heart Failure. 
  • Emerging biomarkers in heart failure. 
  • Emerging role of the tissue renin-angiotensin systems in congestive heart failure. 
  • Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. 
  • Empagliflozin reduces the risk of a broad spectrum of heart failure outcomes regardless of heart failure status at baseline. 
  • Enalapril in infants with single ventricle: results of a multicenter randomized trial. 
  • End point selection in acute decompensated heart failure clinical trials: economic end points. 
  • End points for clinical trials in acute heart failure syndromes. 
  • End-of-life Heart Failure Care in the United States. 
  • End-of-life care in patients with implantable cardioverter defibrillators: a MADIT-II substudy. 
  • Endothelial nitric oxide synthase increases in left atria of dogs with pacing-induced heart failure. 
  • Endothelium modulation of the effects of nitroglycerin on blood vessels from dogs with pacing-induced heart failure. 
  • Endothelium-dependent relaxations in canine coronary arteries are enhanced in early heart failure and persist in recovery. 
  • Endpoints for diuresis: are we there yet? 
  • Endurance training modulates lymphocyte function in rats with post-MI CHF. 
  • Energetics and metabolism in the failing heart: important but poorly understood. 
  • Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. 
  • Engaging patients and families to create a feasible clinical trial integrating palliative and heart failure care: results of the ENABLE CHF-PC pilot clinical trial. 
  • Enhanced External Counterpulsation (EECP): enough evidence to support this and the next wave? 
  • Enhanced access to primary care for patients with congestive heart failure. Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. 
  • Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. 
  • Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. 
  • Enhancement of cardiac function after adenoviral-mediated in vivo intracoronary beta2-adrenergic receptor gene delivery. 
  • Enrollment and events of hospice patients with heart failure vs. cancer. 
  • Enrollment in Heart Failure Clinical Trials: Insights Into Which Entry Criteria Exclude Patients. 
  • Enrollment of Older Patients, Women, and Racial and Ethnic Minorities in Contemporary Heart Failure Clinical Trials: A Systematic Review. 
  • Enterococcal endocarditis in the beginning of the 21st century: analysis from the International Collaboration on Endocarditis-Prospective Cohort Study. 
  • Epidemiology and risk factors for heart failure in the elderly. 
  • Epidemiology of cardiorenal syndrome. 
  • Epidemiology of cardiorenal syndrome. 
  • Epidemiology of drug-disease interactions in older veteran nursing home residents. 
  • Epidemiology, Clinical Features, and Outcome of Infective Endocarditis due to Abiotrophia Species and Granulicatella Species: Report of 76 Cases, 2000-2015. 
  • Epidemiology, management, and outcomes of sustained ventricular arrhythmias after continuous-flow left ventricular assist device implantation. 
  • Epidemiology, pathophysiology, and in-hospital management of pulmonary edema: data from the Romanian Acute Heart Failure Syndromes registry. 
  • Eplerenone in mild heart failure. 
  • Eplerenone in patients with acute myocardial infarction complicated by heart failure. 
  • Equitable improvement for women and men in the use of guideline-recommended therapies for heart failure: findings from IMPROVE HF. 
  • Equivalence Ratio for Daunorubicin to Doxorubicin in Relation to Late Heart Failure in Survivors of Childhood Cancer. 
  • Erythropoietin treatment in patients with chronic heart failure: a meta-analysis. 
  • Erythropoietin, haemoglobin, heart failure, and mortality. 
  • Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials. 
  • Established and Emerging Roles of Biomarkers in Heart Failure. 
  • Establishing a pragmatic framework to optimise health outcomes in heart failure and multimorbidity (ARISE-HF): A multidisciplinary position statement. 
  • Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. 
  • Evaluating Discrimination of Risk Prediction Models: The C Statistic. 
  • Evaluating strict and conventional left bundle branch block criteria using electrocardiographic simulations. 
  • Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: analyzing data using a global method. 
  • Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE): design and rationale. 
  • Evaluation of New-Onset Ascites. 
  • Evaluation of Novel Metrics of Symptom Relief in Acute Heart Failure: The Worst Symptom Score. 
  • Evaluation of a provocative dyspnea severity score in acute heart failure. 
  • Evaluation of heart failure websites for patient education. 
  • Evaluation of indices of left ventricular contractility and relaxation in evolving canine experimental heart failure. 
  • Evaluation of mechanical dyssynchrony and myocardial perfusion using phase analysis of gated SPECT imaging in patients with left ventricular dysfunction. 
  • Evaluation of platelets in heart failure: is platelet activity related to etiology, functional class, or clinical outcomes? 
  • Evaluation of risk indices in continuous-flow left ventricular assist device patients. 
  • Evaluation of the Incremental Prognostic Utility of Increasingly Complex Testing in Chronic Heart Failure. 
  • Evaluation of the role of endomyocardial biopsy in 851 patients with unexplained heart failure from 2000-2009. 
  • Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. 
  • Evidence for tissue-specific activation of renal angiotensinogen mRNA expression in chronic stable experimental heart failure. 
  • Evidence of clinical practice heterogeneity in the use of implantable cardioverter-defibrillators in heart failure and post-myocardial infarction left ventricular dysfunction: Findings from IMPROVE HF. 
  • Evolution of Left Ventricular Assist Device Therapy for Advanced Heart Failure: A Review. 
  • Evolution of amino-terminal pro-B type natriuretic peptide testing in heart failure. 
  • Evolution of natriuretic peptide biomarkers in heart failure: Implications for clinical care and clinical trials. 
  • Examining the interrelatedness of patient and spousal stress in heart failure: conceptual model and pilot data. 
  • Excess body mass index- and waist circumference-years and incident cardiovascular disease: the CARDIA study. 
  • Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. 
  • Exercise blood pressure response during assisted circulatory support: comparison of the total artificial [corrected] heart with a left ventricular assist device during rehabilitation. 
  • Exercise capacity and mortality in patients with ischemic left ventricular dysfunction randomized to coronary artery bypass graft surgery or medical therapy: an analysis from the STICH trial (Surgical Treatment for Ischemic Heart Failure). 
  • Exercise training and implantable cardioverter-defibrillator shocks in patients with heart failure: results from HF-ACTION (Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing). 
  • Exercise training and pacing status in patients with heart failure: results from HF-ACTION. 
  • Exercise training as therapy for heart failure: current status and future directions. 
  • Exercise training changes IL-10/TNF-alpha ratio in the skeletal muscle of post-MI rats. 
  • Exercise training for chronic heart failure (ExTraMATCH II): protocol for an individual participant data meta-analysis. 
  • Exercise training of patients with ventricular dysfunction and heart failure. 
  • Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology. 
  • Exertional dyspnea in heart failure: a symptom unrelated to pulmonary function at rest or during exercise. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group. 
  • Experimental congestive heart failure produced by rapid ventricular pacing in the dog: cardiac effects. 
  • Expert consensus document: Mitochondrial function as a therapeutic target in heart failure. 
  • Exploring New Cardiovascular Pathways: Are Soluble Guanylate Cyclase Stimulators the Right Direction? 
  • Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction. 
  • Exploring the role of the beta-adrenergic receptor kinase in cardiac disease using gene-targeted mice. 
  • Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. 
  • Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. 
  • Extent of coronary artery disease as a predictor of outcomes in acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. 
  • Extracorporeal membrane oxygenation support and post-heart transplant outcomes among United States adults. 
  • FDA in the 21st Century: Focus on Tobacco Policies and Heart Failure Prevention. 
  • Factors Associated With and Prognostic Implications of Cardiac Troponin Elevation in Decompensated Heart Failure With Preserved Ejection Fraction: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program. 
  • Factors associated with improvement in ejection fraction in clinical practice among patients with heart failure: findings from IMPROVE HF. 
  • Factors associated with improvement in guideline-based use of ICDs in eligible heart failure patients. 
  • Factors associated with improvement in utilization of cardiac resynchronization therapy in eligible heart failure patients: findings from IMPROVE HF. 
  • Factors associated with isolated right heart failure in women: a pilot study from western Kenya. 
  • Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. 
  • Factors related to morbidity and mortality in patients with chronic heart failure with systolic dysfunction: the HF-ACTION predictive risk score model. 
  • Failure of platelet parameters and biomarkers to correlate platelet function to severity and etiology of heart failure in patients enrolled in the EPCOT trial. With special reference to the Hemodyne hemostatic analyzer. Whole Blood Impedance Aggregometry for the Assessment of Platelet Function in Patients with Congestive Heart Failure. 
  • Familial aggregation of left ventricular geometry and association with parental heart failure: the Framingham Heart Study. 
  • Family history of dilated cardiomyopathy among patients with heart failure from the HF-ACTION genetic ancillary study. 
  • Fatal myocardial rupture after acute myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALsartan In Acute myocardial iNfarcTion Trial (VALIANT). 
  • Fatigability, Exercise Intolerance, and Abnormal Skeletal Muscle Energetics in Heart Failure. 
  • Feasibility and safety of moderate hypothermia after massive hemispheric infarction. 
  • Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. 
  • Fibroblast growth factor-23 and cardiovascular events in CKD. 
  • Financial implications of a model heart failure disease management program for providers, hospital, healthcare systems, and payer perspectives. 
  • Finding the road to recovery: therapeutic and clinical trial implications of dysfunctional viable myocardium in heart failure with reduced ejection fraction. 
  • Finerenone in heart failure: walking a fine line. 
  • First Medical Contact-to-Device Time and Heart Failure Outcomes Among Patients Undergoing Primary Percutaneous Coronary Intervention. 
  • First successful bridge to cardiac transplantation using direct mechanical ventricular actuation. 
  • First-degree AV block-an entirely benign finding or a potentially curable cause of cardiac disease? 
  • Fluid removal in acute heart failure: diuretics versus devices. 
  • Focused cardiac ultrasound as a predictor of readmission in acute decompensated heart failure. 
  • Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. 
  • Frailty in the End-Stage Lung Disease or Heart Failure Patient: Implications for the Perioperative Transplant Clinician. 
  • Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST-segment elevation acute myocardial infarction: lessons from 4 international fibrinolytic therapy trials. 
  • From acute decompensated to chronic heart failure. 
  • Functional status in left ventricular assist device-supported patients: a literature review. 
  • Further aspects of anemia, heart failure, and erythropoietin. 
  • Fusion of aortic valve commissures in patients supported by a continuous axial flow left ventricular assist device. 
  • G protein-coupled receptor signalling in in vivo cardiac overload. 
  • G-Protein-Coupled Receptors in Heart Disease. 
  • G-protein-coupled receptor function in heart failure. 
  • GIANT PATENT DUCTUS ARTERIOSUS. 
  • GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study. 
  • Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. 
  • Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. 
  • Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. 
  • Galectin-3 in heart failure: more answers or more questions? 
  • Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. 
  • Gastrointestinal bleeding in high risk survivors of myocardial infarction: the VALIANT Trial. 
  • Gender does not affect postdischarge outcomes in patients hospitalized for worsening heart failure with reduced ejection fraction (from the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan [EVEREST] Trial). 
  • Gene delivery approaches to heart failure treatment. 
  • Gene expression analysis of cardiovascular diseases: novel insights into biology and clinical applications. 
  • Gene therapy and genomic strategies for cardiovascular surgery: The emerging field of surgiomics. 
  • Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. 
  • Genetic variants are not associated with outcome in patients with coronary artery disease and left ventricular dysfunction: results of the Genetic Substudy of the Surgical Treatment for Ischemic Heart Failure (STICH) trials. 
  • Genomics and the circulation. 
  • Genomics and the pathophysiology of heart failure. 
  • Geographic Differences in Patients in a Global Acute Heart Failure Clinical Trial (from the ASCEND-HF Trial). 
  • Get With The Guidelines program participation, process of care, and outcome for Medicare patients hospitalized with heart failure. 
  • Gleaning physiologic information from the conventional chest radiograph. 
  • Glenn shunt facilitated weaning of right ventricular mechanical support. 
  • Global Variations in Patient Populations and Outcomes in Heart Failure Clinical Trials. 
  • Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes. 
  • Global variation in clinical profile, management, and post-discharge outcomes among patients hospitalized for worsening chronic heart failure: findings from the ASTRONAUT trial. 
  • Global variation in quality of care among patients hospitalized with acute heart failure in an international trial: findings from the acute study clinical effectiveness of nesiritide in decompensated heart failure trial (ASCEND-HF). 
  • Glycated Hemoglobin and Outcomes of Heart Failure (from Get With the Guidelines-Heart Failure). 
  • Glycogen-branching enzyme deficiency leads to abnormal cardiac development: novel insights into glycogen storage disease IV. 
  • Grassroots marketing in a global era: more lessons from BiDil. 
  • Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. 
  • Guideline-Appropriate Care and In-Hospital Outcomes in Patients With Heart Failure in Teaching and Nonteaching Hospitals: Findings From Get With The Guidelines-Heart Failure. 
  • HFSA 2010 Comprehensive Heart Failure Practice Guideline. 
  • HFpEF: From Early Observations to Worldwide Awareness. 
  • HVAD: The ENDURANCE Supplemental Trial. 
  • Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. 
  • Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. 
  • Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction. 
  • Haplo-insufficiency of Bcl2-associated athanogene 3 in mice results in progressive left ventricular dysfunction, β-adrenergic insensitivity, and increased apoptosis. 
  • Happy 50th Birthday, Cardiac Transplantation: Happy 5th Birthday, JACC: Heart Failure. 
  • Has Public Reporting of Hospital Readmission Rates Affected Patient Outcomes?: Analysis of Medicare Claims Data. 
  • HbA 1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. 
  • Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. 
  • Health Status Disparities by Sex, Race/Ethnicity, and Socioeconomic Status in Outpatients With Heart Failure. 
  • Health Status Variation Across Practices in Outpatients With Heart Failure: Insights From the CHAMP-HF (Change the Management of Patients With Heart Failure) Registry. 
  • Health status and depression remission in patients with chronic heart failure: patient-reported outcomes from the SADHART-CHF trial. 
  • Health status identifies heart failure outpatients at risk for hospitalization or death. 
  • Healthcare Resource Use and Cost Implications in the MOMENTUM 3 Long-Term Outcome Study. 
  • Heart Failure "End Result Cards": Solid B. 
  • Heart Failure Clinical Trials in East and Southeast Asia: Understanding the Importance and Defining the Next Steps. 
  • Heart Failure Complicated by Atrial Fibrillation: Don't Bury the Beta-Blockers Just Yet. 
  • Heart Failure Epidemiology in Patients With Diabetes Mellitus Without Coronary Heart Disease. 
  • Heart Failure Health Care 2018: Challenges and Opportunities. 
  • Heart Failure Is Common and Under-Recognized in Patients With Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. 
  • Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. 
  • Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. 
  • Heart Failure With Reduced Ejection Fraction in Human Immunodeficiency Virus Infection: The More Things Stay the Same. 
  • Heart Failure in Non-Caucasians, Women, and Older Adults: A White Paper on Special Populations From the Heart Failure Society of America Guideline Committee. 
  • Heart Rate or Beta-Blocker Dose? Association With Outcomes in Ambulatory Heart Failure Patients With Systolic Dysfunction: Results From the HF-ACTION Trial. 
  • Heart Transplantation and Mechanical Circulatory Support in Adults with Congenital Heart Disease. 
  • Heart failure after myocardial infarction: A good heart is hard to find. 
  • Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. 
  • Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and rationale. 
  • Heart failure and cyanosis in a newborn. 
  • Heart failure and depression. 
  • Heart failure and the elderly: disease diversity, data, and delivery of care. 
  • Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. 
  • Heart failure complicating non-ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. 
  • Heart failure disease management program experience in 4,545 heart failure admissions to a community hospital. 
  • Heart failure drug treatment. 
  • Heart failure during cardiac pacing. 
  • Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. 
  • Heart failure event definitions in drug trials in patients with type 2 diabetes. 
  • Heart failure hospitalization is more common in pacemaker patients with sinus node dysfunction and a prolonged paced QRS duration. 
  • Heart failure in 2010: one step forward, two steps back. 
  • Heart failure in elderly patients: distinctive features and unresolved issues. 
  • Heart failure in sub-Saharan Africa. 
  • Heart failure medications prescribed at discharge for patients with left ventricular assist devices. 
  • Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry. 
  • Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity-score matched study. 
  • Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy (PROTECT) study. 
  • Heart failure performance measures and outcomes: real or illusory gains. 
  • Heart failure preserved ejection fraction (HFpEF): an integrated and strategic review. 
  • Heart failure severity, inappropriate ICD therapy, and novel ICD programming: a MADIT-RIT substudy. 
  • Heart failure survival score in patients with Chagas disease: correlation with functional variables. 
  • Heart failure therapeutics on the basis of a biased ligand of the angiotensin-2 type 1 receptor. Rationale and design of the BLAST-AHF study (Biased Ligand of the Angiotensin Receptor Study in Acute Heart Failure). 
  • Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. 
  • Heart failure with preserved ejection fraction: a nephrologist-directed primer. 
  • Heart failure with preserved ejection fraction: comparison of patients with and without angina pectoris (from the Duke Databank for Cardiovascular Disease). 
  • Heart failure with preserved left ventricular systolic function among patients with non-ST-segment elevation acute coronary syndromes. 
  • Heart failure with reduced ejection fraction. 
  • Heart failure: evaluation and care of patients with left ventricular systolic dysfunction. 
  • Heart failure: management of patients with left ventricular systolic dysfunction. Agency for Health Care Policy and Research. 
  • Heart failure: where the paths cross. 
  • Heart rate at hospital discharge in patients with heart failure is associated with mortality and rehospitalization. 
  • Heart rate control in chronic heart failure: resting versus mean heart rate with prolonged ambulatory ECG recording. 
  • Heart rate is associated with progression of atrial fibrillation, independent of rhythm. 
  • Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. 
  • Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. 
  • Heart transplantation for adults with congenital heart disease: analysis of the United network for organ sharing database. 
  • Heart transplantation in children with markedly elevated pulmonary vascular resistance: impact of right ventricular failure on outcome. 
  • Heartmate III Replacement for Recurring Left Ventricular Assist Device Pump Thrombosis. 
  • Hemiazygous coil placement for high-defibrillation thresholds in a patient with a right-sided implantable cardioverter defibrillator. 
  • Hemocompatibility-Related Outcomes in the MOMENTUM 3 Trial at 6 Months: A Randomized Controlled Study of a Fully Magnetically Levitated Pump in Advanced Heart Failure. 
  • Hemoconcentration-guided diuresis in heart failure. 
  • Hemodynamic Predictors of Heart Failure Morbidity and Mortality: Fluid or Flow? 
  • Hemodynamic effects of labetalol in patients with combined hypertension and left ventricular failure. 
  • Hemodynamic evaluation of glucagon in symptomatic heart disease. 
  • Hemodynamic profiles of advanced heart failure: association with clinical characteristics and long-term outcomes. 
  • Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. 
  • Hemoglobin S-nitrosylation plays an essential role in cardioprotection. 
  • Hemoglobin and N-terminal pro-brain natriuretic peptide: Independent and synergistic predictors of mortality in patients with acute heart failure Results from the International Collaborative of NT-proBNP (ICON) Study. 
  • Hemoglobin, exercise training, and health status in patients with chronic heart failure (from the HF-ACTION randomized controlled trial). 
  • Hemostatic abnormalities in patients with congestive heart failure: diagnostic significance and clinical challenge. 
  • High Heart Failure Readmission Rates: Is It the Health System's Fault? 
  • High early event rates in patients with questionable eligibility for advanced heart failure therapies: Results from the Medical Arm of Mechanically Assisted Circulatory Support (Medamacs) Registry. 
  • High mortality without ESCAPE: the registry of heart failure patients receiving pulmonary artery catheters without randomization. 
  • High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. 
  • High-Sensitivity Troponin I in Hospitalized and Ambulatory Patients With Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. 
  • High-dose influenza vaccine to reduce clinical outcomes in high-risk cardiovascular patients: Rationale and design of the INVESTED trial. 
  • High-normal albuminuria and risk of heart failure in the community. 
  • High-output cardiac failure in fetuses with large sacrococcygeal teratoma: diagnosis by echocardiography and Doppler ultrasound. 
  • High-sensitivity C-reactive protein in acute heart failure: insights from the ASCEND-HF trial. 
  • High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study. 
  • High-sensitivity troponin T, NT-proBNP and glomerular filtration rate: A multimarker strategy for risk stratification in chronic heart failure. 
  • Highlights of the 2007 Scientific Meeting of the Heart Failure Society of America: Washington, DC, September 16-19, 2007. 
  • Highlights of the 2008 Scientific Sessions of the Heart Failure Society of America. Toronto, Ontario, Canada, September 20-23, 2008. 
  • Highlights of the 2010 scientific sessions of the Heart Failure Society of America, San Diego, California, September 12-15, 2010. 
  • Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. 
  • Histologic and electron microscopy findings in myocardium of treated Fabry disease. 
  • Home-Time After Discharge Among Patients Hospitalized With Heart Failure. 
  • Hospital use and costs among patients with nonischemic cardiomyopathy in the first prospective randomized amlodipine survival evaluation study. 
  • Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry. 
  • Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines. 
  • Hospital-based quality improvement interventions for patients with heart failure: a systematic review. 
  • Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. 
  • Hospitalized Heart Failure in the United States: Lessons Learned from Clinical Trial Populations. 
  • How does intermittent pacing modify the response to rapid ventricular pacing in experimental heart failure? 
  • How many patients with heart failure are eligible for cardiac resynchronization? Insights from two prospective cohorts. 
  • Human Immunodeficiency Virus and Heart Failure in Low- and Middle-Income Countries. 
  • Hyperkalemia in Heart Failure: Probably Not O"K". 
  • Hypertension and heart failure. Roundtable discussion. 
  • Hypertension with acute coronary syndrome and heart failure. 
  • Hypertensive heart failure: patient characteristics, treatment, and outcomes. 
  • Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. 
  • Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. 
  • Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia. 
  • Hyponatremia and long-term outcomes in chronic heart failure--an observational study from the Duke Databank for Cardiovascular Diseases. 
  • Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. 
  • Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study. 
  • Hypoplastic right lung with systemic blood supply and anomalous pulmonary venous drainage: reversal of pulmonary hypertension with surgical management in infancy. 
  • Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HF. 
  • I Brazilian Registry of Heart Failure - Clinical Aspects, Care Quality and Hospitalization Outcomes. 
  • I Don't Care How Low My BNP Is, I Want to Feel Good. 
  • IGF-1 predicts survival in chronic heart failure. Insights from the T.O.S.CA. (Trattamento Ormonale Nello Scompenso CArdiaco) registry. 
  • IGFBP7 (Insulin-Like Growth Factor-Binding Protein-7) and Neprilysin Inhibition in Patients With Heart Failure. 
  • INDIE-HFpEF (Inorganic Nitrite Delivery to Improve Exercise Capacity in Heart Failure With Preserved Ejection Fraction): Rationale and Design. 
  • INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) Profiling Identifies Ambulatory Patients at High Risk on Medical Therapy After Hospitalizations for Heart Failure. 
  • INTERMACS: interval analysis of registry data. 
  • Identifying Barriers and Practical Solutions to Conducting Site-Based Research in North America: Exploring Acute Heart Failure Trials As a Case Study. 
  • Identifying responders to oral iron supplementation in heart failure with a reduced ejection fraction: a post-hoc analysis of the IRONOUT-HF trial. 
  • Identifying, recruiting, and retaining seriously-ill patients and their caregivers in longitudinal research. 
  • Imaging surrogate end points in heart failure trials. 
  • Impact of Current Versus Previous Cardiac Resynchronization Therapy Guidelines on the Proportion of Patients With Heart Failure Eligible for Therapy. 
  • Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. 
  • Impact of Ejection Fraction and Aortic Valve Gradient on Outcomes of Transcatheter Aortic Valve Replacement. 
  • Impact of Intubation Time on Survival following Coronary Artery Bypass Grafting: Insights from the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. 
  • Impact of Non-Infarct-Related Artery Disease on Infarct Size and Outcomes (from the CRISP-AMI Trial). 
  • Impact of a depression care management program for hospitalized cardiac patients. 
  • Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. 
  • Impact of advance care planning on the care of patients with heart failure: study protocol for a randomized controlled trial. 
  • Impact of age, sex, therapeutic intent, race and severity of advanced heart failure on short-term principal outcomes in the MOMENTUM 3 trial. 
  • Impact of an expanded hospital recognition program for heart failure quality of care. 
  • Impact of atrial fibrillation on exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. 
  • Impact of baseline heart failure burden on post-implantable cardioverter-defibrillator mortality among medicare beneficiaries. 
  • Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. 
  • Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction). 
  • Impact of center volume on outcomes of left ventricular assist device implantation as destination therapy: analysis of the Thoratec HeartMate Registry, 1998 to 2005. 
  • Impact of concurrent surgical valve procedures in patients receiving continuous-flow devices. 
  • Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. 
  • Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. 
  • Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Impact of enalapril therapy on in vitro coronary artery responsiveness in pacing-induced heart failure. 
  • Impact of exercise-based cardiac rehabilitation in patients with heart failure (ExTraMATCH II) on mortality and hospitalisation: an individual patient data meta-analysis of randomised trials. 
  • Impact of genetic polymorphisms on heart failure prognosis. 
  • Impact of heart failure on patients undergoing major noncardiac surgery. 
  • Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. 
  • Impact of immortal person-time and time scale in comparative effectiveness research for medical devices: a case for implantable cardioverter-defibrillators. 
  • Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. 
  • Impact of kidney dysfunction on plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute heart failure. 
  • Impact of mitral valve regurgitation evaluated by intraoperative transesophageal echocardiography on long-term outcomes after coronary artery bypass grafting. 
  • Impact of nonfatal myocardial infarction on outcomes in patients with advanced heart failure and the effect of bucindolol therapy. 
  • Impact of obesity on cardiovascular disease. 
  • Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study. 
  • Impact of specialist follow-up in outpatients with congestive heart failure. 
  • Impact of the 2014 expert panel recommendations for management of high blood pressure on contemporary cardiovascular practice: insights from the NCDR PINNACLE registry. 
  • Impact of tricuspid valve regurgitation in patients treated with implantable left ventricular assist devices. 
  • Impact of using a telescoping-support catheter system for left ventricular lead placement on implant success and procedure time of cardiac resynchronization therapy. 
  • Impairment of activities of daily living and incident heart failure in community-dwelling older adults. 
  • Implantable Cardioverter-Defibrillators in Patients With Left Ventricular Assist Devices: On Trial and in Need of a Trial. 
  • Implantable cardioverter defibrillators and cardiac resynchronization therapy in patients with left ventricular dysfunction: randomized trial evidence through 2004. 
  • Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions. 
  • Implantable cardioverter-defibrillator therapy and risk of congestive heart failure or death in MADIT II patients with atrial fibrillation. 
  • Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes. 
  • Implantable cardioverter-defibrillators in patients hospitalized for heart failure with chronically reduced left ventricular ejection fraction. 
  • Implantable cardioverter-defibrillators. 
  • Implantable left ventricular assist devices: new hope for patients with end-stage heart failure. 
  • Implementing Electronic Tablet-Based Education of Acute Care Patients. 
  • Implementing shared medical appointments for heart failure patients in a community cardiology practice: a pilot study. 
  • Implications of Alternative Hepatorenal Prognostic Scoring Systems in Acute Heart Failure (from DOSE-AHF and ROSE-AHF). 
  • Implications of Serum Chloride Homeostasis in Acute Heart Failure (from ROSE-AHF). 
  • Implications of Using Different Definitions on Outcomes in Worsening Heart Failure. 
  • Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. 
  • Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations. 
  • Importance of angina in patients with coronary disease, heart failure, and left ventricular systolic dysfunction: insights from STICH. 
  • Importance of echocardiography in patients with severe nonischemic heart failure: the second Prospective Randomized Amlodipine Survival Evaluation (PRAISE-2) echocardiographic study. 
  • Importance of rigorous evaluation in comparative biomarker studies. 
  • Improved early survival with a nonsternotomy approach for continuous-flow left ventricular assist device replacement. 
  • Improved outcome in heart failure. 
  • Improved survival in patients enrolled promptly into remote monitoring following cardiac implantable electronic device implantation. 
  • Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial. 
  • Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. 
  • Improvement in the function of hibernating myocardium in a patient with heart failure due to coronary artery disease receiving high-dose simvastatin. 
  • Improvement in the mechanical efficiency of walking: an explanation for the "placebo effect" seen during repeated exercise testing of patients with heart failure. Duke University Clinical Cardiology Studies (DUCCS) Exercise Group. 
  • Improvements in signs and symptoms during hospitalization for acute heart failure follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). 
  • Improving Congestive Heart Failure Care with a Clinical Decision Unit. 
  • Improving Heart Failure Therapeutics Development in the United States: The Heart Failure Collaboratory. 
  • Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. 
  • Improving evidence-based care for heart failure in outpatient cardiology practices: primary results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). 
  • Improving heart failure health: is there a secret Swedish sauce? 
  • Improving postdischarge outcomes in patients hospitalized for acute heart failure syndromes. 
  • Improving the Use of Primary Prevention Implantable Cardioverter-Defibrillators Therapy With Validated Patient-Centric Risk Estimates. 
  • Improving the diagnosis of acute heart failure using a validated prediction model. 
  • Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry. 
  • In Reply: B-type natriuretic peptide level and postdischarge thrombotic events in older patients hospitalized with heart failure: Insights from the ADHERE registry. 
  • In heart failure, automatic implant-based telemonitoring reduced a composite of cardiac events and mortality. 
  • In search of the efficient way to medical decisions: the case of acute heart failure syndrome. 
  • In vivo inhibition of elevated myocardial beta-adrenergic receptor kinase activity in hybrid transgenic mice restores normal beta-adrenergic signaling and function. 
  • In-Hospital and Three-Year Outcomes of Heart Failure Patients in South India: The Trivandrum Heart Failure Registry. 
  • In-hospital management of patients with atrial flutter. 
  • In-hospital resource use and medical costs in the last year of life by mode of death (from the HF-ACTION randomized controlled trial). 
  • In-hospital worsening heart failure and associations with mortality, readmission, and healthcare utilization. 
  • In-hospital worsening heart failure. 
  • Inactivation of the Glucose-Dependent Insulinotropic Polypeptide Receptor Improves Outcomes following Experimental Myocardial Infarction. 
  • Incidence and outcomes associated with early heart failure pharmacotherapy in patients with ongoing cardiogenic shock. 
  • Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. 
  • Incidence and prevalence of heart failure in elderly persons, 1994-2003. 
  • Incidence and survival of hospitalized acute decompensated heart failure in four US communities (from the Atherosclerosis Risk in Communities Study). 
  • Incidence of heart failure and mortality after acute coronary syndromes. 
  • Incidence, Management, and Outcomes of Trauma in Patients with a Left Ventricular Assist Device in North Carolina. 
  • Incidence, Predictors, and Outcomes of Permanent Pacemaker Implantation Following Transcatheter Aortic Valve Replacement: Analysis From the U.S. Society of Thoracic Surgeons/American College of Cardiology TVT Registry. 
  • Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. 
  • Incidence, risk, and consequences of atrial arrhythmias in patients with continuous-flow left ventricular assist devices. 
  • Incident Cardiovascular Disease Among Adults With Blood Pressure <140/90 mm Hg. 
  • Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography. 
  • Incorporating patient preferences into clinical trial design: results of the opinions of patients on treatment implications of new studies (OPTIONS) project. 
  • Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. 
  • Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy. 
  • Increases of cardiac troponin in conditions other than acute coronary syndrome and heart failure. 
  • Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. 
  • Incremental value of clinical data beyond claims data in predicting 30-day outcomes after heart failure hospitalization. 
  • Incremental value of cystatin C over conventional renal metrics for predicting clinical response and outcomes in cardiac resynchronization therapy: The BIOCRT study. 
  • Incremental value of echocardiographic assessment beyond clinical evaluation for prediction of death and development of heart failure after high-risk myocardial infarction. 
  • Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. 
  • Independent prognostic value of echocardiography and N-terminal pro-B-type natriuretic peptide in patients with heart failure. 
  • Indications for cardiac resynchronization therapy: 2011 update from the Heart Failure Society of America Guideline Committee. 
  • Individual prediction of heart failure among childhood cancer survivors. 
  • Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? 
  • Infection and noncardiovascular death in the elderly-Heart failure's dirty little secret. 
  • Inferior vena cava assessment in the bedside diagnosis of acute heart failure. 
  • Inflammation Markers and Major Depressive Disorder in Patients With Chronic Heart Failure: Results From the Sertraline Against Depression and Heart Disease in Chronic Heart Failure Study. 
  • Inflammatory biomarkers in heart failure. 
  • Influence of Baseline Characteristics, Operative Conduct, and Postoperative Course on 30-Day Outcomes of Coronary Artery Bypass Grafting Among Patients With Left Ventricular Dysfunction: Results From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. 
  • Influence of Baseline Physical Activity Level on Exercise Training Response and Clinical Outcomes in Heart Failure: The HF-ACTION Trial. 
  • Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Influence of Patient Goals of Care on Performance Measures in Patients Hospitalized for Heart Failure: An Analysis of the Enhanced Feedback For Effective Cardiac Treatment (EFFECT) Registry. 
  • Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). 
  • Influence of age on the management of heart failure: findings from Get With the Guidelines-Heart Failure (GWTG-HF). 
  • Influence of atrial fibrillation on post-discharge natriuretic peptide trajectory and clinical outcomes among patients hospitalized for heart failure: insights from the ASTRONAUT trial. 
  • Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. 
  • Influence of coronary angiography on the utilization of therapies in patients with acute heart failure syndromes: findings from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: a report from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). 
  • Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF). 
  • Influence of diabetes mellitus on the clinical manifestations and prognosis of infective endocarditis: a report from the International Collaboration on Endocarditis-Merged Database. 
  • Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. 
  • Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. 
  • Influence of exercise training on T-wave alternans assessed during exercise test in heart failure patients. 
  • Influence of global region on outcomes in heart failure β-blocker trials. 
  • Influence of heart failure symptoms and ejection fraction on short- and long-term outcomes for older patients with non-ST-segment elevation myocardial infarction. 
  • Influence of hospital length of stay for heart failure on quality of care. 
  • Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. 
  • Influence of imprecision on ROC curve analysis for cardiac markers. 
  • Influence of life-course socioeconomic position on incident heart failure in blacks and whites: the Atherosclerosis Risk in Communities Study. 
  • Influence of mitral regurgitation repair on survival in the surgical treatment for ischemic heart failure trial. 
  • Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. 
  • Influence of patient age and sex on delivery of guideline-recommended heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. 
  • Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. 
  • Influence of renal function on the use of guideline-recommended therapies for patients with heart failure. 
  • Influence of skin site on bioavailability of nitroglycerin ointment in congestive heart failure. 
  • Inhaled nitric oxide after left ventricular assist device implantation: a prospective, randomized, double-blind, multicenter, placebo-controlled trial. 
  • Inherited restrictive cardiomyopathy in a 74-year-old woman: a case of Fabry's disease. 
  • Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. 
  • Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. 
  • Inhibitory role of the coronary arterial endothelium to alpha-adrenergic stimulation in experimental heart failure. 
  • Initial Experience of Left Ventricular Assist Device Support for Adult Patients with Transposition of the Great Vessels. 
  • Initial United States experience with the Paracor HeartNet myocardial constraint device for heart failure. 
  • Initial assessment of a new instrument to measure quality of life at the end of life. 
  • Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction. 
  • Inotropes in the management of acute heart failure. 
  • Inotropic drugs and neurohormonal antagonists in the treatment of HF in the elderly. 
  • Inotropic therapy for heart failure: an evidence-based approach. 
  • Inpatient Management of Heart Failure: Are We Shooting at the Right Target? 
  • Inpatient Unit Heart Failure Discharge Volume Predicts All-cause 30-Day Hospital Readmission. 
  • Insights into the contemporary epidemiology and outpatient management of congestive heart failure. 
  • Insufficient reduction in heart rate during hospitalization despite beta-blocker treatment in acute decompensated heart failure: insights from the ASCEND-HF trial. 
  • Insulin resistance in heart failure: widening the divide between reduced and preserved ejection fraction? 
  • Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. 
  • Intact negative feedback of four cardiac hormones in congestive heart failure. 
  • Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. 
  • Intensity and focus of heart failure disease management after hospital discharge. 
  • Interaction of Body Mass Index on the Association Between N-Terminal-Pro-b-Type Natriuretic Peptide and Morbidity and Mortality in Patients With Acute Heart Failure: Findings From ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure). 
  • Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) analysis of pump thrombosis in the HeartMate II left ventricular assist device. 
  • International REgistry to assess medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): rationale for and design of a global registry. 
  • International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee. 
  • International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short-term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial. 
  • International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. 
  • International variation in use of oral anticoagulation among heart failure patients with atrial fibrillation. 
  • Intracellular protein aggregation is a proximal trigger of cardiomyocyte autophagy. 
  • Intramyocardial Injection of Mesenchymal Precursor Cells and Successful Temporary Weaning From Left Ventricular Assist Device Support in Patients With Advanced Heart Failure: A Randomized Clinical Trial. 
  • Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure. 
  • Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. 
  • Intravenous nisoldipine in severe congestive heart failure. 
  • Intrinsic myocyte dysfunction and tyrosine kinase pathway activation underlie the impaired wall thickening of adjacent regions during postinfarct left ventricular remodeling. 
  • Introduction of the Tools for Economic Analysis of Patient Management Interventions in Heart Failure Costing Tool: a user-friendly spreadsheet program to estimate costs of providing patient-centered interventions. 
  • Introduction: Vasopressin therapy. 
  • Introduction: exercise in patients with chronic heart failure. 
  • Invited commentary. 
  • Invited commentary. 
  • Is Salt Bad for You? 
  • Is There Still a Role for Digoxin in the Management of Atrial Fibrillation? 
  • Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes? 
  • Is Time of the Essence? The Impact of Time of Hospital Presentation in Acute Heart Failure: Insights From ASCEND-HF Trial. 
  • Is acute heart failure a highly prevalent orphan disease? 
  • Is an Admission for Decompensated Heart Failure Inevitable? 
  • Is heart failure guideline adherence being underestimated? The impact of therapeutic contraindications. 
  • Is it Time to Get More Aggressive With Aortic Valve Insufficiency During LVAD Implantation? 
  • Is it time for a randomized trial of surgical treatment of ischemic heart failure? 
  • Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure? 
  • Is rhythm control superior to rate control in patients with atrial fibrillation and congestive heart failure? 
  • Is specialty care associated with improved survival of patients with congestive heart failure? 
  • Is there a rationale for antiplatelet therapy in acute heart failure? 
  • Is there a role for albumin and C-reactive protein levels for prognostication in acute heart failure? 
  • Is there a role for upper-extremity intra-aortic balloon counterpulsation as a bridge-to-recovery or a bridge-to-transplant in the treatment of end-stage heart failure? 
  • Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. 
  • Isolated hormone receptors: physiologic and clinical implications. 
  • Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. 
  • It Is Time to Discuss Dying. 
  • It is time to exercise change for heart failure. 
  • IxCELL-DCM: rejuvenation for cardiac regenerative therapy? 
  • JACC: Heart Failure Series: FDA in the 21st Century: Focus on Nutrition and Heart Failure Prevention. 
  • JACC: Heart Failure fellows program: training the next generation. 
  • Junctophilin-2 is necessary for T-tubule maturation during mouse heart development. 
  • LCZ696: too good to be true? 
  • Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. 
  • Lack of association between electronic health record systems and improvement in use of evidence-based heart failure therapies in outpatient cardiology practices. 
  • Lack of effect of increased inspired oxygen concentrations on maximal exercise capacity or ventilation in stable heart failure. 
  • Laparoscopy is safe among patients with congestive heart failure undergoing general surgery procedures. 
  • Large opaque hemithorax due to cardiomegaly and atelectasis. 
  • Late "adult form" scimitar syndrome presenting with "infant form" complications. 
  • Late gadolinium enhancement magnetic resonance imaging in the diagnosis and prognosis of endomyocardial fibrosis patients. 
  • Learning from recent trials and shaping the future of acute heart failure trials. 
  • Left Atrial Structure and Function in Heart Failure with Preserved Ejection Fraction: A RELAX Substudy. 
  • Left Bundle Branch Block: Is it "Unsafe at Any Speed"? 
  • Left atrial decompression pump for severe heart failure with preserved ejection fraction: theoretical and clinical considerations. 
  • Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study. 
  • Left bundle branch block-induced left ventricular remodeling and its potential for reverse remodeling. 
  • Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy. 
  • Left ventricular assist device destination therapy versus extended criteria cardiac transplant. 
  • Left ventricular assist device effects on metabolic substrates in the failing heart. 
  • Left ventricular assist device therapy in advanced heart failure: patient selection and outcomes. 
  • Left ventricular assist devices as destination therapy for end-stage heart failure. 
  • Left ventricular assist devices versus medical management in ambulatory heart failure patients: An analysis of INTERMACS Profiles 4 and 5 to 7 from the ROADMAP study. 
  • Left ventricular dysfunction: causes, natural history, and hopes for reversal. 
  • Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. 
  • Left ventricular ejection fraction test rates for Medicare beneficiaries with heart failure. 
  • Left ventricular global longitudinal strain in patients with heart failure with preserved ejection fraction: outcomes following an acute heart failure hospitalization. 
  • Left ventricular hypertrophy patterns and incidence of heart failure with preserved versus reduced ejection fraction. 
  • Left ventricular lead position and clinical outcome in the multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy (MADIT-CRT) trial. 
  • Left ventricular myocardial blood flow, metabolism, and effects of treatment with enalapril: further insights into the mechanisms of canine experimental pacing-induced heart failure. 
  • Left ventricular myocardial performance index change for detection of acute cellular rejection in pediatric heart transplantation. 
  • Left ventricular remodelling and disparate changes in contractility and relaxation during the development of and recovery from experimental heart failure. 
  • Left ventricular systolic dysfunction, heart failure, and the risk of stroke and systemic embolism in patients with atrial fibrillation: insights from the ARISTOTLE trial. 
  • Length of hospital stay and 30-day readmission following heart failure hospitalization: insights from the EVEREST trial. 
  • Lessons from the TOPCAT trial. 
  • Lessons learned from a clinical trial: Design, rationale, and insights from The Cardiovascular Improvements with Minute Ventilation-targeted Adaptive Sero-Ventilation (ASV) Therapy in Heart Failure (CAT-HF) Study. 
  • Lessons learned from clinical trials in acute heart failure: phase 3 drug trials. 
  • Letter by Makkar et al regarding article, "Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions". 
  • Letter by Moris et al Regarding Article, "Cardioprotective Role of Myeloid-Derived Suppressor Cells in Heart Failure". 
  • Letter by van Kimmenade et al regarding article, "urinary N-terminal prohormone brain natriuretic peptide excretion in patients with chronic heart failure". 
  • Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure. 
  • Leveraging Behavioral Economics to Improve Heart Failure Care and Outcomes. 
  • Life-threatening congestive heart failure as the presentation of centronuclear myopathy. 
  • Light Chains and the Failing Heart: Important Mechanistic Link or Fifty Shades of Gray? 
  • Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. 
  • Link between decisions regarding resuscitation and preferences for quality over length of life with heart failure. 
  • Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. 
  • Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. 
  • Lipids, statins, and clinical outcomes in heart failure: rethinking the data. 
  • Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. 
  • Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. 
  • Liver function tests in patients with acute heart failure and associated outcomes: insights from ASCEND-HF. 
  • Liver function, in-hospital, and post-discharge clinical outcome in patients with acute heart failure-results from the relaxin for the treatment of patients with acute heart failure study. 
  • Local contractile and growth modulators in the myocardium. 
  • Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial. 
  • Long-Term Cognitive Decline After Newly Diagnosed Heart Failure: Longitudinal Analysis in the CHS (Cardiovascular Health Study). 
  • Long-Term Survival in Patients Receiving a Continuous-Flow Left Ventricular Assist Device. 
  • Long-acting natriuretic peptide, vessel dilator, and kaliuretic peptide enhance urinary excretion rate of albumin, total protein, and beta(2)-microglobulin in patients with congestive heart failure. 
  • Long-term ambulatory therapy with prazosin versus placebo for chronic heart failure: relation between clinical response and left ventricular function at rest and during exercise. 
  • Long-term cardiac safety and outcomes of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab with and without lapatinib in patients with early breast cancer. 
  • Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. 
  • Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. 
  • Long-term costs and resource use in elderly participants with congestive heart failure in the Cardiovascular Health Study. 
  • Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study. 
  • Long-term effects of percutaneous coronary intervention of the totally occluded infarct-related artery in the subacute phase after myocardial infarction. 
  • Long-term follow-up of continuous flow left ventricular assist devices: complications and predisposing risk factors. 
  • Long-term healthcare and cost outcomes of disease management in a large, randomized, community-based population with heart failure. 
  • Long-term outcomes and costs of ventricular assist devices among Medicare beneficiaries. 
  • Long-term outcomes and management of the heart transplant recipient. 
  • Long-term outcomes in elderly survivors of in-hospital cardiac arrest. 
  • Long-term outcomes of left bundle branch block in high-risk survivors of acute myocardial infarction: the VALIANT experience. 
  • Long-term outcomes of medicare beneficiaries with worsening renal function during hospitalization for heart failure. 
  • Long-term outcomes of simultaneous heart and kidney transplantation in pediatric recipients. 
  • Long-term predictors of sudden and low output death in chronic congestive heart failure secondary to coronary artery disease. 
  • Long-term prognosis and risk heterogeneity of heart failure complicating acute myocardial infarction. 
  • Long-term survival of patients with ischemic cardiomyopathy treated by coronary artery bypass grafting versus medical therapy. 
  • Long-term trends in the incidence of heart failure after myocardial infarction. 
  • Longitudinal follow-up of implantable cardioverter defibrillator leads. 
  • Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the framingham offspring study. 
  • Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION. 
  • Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF. 
  • Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? 
  • Loop diuretics in heart failure. 
  • Low Accuracy of the HeartMate Risk Score for Predicting Mortality Using the INTERMACS Registry Data. 
  • Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study. The ATLAS Study Group. 
  • Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study. 
  • Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. 
  • Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. 
  • MRI for the assessment of myocardial viability. 
  • Machine Learning Algorithm Predicts Cardiac Resynchronization Therapy Outcomes: Lessons From the COMPANION Trial. 
  • Machine Learning Methods Improve Prognostication, Identify Clinically Distinct Phenotypes, and Detect Heterogeneity in Response to Therapy in a Large Cohort of Heart Failure Patients. 
  • Macrovolt T-wave alternans and polymorphic ventricular tachycardia. 
  • Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. 
  • Major depression and physical illness trajectories in heart failure and pulmonary disease. 
  • Management of acute decompensated heart failure. 
  • Management of asymptomatic chronic aortic regurgitation with left ventricular dysfunction: a decision analysis. 
  • Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction. 
  • Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). 
  • Management of newly treated diabetes in Medicare beneficiaries with and without heart failure. 
  • Management of patients with diabetes and heart failure with reduced ejection fraction: An international comparison. 
  • Marginal Donor Use in Patients Undergoing Heart Transplantation With Left Ventricular Assist Device Explantation. 
  • Marginal cardiac allografts do not have increased primary graft dysfunction in alternate list transplantation. 
  • Marijuana use and inpatient outcomes among hospitalized patients: analysis of the nationwide inpatient sample database. 
  • Marital status improves survival after orthotopic heart transplantation. 
  • Marked enhancement in myocardial function resulting from overexpression of a human beta-adrenergic receptor gene. 
  • Markers of Atherosclerosis, Clinical Characteristics, and Treatment Patterns in Heart Failure: A Case-Control Study of Middle-Aged Adult Heart Failure Patients in Rural Kenya. 
  • Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. 
  • Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. 
  • Maximizing benefits and mitigating risks with mineralocorticoid receptor antagonist therapy. 
  • Maximizing survival benefit with primary prevention implantable cardioverter-defibrillator therapy in a heart failure population. 
  • Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. 
  • Measurement of novel biomarkers to predict chronic heart failure outcomes and left ventricular remodeling. 
  • Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. 
  • Measurement of troponin and natriuretic peptides shortly after admission in patients with heart failure-does it add useful prognostic information? An analysis of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Studies (VERITAS). 
  • Measures of Ventricular-Arterial Coupling and Incident Heart Failure With Preserved Ejection Fraction: A Matched Case-Control Analysis. 
  • Measuring heart failure quality: does perfection matter? 
  • Measuring hospital mortality rates: are 30-day data enough? Ischemic Heart Disease Patient Outcomes Research Team. 
  • Measuring left ventricular mechanical dyssynchrony from ECG-gated SPECT myocardial perfusion imaging. 
  • Measuring shortness of breath in heart failure (SOB-HF): development and validation of a new dyspnoea assessment tool. 
  • Mechanical Circulatory Support Device Utilization and Heart Transplant Waitlist Outcomes in Patients With Restrictive and Hypertrophic Cardiomyopathy. 
  • Mechanical dyssynchrony after myocardial infarction in patients with left ventricular dysfunction, heart failure, or both. 
  • Mechanical unloading promotes myocardial energy recovery in human heart failure. 
  • Mechanical ventricular support lowers pulmonary vascular resistance in a patient with congential heart disease. 
  • Mechanism of action of angiotensin-converting enzyme (ACE) inhibitors in hypertension and heart failure. Role of plasma versus tissue ACE. 
  • Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. 
  • Mechanisms of inappropriate defibrillator therapy in a modern cohort of remotely monitored patients. 
  • Mechanisms of membrane-receptor regulation. Biochemical, physiological, and clinical insights derived from studies of the adrenergic receptors. 
  • Mechanosensitive channels in striated muscle and the cardiovascular system: not quite a stretch anymore. 
  • Mediastinitis after coronary artery bypass graft surgery. Risk factors and long-term survival. 
  • Medical Management of Patients With a Left Ventricular Assist Device for the Non-Left Ventricular Assist Device Specialist. 
  • Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry. 
  • Medical advances in the treatment of congestive heart failure. 
  • Medical editors' grand rounds: a discussion of timely topics and editorial emergencies. 
  • Medical resource use, costs, and quality of life in patients with acute decompensated heart failure: findings from ASCEND-HF. 
  • Medicare Expenditures by Race/Ethnicity After Hospitalization for Heart Failure With Preserved Ejection Fraction. 
  • Medication Initiation Burden Required to Comply With Heart Failure Guideline Recommendations and Hospital Quality Measures. 
  • Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges. 
  • Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: findings from IMPROVE HF. 
  • Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. 
  • Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update. 
  • Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure. 
  • Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. 
  • Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. 
  • Metaanalysis and review of heart failure disease management randomized controlled clinical trials. 
  • Metaanalysis on effects of cardiac resynchronization therapy in heart failure patients with narrow QRS complex. 
  • Metabolic Dysfunction in Heart Failure: Diagnostic, Prognostic, and Pathophysiologic Insights From Metabolomic Profiling. 
  • Metabolomic Profiling Identifies Novel Circulating Biomarkers of Mitochondrial Dysfunction Differentially Elevated in Heart Failure With Preserved Versus Reduced Ejection Fraction: Evidence for Shared Metabolic Impairments in Clinical Heart Failure. 
  • Metabolomic differences in heart failure patients with and without major depression. 
  • Metabolomic profiling for the identification of novel biomarkers and mechanisms related to common cardiovascular diseases: form and function. 
  • Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy. 
  • MicroRNAs Associated With Reverse Left Ventricular Remodeling in Humans Identify Pathways of Heart Failure Progression. 
  • MicroRNAs relate to early worsening of renal function in patients with acute heart failure. 
  • Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea. 
  • Mid-regional pro-atrial natriuretic peptide to predict clinical course in heart failure patients undergoing cardiac resynchronization therapy. 
  • Midregional proadrenomedullin predicts mortality and major adverse cardiac events in patients presenting with chest pain: results from the CHOPIN trial. 
  • Migration of Intraaortic Balloon Pump Placed Via the Axillary Artery. 
  • Mind the Gap: Current Challenges and Future State of Heart Failure Care. 
  • Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF: Preserving Hope. 
  • Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). 
  • Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. 
  • Minor depression and physical outcome trajectories in heart failure and pulmonary disease. 
  • Mode of Death After Acute Heart Failure Hospitalization　- A Clue to Possible Mechanisms. 
  • Mode of death and hospitalization from the Second Follow-up Serial Infusions of Nesiritide (FUSION II) trial and comparison of clinical events committee adjudicated versus investigator reported outcomes. 
  • Modifier genes and heart failure. 
  • Modifying the mechanics of healing infarcts: Is better the enemy of good? 
  • Modulation of IL-33/ST2 system in postinfarction heart failure: correlation with cardiac remodelling markers. 
  • Molecular biology and pathophysiology of the intrarenal renin-angiotensin system. 
  • Monitoring clinical changes in patients with heart failure: a comparison of methods. 
  • More Evidence That Caffeine Consumption Appears to Be Safe in Patients With Heart Failure. 
  • More bad news for cardiac resynchronization therapy in atrial fibrillation patients: what to do? 
  • Mortality and Macrovascular Risk in Elderly With Hypertension and Diabetes: Effect of Intensive Drug Therapy. 
  • Mortality and morbidity remain high despite captopril and/or Valsartan therapy in elderly patients with left ventricular systolic dysfunction, heart failure, or both after acute myocardial infarction: results from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Mortality and rate of stroke or embolism in atrial fibrillation during long-term follow-up in the embolism in left atrial thrombi (ELAT) study. 
  • Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Moving Beyond the Walls of the Clinic: Opportunities and Challenges to the Future of Telehealth in Heart Failure. 
  • Multi-center validation of the Response Biomedical Corporation RAMP NT-proBNP assay with comparison to the Roche Diagnostics GmbH Elecsys proBNP assay. 
  • Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry. 
  • Multi-marker strategies in heart failure: clinical and statistical approaches. 
  • Multifaceted intervention to promote beta-blocker use in heart failure. 
  • Multimarker Risk Stratification in Patients With Acute Myocardial Infarction. 
  • Multinational and multiethnic variations in health-related quality of life in patients with chronic heart failure. 
  • Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). 
  • Multiple Comorbidities and Response to Cardiac Resynchronization Therapy: MADIT-CRT Long-Term Follow-Up. 
  • Multiple quantitative trait loci modify the heart failure phenotype in murine cardiomyopathy. 
  • Myocardial G protein-coupled receptor kinases: implications for heart failure therapy. 
  • Myocardial beta-adrenergic receptor signaling in vivo: insights from transgenic mice. 
  • Myocardial myoglobin deficiency in various animal models of congestive heart failure. 
  • Myocardial perfusion, function, and dyssynchrony in patients with heart failure: baseline results from the single-photon emission computed tomography imaging ancillary study of the Heart Failure and A Controlled Trial Investigating Outcomes of Exercise TraiNing (HF-ACTION) Trial. 
  • Myocardial scar in sarcoidosis by 12-lead ECG and pathology. 
  • Myocardial viability and impact of surgical ventricular reconstruction on outcomes of patients with severe left ventricular dysfunction undergoing coronary artery bypass surgery: results of the Surgical Treatment for Ischemic Heart Failure trial. 
  • Myocardial viability and survival in ischemic left ventricular dysfunction. 
  • N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study. 
  • N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. 
  • N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. 
  • N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. 
  • N-terminal proBNP: a novel biomarker for the diagnosis, risk stratification and management of congestive heart failure. 
  • NICE guideline for management of chronic heart failure in adults. 
  • NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. 
  • NT-proBNP levels, echocardiographic findings, and outcomes in breathless patients: results from the ProBNP Investigation of Dyspnoea in the Emergency Department (PRIDE) echocardiographic substudy. 
  • NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. 
  • Nasally Inhaled Nitric Oxide for Sudden Right-Sided Heart Failure in the Intensive Care Unit: NO Time Like the Present. 
  • National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. 
  • National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: Clinical utilization of cardiac biomarker testing in heart failure. 
  • National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure. 
  • National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. 
  • National survey of hospital strategies to reduce heart failure readmissions: findings from the Get With the Guidelines-Heart Failure registry. 
  • Natriuretic Peptide-Guided Heart Failure Therapy After the GUIDE-IT Study. 
  • Natriuretic Peptide-guided therapy for heart failure. 
  • Natriuretic Peptides in Older Patients With Heart Failure: A Look Into the Seeds of Time. 
  • Natriuretic peptide guided heart failure management. 
  • Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting. 
  • Natriuretic peptide testing for predicting adverse events following heart failure hospitalization. 
  • Natriuretic peptide testing in clinical medicine. 
  • Natriuretic peptide testing in heart failure. 
  • Natriuretic peptide testing: a window into the diagnosis and prognosis of heart failure. 
  • Natriuretic peptide-guided heart failure management. 
  • Natriuretic peptide-guided management in heart failure. 
  • Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm. 
  • Natriuretic peptides as biomarkers in heart failure. 
  • Natriuretic peptides for guiding heart failure therapy. 
  • Natriuretic peptides in heart failure and acute coronary syndrome. 
  • Natriuretic peptides in heart failure with preserved ejection fraction. 
  • Natriuretic peptides in heart failure. 
  • Natriuretic peptides in the diagnosis and management of acute heart failure. 
  • Natriuretic peptides in the diagnosis and management of heart failure. 
  • Natriuretic peptides, ejection fraction, and prognosis: parsing the phenotypes of heart failure. 
  • Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status. 
  • Natural history and clinical effect of aortic valve regurgitation after left ventricular assist device implantation. 
  • Nebivolol in older adults with heart failure: reduced rates for seniors? 
  • Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. 
  • Neonatal congestive heart failure due to a subclavian artery to subclavian vein fistula diagnosed by noninvasive procedures. 
  • Nesiritide in acute decompensated heart failure. 
  • Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials. 
  • Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF). 
  • Neural modulation for hypertension and heart failure. 
  • Neurocognitive assessments in advanced heart failure patients receiving continuous-flow left ventricular assist devices. 
  • Neurocognitive function in destination therapy patients receiving continuous-flow vs pulsatile-flow left ventricular assist device support. 
  • Neurohumoral mechanisms in heart failure: role in pathogenesis, therapy, and drug tolerance. 
  • Neutrophil CD11b upregulation during cardiopulmonary bypass is associated with postoperative renal injury. 
  • New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials. 
  • New York Heart Association class versus amino-terminal pro-B type natriuretic peptide for acute heart failure prognosis. 
  • New York Heart Association functional class predicts exercise parameters in the current era. 
  • New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. 
  • New developments in cardiovascular adrenergic receptor pharmacology: molecular mechanisms and clinical relevance. 
  • New diagnostic devices in heart failure. 
  • New frontiers in cardiovascular behavioral medicine: comparative effectiveness of exercise and medication in treating depression. 
  • New insights into diastolic heart failure: role of diabetes mellitus. 
  • Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. 
  • Nifedipine in severely hypertensive patients with congestive heart failure and preserved ventricular systolic function. 
  • Nitrate's effect on activity tolerance in heart failure with preserved ejection fraction trial: rationale and design. 
  • No benefit from defibrillation threshold testing in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • No benefit of a dual coil over a single coil ICD lead: evidence from the Sudden Cardiac Death in Heart Failure Trial. 
  • Non-culprit coronary artery percutaneous coronary intervention during acute ST-segment elevation myocardial infarction: insights from the APEX-AMI trial. 
  • Non-evidence-based ICD implantations in the United States. 
  • Noncardiac comorbidities and acute heart failure patients. 
  • Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. 
  • Noninvasive assessment of hemodynamics: an emphasis on bioimpedance cardiography. 
  • Noninvasive radionuclide assessment of cardiac function in patients with peripheral vascular disease. 
  • Nonpharmacologic therapy in heart failure: an overview. 
  • Normal skeletal muscle Na(+)-K(+) pump concentration in patients with chronic heart failure. 
  • Normalization of hematocrit in hemodialysis patients does not affect silent ischemia. 
  • Not Your Mother's FDA. 
  • Not time to RELAX in acute heart failure. 
  • Novel Biomarkers for the Risk Stratification of Heart Failure with Preserved Ejection Fraction. 
  • Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study. 
  • Novel Mitochondria-Targeting Peptide in Heart Failure Treatment: A Randomized, Placebo-Controlled Trial of Elamipretide. 
  • Novel Utilization of the Bridge During Weaning Off Venoarterial ECMO: The Hoffman Clamp Method. 
  • Novel biomarkers in chronic heart failure. 
  • Novel mechanism of premature battery failure due to lithium cluster formation in implantable cardioverter-defibrillators. 
  • Novel vascular effects of isoprenaline following pacing-induced heart failure in the dog. 
  • Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy. 
  • Older patients' experiences of heart failure-an integrative literature review. 
  • Operating in the Dark: When Is Surgery Necessary for Left Ventricular Assist Device Hemolysis? 
  • Opioids for chronic refractory breathlessness: patient predictors of beneficial response. 
  • Optimal timing of hydration to erase contrast-associated nephropathy: the OTHER CAN study. 
  • Optimal utilization and management of implanted cardiac rhythm devices in patients hospitalized for heart failure. 
  • Optimism, Pessimism, and Pragmatism: Musings on the Cost of Medical Innovation. 
  • Optimizing clinical use of biomarkers in high-risk acute heart failure patients. 
  • Oral Iron Therapy for Heart Failure With Reduced Ejection Fraction: Design and Rationale for Oral Iron Repletion Effects on Oxygen Uptake in Heart Failure. 
  • Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF): rationale and design. 
  • Orthodromic reciprocating tachycardia and heart failure in a dog with a concealed posteroseptal accessory pathway. 
  • Orthostatic Hypotension in Patients With Left Ventricular Assist Devices: Acquired Autonomic Dysfunction. 
  • Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Outcome in medically treated coronary artery disease. Ischemic events: nonfatal infarction and death. 
  • Outcomes After Extracorporeal Right Ventricular Assist Device Combined With Durable Left Ventricular Assist Device Support. 
  • Outcomes after implantable left ventricular assist device replacement procedures. 
  • Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. 
  • Outcomes and costs within a disease management program for advanced congestive heart failure. 
  • Outcomes and predictors of recovery in acute-onset cardiomyopathy: A single-center experience of patients undergoing endomyocardial biopsy for new heart failure. 
  • Outcomes and worsening renal function in patients hospitalized with heart failure with preserved ejection fraction. 
  • Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. 
  • Outcomes by race and etiology of patients with left ventricular systolic dysfunction. 
  • Outcomes in Patients Bridged With Univentricular and Biventricular Devices in the Modern Era of Heart Transplantation. 
  • Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. 
  • Outcomes in heart failure patients after major noncardiac surgery. 
  • Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. 
  • Outcomes of Adult Patients with Small Body Size Supported with a Continuous-Flow Left Ventricular Assist Device. 
  • Outcomes of Laparoscopic Cholecystectomy in Patients Supported with a Left Ventricular Assist Device. 
  • Outcomes of Medicare beneficiaries undergoing catheter ablation for atrial fibrillation. 
  • Outcomes of acute exacerbation of severe congestive heart failure: quality of life, resource use, and survival. SUPPORT Investigators. The Study to Understand Prognosis and Preferences for Outcomes and Risks of Treatments. 
  • Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials. 
  • Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. 
  • Outcomes of medicare beneficiaries with heart failure and atrial fibrillation. 
  • Outcomes of patients with acute decompensated heart failure managed by cardiologists versus noncardiologists. 
  • Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. 
  • Outcomes research in cardiovascular imaging: report of a workshop sponsored by the National Heart, Lung, and Blood Institute. 
  • Outcomes, health policy, and managed care: relationships between patient-reported outcome measures and clinical measures in outpatients with heart failure. 
  • Outpatient Worsening Heart Failure as a Target for Therapy: A Review. 
  • Outpatient cardiology practices with advanced practice nurses and physician assistants provide similar delivery of recommended therapies (findings from IMPROVE HF). 
  • Outpatient management of heart failure in the United States, 2006-2008. 
  • Outpatient versus inpatient worsening heart failure: distinguishing biology and risk from location of care. 
  • Over-time mitral regurgitation changes following cardiac resynchronization therapy. 
  • Overexpression of the cardiac beta(2)-adrenergic receptor and expression of a beta-adrenergic receptor kinase-1 (betaARK1) inhibitor both increase myocardial contractility but have differential effects on susceptibility to ischemic injury. 
  • Overview of current noninodilator therapies for acute heart failure syndromes. 
  • Oxidative phenotype protects myofibers from pathological insults induced by chronic heart failure in mice. 
  • PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy. 
  • PREVENtion of HeartMate II Pump Thrombosis Through Clinical Management: The PREVENT multi-center study. 
  • Paced QRS duration as a predictor for clinical heart failure events during right ventricular apical pacing in patients with idiopathic complete atrioventricular block: results from an observational cohort study (PREDICT-HF). 
  • Pacemaker-induced transient asynchrony suppresses heart failure progression. 
  • Pacing-induced heart failure in the dog: evaluation of peripheral vascular alpha-adrenoceptor subtypes. 
  • Pacing-induced heart failure: a model to study the mechanism of disease progression and novel therapy in heart failure. 
  • Palliative Care in Heart Failure: The PAL-HF Randomized, Controlled Clinical Trial. 
  • Palliative care and hospital readmissions in patients with advanced heart failure: Insights from the PAL-HF trial. 
  • Pancreatic beta-cell function as a predictor of cardiovascular outcomes and costs: findings from the Cardiovascular Health Study. 
  • Partial adenosine A1 receptor agonism: a potential new therapeutic strategy for heart failure. 
  • Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. 
  • Pathophysiological role of changing atrial size and pressure in modulation of atrial natriuretic factor during evolving experimental heart failure. 
  • Pathophysiology and clinical evaluation of acute heart failure. 
  • Pathophysiology and treatment options for cardiac anorexia. 
  • Pathophysiology of the cardiorenal syndromes: executive summary from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). 
  • Patient Portals: Who uses them? What features do they use? And do they reduce hospital readmissions? 
  • Patient and hospital characteristics associated with traditional measures of inpatient quality of care for patients with heart failure. 
  • Patient and implanting physician factors associated with mortality and complications after implantable cardioverter-defibrillator implantation, 2002-2005. 
  • Patient and informal caregivers' knowledge of heart failure: necessary but insufficient for effective self-care. 
  • Patient characteristics associated with care by a cardiologist among adults hospitalized with severe congestive heart failure. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. 
  • Patient characteristics from a regional multicenter database of acute decompensated heart failure in Asia Pacific (ADHERE International-Asia Pacific). 
  • Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. 
  • Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. 
  • Patient perspectives on having multiple versus single prescribers of chronic disease medications: results of a qualitative study in a veteran population. 
  • Patient satisfaction and use of Veterans Affairs versus non-Veterans Affairs healthcare services by veterans. 
  • Patient selection for advanced heart failure therapy referral. 
  • Patient selection for left ventricular assist devices. 
  • Patient selection for mechanical circulatory support. 
  • Patient selection in heart failure with preserved ejection fraction clinical trials. 
  • Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United States. 
  • Patient, physician, and procedural factors influencing the use of defibrillation testing during initial implantable cardioverter defibrillator insertion: findings from the NCDR®. 
  • Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management: Results From the ROADMAP Study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management). 
  • Patients Commonly Believe Their Heart Failure Hospitalizations Are Preventable and Identify Worsening Heart Failure, Nonadherence, and a Knowledge Gap as Reasons for Admission. 
  • Patients with CHF and depression have greater risk of mortality and morbidity than patients without depression. 
  • Patients with prior coronary artery bypass grafting have a poor outcome after myocardial infarction: an analysis of the VALsartan in acute myocardial iNfarcTion trial (VALIANT). 
  • Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. 
  • Patterns and predictors of evidence-based medication continuation among hospitalized heart failure patients (from Get With the Guidelines-Heart Failure). 
  • Patterns of intensive care unit admissions in patients hospitalized for heart failure: insights from the RO-AHFS registry. 
  • Patterns of leukocyte counts on admissions for acute heart failure--presentation and outcome--results from a community based registry. 
  • Payment source, quality of care, and outcomes in patients hospitalized with heart failure. 
  • Peak exercise cardiac power output; a direct indicator of cardiac function strongly predictive of prognosis in chronic heart failure. 
  • Peer Review of Peer Review: Somewhere Over the Rainbow. 
  • Perceived Discrimination and Cardiovascular Outcomes in Older African Americans: Insights From the Jackson Heart Study. 
  • Percutaneous edge-to-edge leaflet repair: a solution to the risk-treatment paradox of mitral regurgitation complicated by pulmonary hypertension? 
  • Percutaneous repair or surgery for mitral regurgitation. 
  • Percutaneous transcatheter aortic valve closure successfully treats left ventricular assist device-associated aortic insufficiency and improves cardiac hemodynamics. 
  • Perioperative experience with amrinone. 
  • Perioperative morbidity and mortality in combined vs. staged approaches to carotid and coronary revascularization. 
  • Peripartum cardiomyopathy: Causes, diagnosis, and treatment. 
  • Permanent pacemaker use among patients with heart failure and preserved ejection fraction: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE) National Registry. 
  • Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. 
  • Persistent high serum bicarbonate and the risk of heart failure in patients with chronic kidney disease (CKD): A report from the Chronic Renal Insufficiency Cohort (CRIC) study. 
  • Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. 
  • Pharmacogenetics in heart failure trials. 
  • Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. 
  • Pharmacokinetic-hemodynamic studies of intravenous nitroglycerin in congestive cardiac failure. 
  • Pharmacokinetic-hemodynamic studies of nitroglycerin in congestive cardiac failure. 
  • Pharmacokinetic-hemodynamic studies of nitroglycerin ointment in congestive heart failure. 
  • Pharmacokinetic-hemodynamic studies of transdermal nitroglycerin in congestive heart failure. 
  • Pharmacokinetics, hemodynamic, renal, and neurohormonal effects of atrial natriuretic factor in experimental heart failure. 
  • Pharmacologic and mechanical methods of discontinuing extracorporeal circulation in patients with heart failure. 
  • Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims. 
  • Pharmacologic therapy for patients with chronic heart failure and reduced systolic function: review of trials and practical considerations. 
  • Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. 
  • Phosphoproteomic profiling of human myocardial tissues distinguishes ischemic from non-ischemic end stage heart failure. 
  • Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease. 
  • Physical Function, Frailty, Cognition, Depression, and Quality of Life in Hospitalized Adults ≥60 Years With Acute Decompensated Heart Failure With Preserved Versus Reduced Ejection Fraction. 
  • Physical activity to combat depression in chronic heart failure. 
  • Physician attitudes toward treatment of depression in older medical inpatients. 
  • Physician-determined worsening heart failure: a novel definition for early worsening heart failure in patients hospitalized for acute heart failure--association with signs and symptoms, hospitalization duration, and 60-day outcomes. 
  • Physiological basis of fatigue. 
  • Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients. 
  • Plasma Levels of MicroRNA-155 Are Upregulated with Long-Term Left Ventricular Assist Device Support. 
  • Plasma and cardiac tissue atrial and brain natriuretic peptides in experimental heart failure. 
  • Plasma biomarkers to predict or rule out early post-discharge events after hospitalization for acute heart failure. 
  • Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome. 
  • Plasma omega-3 polyunsaturated fatty acids and survival in patients with chronic heart failure and major depressive disorder. 
  • Platelet activation in patients with congestive heart failure: do we have enough evidence to consider clopidogrel? 
  • Pleiotropic Associations of Allelic Variants in a 2q22 Region with Risks of Major Human Diseases and Mortality. 
  • Politically Correct Heart Failure Research in America to Avoid Geographic Variation. 
  • Polygenic loading for major depression is associated with specific medical comorbidity. 
  • Positive Pressure Ventilation in the Cardiac Intensive Care Unit. 
  • Possible protein binding displacement interaction between glibenclamide and metolazone. 
  • Post-Myocardial Infarction Heart Failure. 
  • Post-Traumatic Stress Disorder and Heart Failure in Men Within the Veteran Affairs Health System. 
  • Post-acute care: the role of natriuretic peptides. 
  • Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables. 
  • Post-discharge Follow-up Characteristics Associated With 30-Day Readmission After Heart Failure Hospitalization. 
  • Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. 
  • Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. 
  • Postdischarge international normalized ratio testing and long-term clinical outcomes of patients with heart failure receiving warfarin: findings from the ADHERE registry linked to Medicare claims. 
  • Postimplantation ventricular ectopic burden and clinical outcomes in cardiac resynchronization therapy-defibrillator patients: a MADIT-CRT substudy. 
  • Postoperative management of heart transplantation patients. 
  • Potential Mortality Reduction With Optimal Implementation of Angiotensin Receptor Neprilysin Inhibitor Therapy in Heart Failure. 
  • Potential advantages of torsemide in patients with heart failure: more than just a 'water pill'? 
  • Potential applications of pharmacogenomics to heart failure therapies. 
  • Potential impact of optimal implementation of evidence-based heart failure therapies on mortality. 
  • Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. 
  • Pre-operative proteinuria in left ventricular assist devices and clinical outcome. 
  • Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. 
  • Pre-transplant panel reactive antibody in lung transplant recipients is associated with significantly worse post-transplant survival in a multicenter study. 
  • Precipitating Clinical Factors, Heart Failure Characterization, and Outcomes in Patients Hospitalized With Heart Failure With Reduced, Borderline, and Preserved Ejection Fraction. 
  • Precision Medicine for Heart Failure: Lessons From Oncology. 
  • Precision and predictive medicine: lessons learned from our oncology colleagues. 
  • Predicting Outcomes Over Time in Patients With Heart Failure, Left Ventricular Systolic Dysfunction, or Both Following Acute Myocardial Infarction. 
  • Predicting Prognosis in Heart Failure: Important, But Easier Said Than Done. 
  • Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II. 
  • Predicting costs among medicare beneficiaries with heart failure. 
  • Predicting freedom from clinical events in non-ST-elevation acute coronary syndromes: the Global Registry of Acute Coronary Events. 
  • Predicting maximal HR in heart failure patients on β-blockade therapy. 
  • Predicting new-onset HF in patients undergoing coronary or peripheral angiography: results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. 
  • Predicting non-elective hospital readmissions: a multi-site study. Department of Veterans Affairs Cooperative Study Group on Primary Care and Readmissions. 
  • Predicting survival in patients receiving continuous flow left ventricular assist devices: the HeartMate II risk score. 
  • Prediction of 30-Day All-Cause Readmissions in Patients Hospitalized for Heart Failure: Comparison of Machine Learning and Other Statistical Approaches. 
  • Prediction of all-cause mortality and heart failure admissions from global left ventricular longitudinal strain in patients with acute myocardial infarction and preserved left ventricular ejection fraction. 
  • Prediction of incident heart failure in general practice: the Atherosclerosis Risk in Communities (ARIC) Study. 
  • Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial. 
  • Prediction of survival and magnitude of reverse remodeling using the ST2-R2 score in heart failure: A multicenter study. 
  • Predictive models in heart failure: who cares? 
  • Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. 
  • Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS. 
  • Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. 
  • Predictors and outcomes of heart failure with mid-range ejection fraction. 
  • Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction. 
  • Predictors of clinical outcomes in acute decompensated heart failure: Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure outcome models. 
  • Predictors of contemporary coronary artery bypass grafting outcomes. 
  • Predictors of costs of caring for elderly patients discharged with heart failure. 
  • Predictors of delivery of hospital-based heart failure patient education: a report from OPTIMIZE-HF. 
  • Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. 
  • Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. 
  • Predictors of hospital length of stay in heart failure: findings from Get With the Guidelines. 
  • Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study. 
  • Predictors of intra-aortic balloon pump hemodynamic failure in non-acute myocardial infarction cardiogenic shock. 
  • Predictors of long-term clinical endpoints in patients with refractory angina. 
  • Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). 
  • Predictors of mortality and morbidity in patients with chronic heart failure. 
  • Predictors of outcome and the lack of effect of percutaneous coronary intervention across the risk strata in patients with persistent total occlusion after myocardial infarction: Results from the OAT (Occluded Artery Trial) study. 
  • Predictors of outcome of myocarditis. 
  • Predictors of postdischarge outcomes from information acquired shortly after admission for acute heart failure: a report from the Placebo-Controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) Study. 
  • Predictors of the first heart failure hospitalization in patients who are stable survivors of myocardial infarction complicated by pulmonary congestion and/or left ventricular dysfunction: a VALIANT study. 
  • Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry. 
  • Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure. 
  • Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the Initiation Management Predischarge: Process for Assessment of Carvedilol Therapy in Heart Failure (IMPACT-HF) trial. 
  • Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. 
  • Preferences of people with advanced heart failure-a structured narrative literature review to inform decision making in the palliative care setting. 
  • Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. 
  • Preliminary single center North American experience with the Berlin Heart pediatric EXCOR device. 
  • Preoperative Determinants of Quality of Life and Functional Capacity Response to Left Ventricular Assist Device Therapy. 
  • Preoperative evaluation for major noncardiac surgery: focusing on heart failure. 
  • Preparedness planning before mechanical circulatory support: a "how-to" guide for palliative medicine clinicians. 
  • Prescriber continuity and medication adherence for complex patients. 
  • Prescribing BiDil: is it black and white? 
  • Prescribing warfarin at discharge for heart failure patients: findings from the Get With The Guidelines-Heart Failure Registry. 
  • Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. 
  • Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines-heart failure. 
  • Preservation of myocardial beta-adrenergic receptor signaling delays the development of heart failure after myocardial infarction. 
  • Pressure flow studies in patients having a pressor response to the Valsalva maneuver. 
  • Prevalence and Prognostic Significance of Left Ventricular Noncompaction in Patients Referred for Cardiac Magnetic Resonance Imaging. 
  • Prevalence and mortality rate of congestive heart failure in the United States. 
  • Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. 
  • Prevalence and prognostic implications of electrocardiographic left ventricular hypertrophy in heart failure: evidence from the CHARM programme. 
  • Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. 
  • Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure. 
  • Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. 
  • Prevalence of symptomatic diastolic heart failure in patients hospitalized with cerebral or peripheral vascular disease. 
  • Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community. 
  • Prevalence, Profile, and Prognosis of Severe Obesity in Contemporary Hospitalized Heart Failure Trial Populations. 
  • Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. 
  • Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. 
  • Prevalent digoxin use and subsequent risk of death or hospitalization in ambulatory heart failure patients with a reduced ejection fraction-Findings from the Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) randomized controlled trial. 
  • Preventing Heart Failure in Diabetes: Glycemic Targets or Class Effect? 
  • Preventing heart failure in atrial fibrillation: In the middle of difficulty lies opportunity. 
  • Preventing heart failure. 
  • Preventing tomorrow's sudden cardiac death today: dissemination of effective therapies for sudden cardiac death prevention. 
  • Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism. 
  • Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. 
  • Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis. 
  • Primary prevention implantable cardioverter defibrillators are effective in preventing overall mortality in older patients. 
  • Primary prevention implantable cardioverter defibrillators in end-stage kidney disease patients on dialysis: a matched cohort study. 
  • Primary prevention implantable cardioverter defibrillators in women: More questions than answers. 
  • Primary prevention implantable cardioverter-defibrillators and survival in older women. 
  • Primary prevention with defibrillator therapy in women: results from the Sudden Cardiac Death in Heart Failure Trial. 
  • Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. 
  • Priorities for comparative effectiveness reviews in cardiovascular disease. 
  • Pro-Inflammatory Biomarkers in Stable Versus Acutely Decompensated Heart Failure With Preserved Ejection Fraction. 
  • Procainamide-induced sinus node dysfunction in patients with chronic renal failure. 
  • Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. 
  • Process of care performance measures and long-term outcomes in patients hospitalized with heart failure. 
  • Prognosis and mechanism of death in treated heart failure: data from the placebo arm of Val-HeFT. 
  • Prognosis of heart failure in the elderly: not an affair of the heart? 
  • Prognosis on chronic dobutamine or milrinone infusions for stage D heart failure. 
  • Prognostic Impact of Pulmonary Artery Pulsatility Index (PAPi) in Patients With Advanced Heart Failure: Insights From the ESCAPE Trial. 
  • Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion: A Post Hoc Analysis of the PROTECT Data. 
  • Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure. 
  • Prognostic Value of High-Sensitivity Troponin T in Chronic Heart Failure: An Individual Patient Data Meta-Analysis. 
  • Prognostic Value of Insulin-Like Growth Factor-Binding Protein 7 in Patients with Heart Failure and Preserved Ejection Fraction. 
  • Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis. 
  • Prognostic implications of quantitative evaluation of baseline Q-wave width in ST-segment elevation myocardial infarction. 
  • Prognostic importance of defibrillator shocks in patients with heart failure. 
  • Prognostic importance of new small Q waves following non-ST-elevation acute coronary syndromes. 
  • Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. 
  • Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. 
  • Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: results from the MAGGIC individual patient data meta-analysis. 
  • Prognostic significance of depression in blacks with heart failure: insights from Heart Failure: a Controlled Trial Investigating Outcomes of Exercise Training. 
  • Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). 
  • Prognostic usefulness of the six-minute walk in patients with advanced congestive heart failure secondary to ischemic or nonischemic cardiomyopathy. 
  • Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. 
  • Prognostic value of anxiety and depression in patients with chronic heart failure. 
  • Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study. 
  • Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. 
  • Prognostic value of left ventricular apical tissue removed for HeartMate II left ventricular assist device placement. 
  • Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). 
  • Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. 
  • Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure. 
  • Prognostic value of serial B-type natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. 
  • Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses. 
  • Progressive mitochondrial protein lysine acetylation and heart failure in a model of Friedreich's ataxia cardiomyopathy. 
  • Prolonged QRS in Heart Failure With Preserved Ejection Fraction: Risk Marker and Therapeutic Target? 
  • Promoting Transparency in Trials: Lessons From the COMPANION Investigators. 
  • Proportion of patients followed in a specialized heart failure clinic needing an implantable cardioverter defibrillator as determined by applying different trial eligibility criteria. 
  • Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry. 
  • Prospective evaluation of beta-blocker use at the time of hospital discharge as a heart failure performance measure: results from OPTIMIZE-HF. 
  • Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure. 
  • Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure. 
  • Prospective study of perceived stress in cardiac patients. 
  • Prospects for cardiovascular research. 
  • Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. 
  • Prosthetic mitral valve replacement: late complications after native valve preservation. 
  • Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3). 
  • Psychosocial Factors, Exercise Adherence, and Outcomes in Heart Failure Patients: Insights From Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION). 
  • Pulmonary Catherization Data Correlate Poorly with Renal Function in Heart Failure. 
  • Pulmonary Hypertension Is Associated With a Higher Risk of Heart Failure Hospitalization and Mortality in Patients With Chronic Kidney Disease: The Jackson Heart Study. 
  • Pulmonary Production of Soluble ST2 in Heart Failure. 
  • Pulsatile hemodynamic effects of candesartan in patients with chronic heart failure: the CHARM Program. 
  • Pulsus alternans: a visual clue to a grave disorder! 
  • Pump speed modulations and sub-maximal exercise tolerance in left ventricular assist device recipients: A double-blind, randomized trial. 
  • Pump thrombosis in the Thoratec HeartMate II device: An update analysis of the INTERMACS Registry. 
  • QRS duration in patients hospitalized for worsening heart failure. 
  • QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy. 
  • Quality of care and outcomes among patients with heart failure and chronic kidney disease: A Get With the Guidelines -- Heart Failure Program study. 
  • Quality of care and outcomes in women hospitalized for heart failure. 
  • Quality of care for atrial fibrillation among patients hospitalized for heart failure. 
  • Quality of care of and outcomes for African Americans hospitalized with heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure) registry. 
  • Quality of life and economic outcomes with surgical ventricular reconstruction in ischemic heart failure: results from the Surgical Treatment for Ischemic Heart Failure trial. 
  • Quality of life with defibrillator therapy or amiodarone in heart failure. 
  • Quality still doesn't pay in heart failure management. 
  • Quality-of-life outcomes with coronary artery bypass graft surgery in ischemic left ventricular dysfunction: a randomized trial. 
  • RV instantaneous intraventricular diastolic pressure and velocity distributions in normal and volume overload awake dog disease models. 
  • Race and Sex Differences in QRS Interval and Associated Outcome Among Patients with Left Ventricular Systolic Dysfunction. 
  • Race and improvements in the use of guideline-recommended therapies for patients with heart failure: findings from IMPROVE HF. 
  • Race, common genetic variation, and therapeutic response disparities in heart failure. 
  • Race, exercise training, and outcomes in chronic heart failure: findings from Heart Failure - a Controlled Trial Investigating Outcomes in Exercise TraiNing (HF-ACTION). 
  • Race/Ethnic Differences in Outcomes Among Hospitalized Medicare Patients With Heart Failure and Preserved Ejection Fraction. 
  • Race/Ethnicity and Cardiovascular Outcomes in Adults With CKD: Findings From the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic CRIC Studies. 
  • Racial analysis of patients with myocardial infarction complicated by heart failure and/or left ventricular dysfunction treated with valsartan, captopril, or both. 
  • Racial and Ethnic Differences in Trajectories of Hospitalization in US Men and Women With Heart Failure. 
  • Racial differences in hospice use and patterns of care after enrollment in hospice among Medicare beneficiaries with heart failure. 
  • Racial differences in the characteristics of patients admitted for acute decompensated heart failure and their relation to outcomes: results from the OPTIME-CHF trial. 
  • Racial differences in the outcomes of patients with diastolic heart failure. 
  • Racial differences in the prevalence and outcomes of atrial fibrillation among patients hospitalized with heart failure. 
  • Racial disparities and the use of technology for self-management in blacks with heart failure: a literature review. 
  • Racial/Ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure. 
  • Radiofrequency catheter ablation for dyssynchrony-induced dilated cardiomyopathy in an infant. 
  • Radiographic and Clinical Predictors of Cardiac Dysfunction Following Isolated Traumatic Brain Injury. 
  • Radionuclide viability testing: should it affect treatment strategy in patients with cardiomyopathy and significant coronary artery disease? 
  • Ramp Study Hemodynamics, Functional Capacity, and Outcome in Heart Failure Patients with Continuous-Flow Left Ventricular Assist Devices. 
  • Randomized Clinical Trials of Catheter Ablation of Atrial Fibrillation in Congestive Heart Failure: Knowns and Unmet Needs. 
  • Randomized Evaluation of Heart Failure With Preserved Ejection Fraction Patients With Acute Heart Failure and Dopamine: The ROPA-DOP Trial. 
  • Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. 
  • Randomized trial of a nurse-administered, telephone-based disease management program for patients with heart failure. 
  • Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. 
  • Randomized trial of primary PCI with or without routine manual thrombectomy. 
  • Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. 
  • Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). 
  • Rapid clinical assessment of patients with acute heart failure: first blood pressure and oxygen saturation--is that all we need? 
  • Rapid correction of anemia with partial exchange transfusion. 
  • Rapid ventricular pacing in the dog: pathophysiologic studies of heart failure. 
  • Rapid ventricular pacing of dogs to heart failure: biochemical and physiological studies. 
  • Rapid-rate nonsustained ventricular tachycardia found on implantable cardioverter-defibrillator interrogation: relationship to outcomes in the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Rate pressure product and the components of heart rate and systolic blood pressure in hospitalized heart failure patients with preserved ejection fraction: Insights from ASCEND-HF. 
  • Rational use of inotropic therapy in heart failure. 
  • Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure. 
  • Rationale and design of a randomized clinical trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with advanced heart failure: the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). 
  • Rationale and design of a randomized controlled trial of allogeneic mesenchymal stem cells in patients with nonischemic cardiomyopathy. 
  • Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF). 
  • Rationale and design of the Children's Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. 
  • Rationale and design of the ICON-RELOADED study: International Collaborative of N-terminal pro-B-type Natriuretic Peptide Re-evaluation of Acute Diagnostic Cut-Offs in the Emergency Department. 
  • Rationale and design of the OPTIME CHF trial: outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure. 
  • Rationale and design of the Transendocardial Injection of Autologous Human Cells (bone marrow or mesenchymal) in Chronic Ischemic Left Ventricular Dysfunction and Heart Failure Secondary to Myocardial Infarction (TAC-HFT) trial: A randomized, double-blind, placebo-controlled study of safety and efficacy. 
  • Rationale and design of the comParIson Of sacubitril/valsartaN versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. 
  • Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). 
  • Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1-receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced (PANTHEON) and preserved (PANACHE) ejection fraction. 
  • Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF). 
  • Rationale and methods of the Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure (PROVE-HF). 
  • Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure. 
  • Rationale for and design of the TRUE-AHF trial: the effects of ularitide on the short-term clinical course and long-term mortality of patients with acute heart failure. 
  • Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial. 
  • Rationale, design, and baseline characteristics of a Program to Assess and Review Trending INformation and Evaluate CorRelation to Symptoms in Patients with Heart Failure (PARTNERS HF). 
  • Re: Desmopressin Use in Refractory Gastrointestinal Bleeding in LVAD Patient. 
  • Reactive hyperemia is associated with adverse clinical outcomes in heart failure. 
  • Reading RVUs: How can we meet the informational needs of cardiologists? 
  • Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure. 
  • Realizing the Potential of Metabolomics in Heart Failure: Signposts on the Path to Clinical Utility. 
  • Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. 
  • Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations. 
  • Reassessing the Role of Surrogate End Points in Drug Development for Heart Failure. 
  • Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. 
  • Reclassifying heart failure: time for disruptive innovation? 
  • Recognition of depression in medical patients with heart failure. 
  • Recommendations for the Use of Mechanical Circulatory Support: Ambulatory and Community Patient Care: A Scientific Statement From the American Heart Association. 
  • Recommendations for the use of mechanical circulatory support: device strategies and patient selection: a scientific statement from the American Heart Association. 
  • Recovery from heart failure: structural and functional analysis in a canine model. 
  • Recovery of attenuated baroreflex sensitivity in conscious dogs after reversal of pacing induced heart failure. 
  • Recurrence of heart failure symptoms after LVAD placement due to bradycardia-induced inflow obstruction. 
  • Red blood cell distribution width and 1-year mortality in acute heart failure. 
  • Red blood cell distribution width predicts new-onset anemia in heart failure patients. 
  • Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. 
  • Red cell distribution width is a predictor of mortality in patients undergoing percutaneous coronary intervention. 
  • Red cell distribution width measurement: what role does it have in heart failure? 
  • Redefining the role of biomarkers in heart failure trials: expert consensus document. 
  • Redirecting cardiac growth mechanisms for therapeutic regeneration. 
  • Reduced ejection fraction, sudden cardiac death, and heart failure death in the mode selection trial (MOST): implications for device selection in elderly patients with sinus node disease. 
  • Reduced junctional Na+/Ca2+-exchanger activity contributes to sarcoplasmic reticulum Ca2+ leak in junctophilin-2-deficient mice. 
  • Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. 
  • Reduced valve replacement surgery and complication rate in Staphylococcus aureus endocarditis patients receiving acetyl-salicylic acid. 
  • Reducing the costs of phase III cardiovascular clinical trials. 
  • Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. 
  • Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. 
  • Reference interval evaluation of high-sensitivity troponin T and N-terminal B-type natriuretic peptide in Vietnam and the US: The North South East West Trial. 
  • Regional absence of mitochondria causing energy depletion in the myocardium of muscle LIM protein knockout mice. 
  • Regional differences in the characteristics and treatment of patients participating in an international heart failure trial. The Assessment of Treatment with Lisinopril and Survival (ATLAS) Trial Investigators. 
  • Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. 
  • Rehabilitation Therapy in Older Acute Heart Failure Patients (REHAB-HF) trial: Design and rationale. 
  • Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. 
  • Relation between pressure and volume unloading during ramp testing in patients supported with a continuous-flow left ventricular assist device. 
  • Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial--Cardiac Resynchronization Therapy (MADIT-CRT). 
  • Relation between volume of exercise and clinical outcomes in patients with heart failure. 
  • Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). 
  • Relation of Early Repolarization (J Point Elevation) to Mortality in Blacks (from the Jackson Heart Study). 
  • Relation of Elevated Heart Rate in Patients With Heart Failure With Reduced Ejection Fraction to One-Year Outcomes and Costs. 
  • Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). 
  • Relation of atrial natriuretic factor to vasoconstrictor hormones and regional blood flow in congestive heart failure. 
  • Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. 
  • Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. 
  • Relation of depression to severity of illness in heart failure (from Heart Failure And a Controlled Trial Investigating Outcomes of Exercise Training [HF-ACTION]). 
  • Relation of dyspnea severity on admission for acute heart failure with outcomes and costs. 
  • Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure. 
  • Relation of low hemoglobin and anemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). 
  • Relation of serum magnesium levels and postdischarge outcomes in patients hospitalized for heart failure (from the EVEREST Trial). 
  • Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). 
  • Relation of temporal creatine kinase-MB release and outcome after thrombolytic therapy for acute myocardial infarction. TAMI Study Group. 
  • Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. 
  • Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study. 
  • Relationship Between Arterial Access and Outcomes in ST-Elevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STrategic Reperfusion Early After Myocardial Infarction (STREAM) Study. 
  • Relationship Between Enrolling Country Income Level and Patient Profile, Protocol Completion, and Trial End Points. 
  • Relationship Between Infarct Size and Outcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. 
  • Relationship between Hospital 30-Day Mortality Rates for Heart Failure and Patterns of Early Inpatient Comfort Care. 
  • Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. 
  • Relationship between anemia and health care costs in heart failure. 
  • Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. 
  • Relationship between cardiac rehabilitation and long-term risks of death and myocardial infarction among elderly Medicare beneficiaries. 
  • Relationship between central hemodynamics and regional blood flow in normal subjects and in patients with congestive heart failure. 
  • Relationship between changing patient-reported outcomes and subsequent clinical events in patients with chronic heart failure: insights from HF-ACTION. 
  • Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. 
  • Relationship between depressive symptoms and long-term mortality in patients with heart failure. 
  • Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. 
  • Relationship between galectin-3 levels and mineralocorticoid receptor antagonist use in heart failure: analysis from HF-ACTION. 
  • Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. 
  • Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials. 
  • Relationship between patient satisfaction with inpatient care and hospital readmission within 30 days. 
  • Relationship between renal function and left ventricular assist device use. 
  • Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry. 
  • Relationship between stage of kidney disease and incident heart failure in older adults. 
  • Relationship of age and exercise performance in patients with heart failure: the HF-ACTION study. 
  • Relationship of depression to death or hospitalization in patients with heart failure. 
  • Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. 
  • Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. 
  • Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT). 
  • Relationship of right- to left-sided ventricular filling pressures in advanced heart failure: insights from the ESCAPE trial. 
  • Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis. 
  • Relationship of technetium-99m tetrofosmin-gated rest single-photon emission computed tomography myocardial perfusion imaging to death and hospitalization in heart failure patients: results from the nuclear ancillary study of the HF-ACTION trial. 
  • Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure. 
  • Relationships between emerging measures of heart failure processes of care and clinical outcomes. 
  • Relative value of amino-terminal pro-B-type natriuretic peptide testing and radiographic standards for the diagnostic evaluation of heart failure in acutely dyspneic subjects. 
  • Relative wall thickness analysis by two-dimensional echocardiography. 
  • Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. 
  • Relaxin, a pleiotropic vasodilator for the treatment of heart failure. 
  • Reliability and construct validity of PROMIS® measures for patients with heart failure who undergo heart transplant. 
  • Reliability of echocardiographic measurements of left ventricular systolic function in potential pediatric heart transplant donors. 
  • Relief and Recurrence of Congestion During and After Hospitalization for Acute Heart Failure: Insights From Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). 
  • Religion and depression in older medical inpatients. 
  • Religion and remission of depression in medical inpatients with heart failure/pulmonary disease. 
  • Remodeled cardiac calcium channels. 
  • Remodeling and reparation of the cardiovascular system. 
  • Renal Function and Exercise Training in AmbulatoryHeart Failure Patients With a Reduced Ejection Fraction. 
  • Renal and circulatory mechanisms in congestive heart failure. 
  • Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. 
  • Renal effects of angiotensin-converting enzyme inhibition in cardiac failure. 
  • Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. 
  • Renal function trajectories and clinical outcomes in acute heart failure. 
  • Renal function, atherothrombosis extent, and outcomes in high-risk patients. 
  • Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. 
  • Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. 
  • Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. 
  • Renin-Angiotensin System Blockade in Heart Failure: More to the Picture Than Meets the Eye. 
  • Renin-angiotensin system and renal circulation in clinical congestive heart failure. 
  • Reoperative sternotomy is associated with increased mortality after heart transplantation. 
  • Replacement of continuous-flow left ventricular assist device via left subcostal incision. 
  • Reply: Adoption of Sacubitril/Valsartan Must Take Into Account Different Heart Failure Patient Types. 
  • Reply: Diuretic Strategies and Renal Dysfunction in Heart Failure With Preserved Ejection Fraction. 
  • Reply: Echocardiographic Substrate for Biventricular Pacing. 
  • Reply: Efficacy of Subcutaneous vs. Intravenous Administration of Furosemide in Patients With Worsening Heart Failure: The Devil Is in the Details. 
  • Reply: Factors That May Affect Body Change During and After Hospitalization for Acute Heart Failure. 
  • Reply: Is Pump the Answer to Heart Failure With Preserved Ejection Fraction? 
  • Reply: Mode of Death Prevention by Serelaxin. 
  • Reply: circadian variations of ventricular arrhythmias and sleep-disordered breathing in HF patients. 
  • Reply: considerations for drug development for heart failure. 
  • Reply: rapid rate nonsustained ventricular tachycardia found on ICD interrogation: relationship of RR-NSVT to outcomes in the SCD-HeFT trial. 
  • Report from a forum on US heart allocation policy. 
  • Report from the 94th Cardiovascular and Renal Drugs Advisory Committee Meeting, October 11, 2001. 
  • Representation of black patients in randomized clinical trials of heart failure with reduced ejection fraction. 
  • Representativeness of RELAX-AHF clinical trial population in acute heart failure. 
  • Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients. 
  • Reproducibility of peak oxygen uptake and other cardiopulmonary exercise testing parameters in patients with heart failure (from the Heart Failure and A Controlled Trial Investigating Outcomes of exercise traiNing). 
  • Resource use and costs of treatment with anticoagulation and antiplatelet agents: results of the WATCH trial economic evaluation. 
  • Resource use and survival of patients hospitalized with congestive heart failure: differences in care by specialty of the attending physician. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. 
  • Resource use in the last 6 months of life among medicare beneficiaries with heart failure, 2000-2007. 
  • Resource use in the last 6 months of life among patients with heart failure in Canada. 
  • Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. 
  • Response by Hess et al to Letter Regarding Article, "Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Program". 
  • Response by Kumbhani et al to Letters Regarding Article, "Association Between Hospital Volume, Processes of Care, and Outcomes in Patients Admitted With Heart Failure: Insights From Get With The Guidelines-Heart Failure". 
  • Response of atrial natriuretic factor to postural change in patients with heart failure versus subjects with normal hemodynamics. 
  • Response to "Getting the right message". 
  • Response to Exercise Training and Outcomes in Patients With Heart Failure and Diabetes Mellitus: Insights From the HF-ACTION Trial. 
  • Response to Letter Regarding Article, "Temporal Trends and Variation in Early Scheduled Follow-up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure. 
  • Response to preventive cardiac resynchronization therapy in patients with ischaemic and nonischaemic cardiomyopathy in MADIT-CRT. 
  • Response to role of the carotid body in obesity-related sympathoactivation. 
  • Responsiveness of atrial natriuretic factor to reduction in right atrial pressure in patients with chronic congestive heart failure. 
  • Restenosis, reocclusion and adverse cardiovascular events after successful balloon angioplasty of occluded versus nonoccluded coronary arteries. Results from the Multicenter American Research Trial With Cilazapril After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR). 
  • Resting Heart Rate and Long-term Outcomes Among the African American Population: Insights From the Jackson Heart Study. 
  • Resting ventricular-vascular function and exercise capacity in heart failure with preserved ejection fraction: a RELAX trial ancillary study. 
  • Restoration of beta-adrenergic receptor signaling and contractile function in heart failure by disruption of the betaARK1/phosphoinositide 3-kinase complex. 
  • Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. 
  • Restrictive left ventricular filling patterns in very old patients with congestive heart failure: clinical correlates and prognostic significance. 
  • Results of the Chronic Heart Failure Intervention to Improve MEdication Adherence study: A randomized intervention in high-risk patients. 
  • Results of the economic evaluation of the first study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial. 
  • Results of the economic evaluation of the first study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial. 
  • Resuscitation preferences among patients with severe congestive heart failure: results from the SUPPORT project. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. 
  • Rethinking Revascularization in Left Ventricular Systolic Dysfunction. 
  • Retinal arteriolar narrowing and left ventricular remodeling: the multi-ethnic study of atherosclerosis. 
  • Retroperitoneal arteriovenous malformation, a rare cause of heart failure in infancy: consideration of therapeutic approaches. 
  • Return on Investment in Implantable Devices: Cardiac Resynchronization Therapy in Mildly Symptomatic Heart Failure. 
  • Revascularization for Heart Failure: Can We Do Better? 
  • Revascularization for heart failure. 
  • Reversal of cardiac remodeling by modulation of adrenergic receptors: a new frontier in heart failure. 
  • Reversed reverse remodeling: can biomonitoring solve the clinical conundrum of the 3Rs? 
  • Review of advanced heart failure device diagnostics examined in clinical trials and the potential benefit from monitoring capabilities. 
  • Review of cardiovascular magnetic resonance (CMR) in heart failure. Preface. 
  • Review: In CAD without HF, RAS inhibitors reduce deaths more than placebo but not active control. 
  • Rhythm control in atrial fibrillation. 
  • Rhythm control in heart failure patients with atrial fibrillation: contemporary challenges including the role of ablation. 
  • Rhythm control versus rate control for atrial fibrillation and heart failure. 
  • Right atrial volume by cardiovascular magnetic resonance predicts mortality in patients with heart failure with reduced ejection fraction. 
  • Right ventricular afterload sensitivity dramatically increases after left ventricular assist device implantation: A multi-center hemodynamic analysis. 
  • Right ventricular diastolic function in canine models of pressure overload, volume overload, and ischemia. 
  • Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. 
  • Right-Sided Cardiac Dysfunction in Heart Failure With Preserved Ejection Fraction and Worsening Renal Function. 
  • Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: Results From the ROADMAP Study. 
  • Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients: The ROADMAP Study 2-Year Results. 
  • Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study. 
  • Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: design and rationale of the ROADMAP clinical trial. 
  • Risk assessment for continuous flow left ventricular assist devices: does the destination therapy risk score work? An analysis of over 1,000 patients. 
  • Risk assessment for incident heart failure in individuals with atrial fibrillation. 
  • Risk factors for hospital admission among older persons with newly diagnosed heart failure: findings from the Cardiovascular Health Study. 
  • Risk factors for mortality in patients admitted to intensive care units with pneumonia. 
  • Risk factors for recurrent heart failure events in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). 
  • Risk factors for stroke on left ventricular assist devices. 
  • Risk factors for surgical site infections in older people. 
  • Risk for cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater-than-normal estimated glomerular filtration rate. 
  • Risk of heart failure complication during hospitalization for acute myocardial infarction in a contemporary population: insights from the National Cardiovascular Data ACTION Registry. 
  • Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. 
  • Risk stratification after hospitalization for decompensated heart failure. 
  • Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial. 
  • Robotic-assisted or minithoracotomy incision for left ventricular lead placement: a single-surgeon, single-center experience. 
  • Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. 
  • Role of Volume Redistribution in the Congestion of Heart Failure. 
  • Role of amiodarone or implantable cardioverter/defibrillator in patients with atrial fibrillation and heart failure. 
  • Role of beta-adrenergic receptor signaling and desensitization in heart failure: new concepts and prospects for treatment. 
  • Role of cytokines in the mechanism of action of amlodipine: the PRAISE Heart Failure Trial. Prospective Randomized Amlodipine Survival Evaluation. 
  • Role of guanylate cyclase modulators in decompensated heart failure. 
  • Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. 
  • Role of phosphoinositide 3-kinase in cardiac function and heart failure. 
  • Role of sodium channel deglycosylation in the genesis of cardiac arrhythmias in heart failure. 
  • Role of soluble and platelet-bound P-selectin in discriminating cardiac from noncardiac chest pain at presentation in the emergency department. 
  • Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. 
  • Routine laboratory results and thirty day and one-year mortality risk following hospitalization with acute decompensated heart failure. 
  • Routine measurement of natriuretic peptide to guide the diagnosis and management of chronic heart failure. 
  • S-Nitrosylation of cardiac ion channels. 
  • SCD-HeFT: Use of R-R interval statistics for long-term risk stratification for arrhythmic sudden cardiac death. 
  • ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. 
  • ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel. 
  • ST2 pathogenetic profile in ambulatory heart failure patients. 
  • ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel. 
  • ST2: a novel biomarker for heart failure. 
  • ST2: a novel remodeling biomarker in acute and chronic heart failure. 
  • STICH (Surgical Treatment for Ischemic Heart Failure) trial enrollment. 
  • Safety and Clinical Outcomes of Catheter Ablation of Atrial Fibrillation in Patients With Chronic Kidney Disease. 
  • Safety and Efficacy of Exercise Training in Patients With an Implantable Cardioverter-Defibrillator: A Meta-Analysis. 
  • Safety and Tolerability of Neladenoson Bialanate, a Novel Oral Partial Adenosine A1 Receptor Agonist, in Patients With Chronic Heart Failure. 
  • Safety and efficacy of aerobic training in patients with cancer who have heart failure: an analysis of the HF-ACTION randomized trial. 
  • Safety and efficacy of sertraline for depression in patients with CHF (SADHART-CHF): a randomized, double-blind, placebo-controlled trial of sertraline for major depression with congestive heart failure. 
  • Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. 
  • Safety of symptom-limited cardiopulmonary exercise testing in patients with chronic heart failure due to severe left ventricular systolic dysfunction. 
  • Same bridge, new destinations rethinking paradigms for mechanical cardiac support in heart failure. 
  • Same protocol, different continents, different patients: should we continue to conduct global heart failure trials? 
  • Sarcoplasmic reticulum Ca-release channel and ATP-synthesis activities are early myocardial markers of heart failure produced by rapid ventricular pacing in dogs. 
  • Scar burden assessed by Selvester QRS score predicts prognosis, not CRT clinical benefit in preventing heart failure event and death: A MADIT-CRT sub-study. 
  • Scintigraphic perfusion patterns in patients with diffuse lung disease. 
  • Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure). 
  • Screening for Hypertension and Lowering Blood Pressure for Prevention of Cardiovascular Disease Events. 
  • Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. 
  • Self-Reported Health and Outcomes in Patients With Stable Coronary Heart Disease. 
  • Self-reported medication adherence for heart failure is associated with lower risk of all-cause hospitalisation and death. 
  • Sepsis and those who are "weak of heart". 
  • Sequential echocardiographic-Doppler assessment of left ventricular remodelling and mitral regurgitation during evolving experimental heart failure. 
  • Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. 
  • Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. 
  • Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX-AHF-2 study. 
  • Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. 
  • Serial Echocardiographic Characteristics, Novel Biomarkers and Cachexia Development in Patients with Stable Chronic Heart Failure. 
  • Serial Heart Rates, Guideline-Directed Beta Blocker Use, and Outcomes in Patients With Chronic Heart Failure With Reduced Ejection Fraction. 
  • Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. 
  • Serial echocardiographic-Doppler assessment of left ventricular geometry and function in rats with pressure-overload hypertrophy. Chronic angiotensin-converting enzyme inhibition attenuates the transition to heart failure. 
  • Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the RELAX-AHF study. 
  • Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. 
  • Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. 
  • Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. 
  • Serum Bicarbonate in Acute Heart Failure: Relationship to Treatment Strategies and Clinical Outcomes. 
  • Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. 
  • Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH Trials). 
  • Serum insulin-like growth factor-1 and its binding protein-7: potential novel biomarkers for heart failure with preserved ejection fraction. 
  • Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. 
  • Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998. 
  • Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. 
  • Sex Differences in Mortality Based on United Network for Organ Sharing Status While Awaiting Heart Transplantation. 
  • Sex Differences in the Management and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients Presenting to the Emergency Department With Acute Heart Failure. 
  • Sex and Race/Ethnicity Differences in Implantable Cardioverter-Defibrillator Counseling and Use Among Patients Hospitalized With Heart Failure: Findings from the Get With The Guidelines-Heart Failure Program. 
  • Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. 
  • Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT). 
  • Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. 
  • Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. 
  • Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction. 
  • Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. 
  • Sex-specific acute heart failure phenotypes and outcomes from PROTECT. 
  • Sharing the care of mechanical circulatory support: collaborative efforts of patients/caregivers, shared-care sites, and left ventricular assist device implanting centers. 
  • Short- and long-term rehospitalization and mortality for heart failure in 4 racial/ethnic populations. 
  • Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. 
  • Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. 
  • Short-term treatment with ranolazine improves mechanical efficiency in dogs with chronic heart failure. 
  • Short-term variability of heart rate turbulence in chronic heart failure. 
  • Should His Bundle Pacing Be Preferred over Cardiac Resynchronization Therapy Following Atrioventricular Junction Ablation? 
  • Shunt vascularity in a young patient with right-sided aortic arch. 
  • Signature of circulating microRNAs in patients with acute heart failure. 
  • Significance of a coronary artery with thrombolysis in myocardial infarction grade 2 flow "patency" (outcome in the thrombolysis and angioplasty in myocardial infarction trials). Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Significance of hyponatremia in heart failure. 
  • Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries. 
  • Sildenafil Treatment in Heart Failure With Preserved Ejection Fraction: Targeted Metabolomic Profiling in the RELAX Trial. 
  • Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. 
  • Simplified peak power reserve in patients with an implantable cardioverter-defibrillator and advanced heart failure. 
  • Simulation of Daily Snapshot Rhythm Monitoring to Identify Atrial Fibrillation in Continuously Monitored Patients with Stroke Risk Factors. 
  • Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. 
  • Site selection for heart failure clinical trials in the USA. 
  • Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. 
  • Size Matters: Normalization of QRS Duration to Left Ventricular Dimension Improves Prediction of Long-Term Cardiac Resynchronization Therapy Outcome. 
  • Skeletal muscle abnormalities and exercise intolerance in older patients with heart failure and preserved ejection fraction. 
  • Sleep-disordered breathing in patients with heart failure. 
  • Smartphone, Mom, and HFpEF. 
  • Social Media: Can It Reduce Heart Failure Events? 
  • Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient-parts 1-6. 
  • Society of Thoracic Surgeons Risk Score and EuroSCORE-2 Appropriately Assess 30-Day Postoperative Mortality in the STICH Trial and a Contemporary Cohort of Patients With Left Ventricular Dysfunction Undergoing Surgical Revascularization. 
  • Socioeconomic and partner status in chronic heart failure: Relationship to exercise capacity, quality of life, and clinical outcomes. 
  • Soluble CD146 Is a Novel Marker of Systemic Congestion in Heart Failure Patients: An Experimental Mechanistic and Transcardiac Clinical Study. 
  • Soluble ST2 and galectin-3 in heart failure. 
  • Soluble ST2 in Heart Failure. 
  • Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes. 
  • Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. 
  • Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. 
  • Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure. 
  • Soluble guanylate cyclase: a potential therapeutic target for heart failure. 
  • Sparing a little may save a lot: lessons from the Studies of Left Ventricular Dysfunction (SOLVD). 
  • Spironolactone did not reduce cardiac outcomes in symptomatic heart failure with preserved ejection fraction. 
  • Splanchnic Nerve Block for Acute Heart Failure. 
  • Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. 
  • Stage A Heart Failure Is Not Adequately Recognized in US Adults: Analysis of the National Health and Nutrition Examination Surveys, 2007-2010. 
  • Standardizing care for acute decompensated heart failure in a large megatrial: the approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). 
  • State of the Art: Newer biomarkers in heart failure. 
  • State of the art: strategies for extracorporeal membrane oxygenation in respiratory failure. 
  • State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. 
  • Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. 
  • Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. 
  • Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. 
  • Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States: executive summary. 
  • Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States: executive summary. 
  • Statin therapy--Part II: Clinical considerations for cardiovascular disease. 
  • Statins and Exercise Training Response in Heart Failure Patients: Insights From HF-ACTION. 
  • Stem cells for the ischaemic heart. 
  • Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial. 
  • Strategies for supporting intervention fidelity in the rehabilitation therapy in older acute heart failure patients (REHAB-HF) trial. 
  • Strategies to attenuate pathological remodeling in heart failure. 
  • Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study. 
  • Structural remodelling in heart failure: gelatinase induction. 
  • Study protocol for a cohort study of patients with advanced heart failure in Singapore. 
  • Sudden Cardiac Death in Patients With Ischemic Heart Failure Undergoing Coronary Artery Bypass Grafting: Results From the STICH Randomized Clinical Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Sudden Death After Hospitalization for Heart Failure With Reduced Ejection Fraction (from the EVEREST Trial). 
  • Sudden cardiac death after acute heart failure hospital admission: insights from ASCEND-HF. 
  • Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. 
  • Sudden death in patients with myocardial infarction. 
  • Summary of the 2015 International Paediatric Heart Failure Summit of Johns Hopkins All Children's Heart Institute. 
  • Supervised exercise training improves aerobic capacity and muscle strength in older women with heart failure. 
  • Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction. 
  • Surfing the biomarker tsunami at JACC: heart failure. 
  • Surgical correction of aortic valve insufficiency after left ventricular assist device implantation. 
  • Surgical treatments for advanced heart failure. 
  • Surgically placed left ventricular leads provide similar outcomes to percutaneous leads in patients with failed coronary sinus lead placement. 
  • Surrogate end points in heart failure trials. 
  • Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. 
  • Survival in renal vascular disease. 
  • Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. 
  • Survival of patients removed from the heart transplant waiting list. 
  • Survival with cardiac-resynchronization therapy in mild heart failure. 
  • Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. 
  • Sympathectomy for Stabilization of Heart Failure Due to Drug-Refractory Ventricular Tachycardia. 
  • Syncope predicts the outcome of cardiomyopathy patients: analysis of the SCD-HeFT study. 
  • Systolic blood pressure reduction during the first 24 h in acute heart failure admission: friend or foe? 
  • TRPC1 channels are critical for hypertrophic signaling in the heart. 
  • Tackling Patient-Reported Outcomes in Atrial Fibrillation and Heart Failure: Identifying Disease-Specific Symptoms? 
  • Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? 
  • Tailoring your heart failure project for success in rural areas. 
  • Taking heart failure to new heights: its pathophysiology at simulated altitude. 
  • Targeted beta-adrenergic receptor kinase (betaARK1) inhibition by gene transfer in failing human hearts. 
  • Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure. 
  • Targeting Comorbidities in Elderly Patients With Heart Failure: The OPTIMIZE-HFPEF Trial. 
  • Targeting I kappa B kinase for the treatment of inflammatory and other disorders. 
  • Targeting heart failure therapeutics: a historical perspective. 
  • Targeting the kidney in acute heart failure: can old drugs provide new benefit? Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) trial. 
  • Targeting the vulnerable phase of heart failure: initiate novel therapies in stable patients prior to hospitalization. 
  • Team-Based Care for Managing Cardiac Comorbidities in Heart Failure. 
  • Technologist Corner: Value of radionuclide ventriculography to assess mechanical dyssynchrony and predict the cardiac resynchronization therapy response. 
  • Temperature-activated ion channels in neural crest cells confer maternal fever-associated birth defects. 
  • Temporal Changes in Postdischarge Mortality Risk After Hospitalization for Heart Failure (from the EVEREST Trial). 
  • Temporal Trends and Factors Associated With Cardiac Rehabilitation Referral Among Patients Hospitalized With Heart Failure: Findings From Get With The Guidelines-Heart Failure Registry. 
  • Temporal Trends and Variation in Early Scheduled Follow-Up After a Hospitalization for Heart Failure: Findings from Get With The Guidelines-Heart Failure. 
  • Temporal Trends of Digoxin Use in Patients Hospitalized With Heart Failure: Analysis From the American Heart Association Get With The Guidelines-Heart Failure Registry. 
  • Temporal alterations in peripheral vascular responsiveness during both the development and recovery from pacing-induced heart failure. 
  • Temporal changes in biomarkers and their relationships to reperfusion and to clinical outcomes among patients with ST segment elevation myocardial infarction. 
  • Temporal trends and factors associated with diabetes mellitus among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure registry. 
  • Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. 
  • Ten-Year Outcomes After Coronary Artery Bypass Grafting According to Age in Patients With Heart Failure and Left Ventricular Systolic Dysfunction: An Analysis of the Extended Follow-Up of the STICH Trial (Surgical Treatment for Ischemic Heart Failure). 
  • Ten-year experience with extended criteria cardiac transplantation. 
  • Testing new targets of therapy in advanced heart failure: the design and rationale of the Strategies for Tailoring Advanced Heart Failure Regimens in the Outpatient Setting: BRain NatrIuretic Peptide Versus the Clinical CongesTion ScorE (STARBRITE) trial. 
  • Testosterone supplementation in heart failure: a meta-analysis. 
  • Testosterone therapy in women with heart failure "why can't a woman be more like a man?". 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4). 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4). 
  • Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4). 
  • Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). 
  • The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. 
  • The ABCs of managing systolic heart failure: Past, present, and future. 
  • The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. 
  • The Axillary Intra-Aortic Balloon Pump as a Bridge to Recovery Allows Early Ambulation in Long-Term Use: Case Series and Literature Review. 
  • The CHARM programme. 
  • The Comparison of the Outcomes between Primary PCI, Fibrinolysis, and No Reperfusion in Patients ≥ 75 Years Old with ST-Segment Elevation Myocardial Infarction: Results from the Chinese Acute Myocardial Infarction (CAMI) Registry. 
  • The Connected Learning Model for disseminating evidence-based care practices in clinical settings. 
  • The Dietary Approaches to Stop Hypertension (DASH) eating pattern in special populations. 
  • The Digital Drag and Drop Pillbox: Design and Feasibility of a Skill-based Education Model to Improve Medication Management. 
  • The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Cardiovascular Drug Development. 
  • The FDA in the 21st Century: How Is the FDA Responding to the New World? A Focus on Heart Failure Devices. 
  • The Failing Heart Relies on Ketone Bodies as a Fuel. 
  • The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study. 
  • The Globalization of Heart Failure Research. 
  • The HVAD Left Ventricular Assist Device: Risk Factors for Neurological Events and Risk Mitigation Strategies. 
  • The Impact of Worsening Heart Failure in the United States. 
  • The Importance of Worsening Heart Failure in Ambulatory Patients: Definition, Characteristics, and Effects of Amino-Terminal Pro-B-Type Natriuretic Peptide Guided Therapy. 
  • The Incidence and Consequence of Prosthesis-Patient Mismatch After Surgical Aortic Valve Replacement. 
  • The Initiation Management Predischarge Process for Assessment of Carvedilol Therapy for Heart Failure (IMPACT-HF) Study: design and implications. 
  • The International Olympic Games: Heart Teams and Heart Failure. 
  • The International ST2 Consensus Panel: Introduction. 
  • The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. 
  • The Obesity and Heart Failure Epidemics Among African Americans: Insights From the Jackson Heart Study. 
  • The PARACHUTE IV trial design and rationale: percutaneous ventricular restoration using the parachute device in patients with ischemic heart failure and dilated left ventricles. 
  • The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction. 
  • The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. 
  • The Perfect Storm: Carcinoid Heart Disease and Acute Right Ventricular Failure. 
  • The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF). 
  • The Potential Impact of Expanding Cardiac Rehabilitation in Heart Failure. 
  • The Risk of Stroke on Left Ventricular Assist Device Support: Steady Gains or Stalled Progress? 
  • The Role of Sodium and Chloride in Heart Failure: Does It Take Two to Tango? 
  • The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. 
  • The S1103Y cardiac sodium channel variant is associated with implantable cardioverter-defibrillator events in blacks with heart failure and reduced ejection fraction. 
  • The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. 
  • The STICH trial (Surgical Treatment for Ischemic Heart Failure): mode-of-death results. 
  • The Support, Education, and Research in Chronic Heart Failure Study (SEARCH): a mindfulness-based psychoeducational intervention improves depression and clinical symptoms in patients with chronic heart failure. 
  • The Valsalva maneuver: a bedside "biomarker" for heart failure. 
  • The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. 
  • The Year in Heart Failure Review 2015 to 2016. 
  • The association between biventricular pacing and cardiac resynchronization therapy-defibrillator efficacy when compared with implantable cardioverter defibrillator on outcomes and reverse remodelling. 
  • The association between blood pressure and long-term outcomes of patients with ischaemic cardiomyopathy with and without surgical revascularization: an analysis of the STICH trial. 
  • The association between depression and chronic kidney disease and mortality among patients hospitalized with congestive heart failure. 
  • The association between meteorological events and acute heart failure: new insights from ASCEND-HF. 
  • The association of the heart failure score with mortality and heart failure hospitalizations in elderly patients: insights from the Mode Selection Trial (MOST). 
  • The benefit of implementing a heart failure disease management program. 
  • The beta-adrenergic receptor in heart failure. 
  • The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction. 
  • The cVAD registry for percutaneous temporary hemodynamic support: A prospective registry of Impella mechanical circulatory support use in high-risk PCI, cardiogenic shock, and decompensated heart failure. 
  • The caregiving perspective in heart failure: a population based study. 
  • The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases. 
  • The clinical course of health status and association with outcomes in patients hospitalized for heart failure: insights from ASCEND-HF. 
  • The clinical course of pulmonary embolism. 
  • The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. 
  • The congestion score: a simple tool for a complicated disease? 
  • The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. 
  • The disconnect between phase II and phase III trials of drugs for heart failure. 
  • The economic burden of chronic cardiovascular disease for major insurers. 
  • The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial. 
  • The economics of heart failure. 
  • The effect of beta-adrenergic blockers on the prognostic value of peak exercise oxygen uptake in patients with heart failure. 
  • The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). 
  • The effects of acute afterload change on systolic ventricular function in conscious dogs with normal vs. failing hearts. 
  • The effects of ejection fraction on N-terminal ProBNP and BNP levels in patients with acute CHF: analysis from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. 
  • The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. 
  • The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients. 
  • The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. 
  • The emerging role of novel antihyperglycemic agents in the treatment of heart failure and diabetes: A focus on cardiorenal outcomes. 
  • The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences. 
  • The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. 
  • The heart failure clinic: a consensus statement of the Heart Failure Society of America. 
  • The hypereosinophilic syndrome in association with acute lymphoblastic leukemia. 
  • The immunological axis in heart failure: importance of the leukocyte differential. 
  • The impact of a failing right heart in patients supported by intra-aortic balloon counterpulsation. 
  • The impact of amino-terminal pro-brain natriuretic peptide testing on hospital length of stay and morbidity in patients with acute decompensated heart failure. 
  • The impact of arrhythmias in acute heart failure. 
  • The importance of consistent, high-quality acute myocardial infarction and heart failure care results from the American Heart Association's Get with the Guidelines Program. 
  • The incidence, risk factors, and outcomes associated with late right-sided heart failure in patients supported with an axial-flow left ventricular assist device. 
  • The inter-relationship of diabetes and left ventricular systolic function on outcome after high-risk myocardial infarction. 
  • The interaction among sex, hemoglobin and outcomes in a specialty heart failure clinic. 
  • The interplay between atrial fibrillation and heart failure on long-term mortality and length of stay: Insights from the, United Kingdom ACALM registry. 
  • The long-term effects of dietary sodium restriction on clinical outcomes in patients with heart failure. The SODIUM-HF (Study of Dietary Intervention Under 100 mmol in Heart Failure): a pilot study. 
  • The meanings associated with medicines in heart failure patients. 
  • The mechanical and hemodynamic effects of left ventricular pacing in heart failure with preserved ejection fraction and left bundle branch block. 
  • The modifying effects of social support on psychological outcomes in patients with heart failure. 
  • The natural history and recommended management of patients with traumatic coronary artery fistulas. 
  • The need for multiple measures of hospital quality: results from the Get with the Guidelines-Heart Failure Registry of the American Heart Association. 
  • The new heart failure guidelines: strategies for implementation. 
  • The nuclear receptor RORα protects against angiotensin II-induced cardiac hypertrophy and heart failure. 
  • The palliative care in heart failure trial: rationale and design. 
  • The past, present and future of renin-angiotensin aldosterone system inhibition. 
  • The pathophysiology of acute heart failure--is it all about fluid accumulation? 
  • The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. 
  • The potential role of natriuretic peptide-guided management for patients hospitalized for heart failure. 
  • The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management. 
  • The potential role of nonpharmacologic electrophysiology-based interventions in improving outcomes in patients hospitalized for heart failure. 
  • The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. 
  • The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry. 
  • The problem of decompensated heart failure: nomenclature, classification, and risk stratification. 
  • The prognostic importance of different definitions of worsening renal function in congestive heart failure. 
  • The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. 
  • The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure. 
  • The rationale and design of the Surgical Treatment for Ischemic Heart Failure (STICH) trial. 
  • The regenerative capacity of zebrafish reverses cardiac failure caused by genetic cardiomyocyte depletion. 
  • The relationship between B-type natriuretic peptide and health status in patients with heart failure. 
  • The relationship between baseline and follow-up left ventricular ejection fraction with adverse events among primary prevention ICD patients. 
  • The relationship between left ventricular ejection fraction and mortality in patients with acute heart failure: insights from the ASCEND-HF Trial. 
  • The relationship between two performance scales: New York Heart Association Classification and Karnofsky Performance Status Scale. 
  • The relationship of patient selection to prognosis following aortocoronary bypass. 
  • The role of cardiac MR in new-onset heart failure. 
  • The role of cardiovascular MRI in heart failure and the cardiomyopathies. 
  • The role of heart failure pharmacotherapy after left ventricular assist device support. 
  • The role of modulatory calcineurin-interacting proteins in calcineurin signaling. 
  • The role of natriuretic peptide testing in guiding chronic heart failure management: review of available data and recommendations for use. 
  • The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure. 
  • The role of type 1 angiotensin receptors on T lymphocytes in cardiovascular and renal diseases. 
  • The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. 
  • The spectrum of complications following left ventricular assist device placement. 
  • The state of exercise training: a need for action. 
  • The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. 
  • The systemic inflammatory response syndrome in patients with ST-segment elevation myocardial infarction. 
  • The third beta is not the charm. 
  • The ubiquitin ligase MuRF1 regulates PPARα activity in the heart by enhancing nuclear export via monoubiquitination. 
  • The use of beta-blockers in a tertiary care heart failure clinic: dosing, tolerance, and outcomes. 
  • The use of digoxin in patients with worsening chronic heart failure: reconsidering an old drug to reduce hospital admissions. 
  • The vulnerable phase after hospitalization for heart failure. 
  • The worst symptom as defined by patients during heart failure hospitalization: implications for response to therapy. 
  • Therapeutic exercise for individuals with heart failure: special attention to older women with heart failure. 
  • Therapeutic implications of biomarkers in chronic heart failure. 
  • Therapies to prevent heart failure post-myocardial infarction. 
  • Therapy and clinical trials. 
  • Thiazolidinediones, peripheral oedema and congestive heart failure: what is the evidence? 
  • Thinking Outside the Box: Treating Acute Heart Failure Outside the Hospital to Improve Care and Reduce Admissions. 
  • Third universal definition of myocardial infarction. 
  • Thromboembolism and antithrombotic therapy in patients with heart failure in sinus rhythm: current status and future directions. 
  • Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. 
  • Thrombus Aspiration in Patients With High Thrombus Burden in the TOTAL Trial. 
  • Thrombus on the inflow cannula of the HeartWare HVAD: an update. 
  • Thyroid function in heart failure and impact on mortality. 
  • Time for Recognition. 
  • Time-dependent analysis in CHF follow-up. 
  • Timing and Causes of Readmission After Acute Heart Failure Hospitalization-Insights From the Heart Failure Network Trials. 
  • Timing of Postdischarge Follow-Up and Medication Adherence Among Patients With Heart Failure. 
  • Timing of cardiac resynchronization therapy device implantation in heart failure patients and its association with outcomes. 
  • Timing of cardiac transplantation in patients with heart failure receiving beta-adrenergic blockers. 
  • Timing of in-hospital coronary artery bypass graft surgery for non-ST-segment elevation myocardial infarction patients results from the National Cardiovascular Data Registry ACTION Registry-GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines). 
  • Tiny solutions for giant cardiac problems. 
  • Tissue renin-angiotensin system in myocardial hypertrophy and failure. 
  • Tocainide kinetics in congestive heart failure. 
  • Tolerance to organic nitrates: clinical and experimental perspectives. 
  • Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival. 
  • Tolvaptan for the treatment of heart failure: a review of the literature. 
  • Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials. 
  • Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure? 
  • Tonapofylline: a selective adenosine-1 receptor antagonist for the treatment of heart failure. 
  • Too much, too little, or just right?: untangling endogenous erythropoietin in heart failure. 
  • Tools for Economic Analysis of Patient Management Interventions in Heart Failure Cost-Effectiveness Model: A Web-based program designed to evaluate the cost-effectiveness of disease management programs in heart failure. 
  • Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). 
  • Torsemide versus furosemide in heart failure patients: insights from Duke University Hospital. 
  • Total shoulder arthroplasty in patients with HIV infection: complications, comorbidities, and trends. 
  • Toward more optimal use of primary prevention implantable cardioverter-defibrillators: how do we get there? 
  • Trained and supervised physician assistants can safely perform diagnostic cardiac catheterization with coronary angiography. 
  • Training trials in heart failure: time to exercise restraint? 
  • Trajectory classes of depression in a randomized depression trial of heart failure patients: a reanalysis of the SADHART-CHF trial. 
  • Trajectory of Congestion Metrics by Ejection Fraction in Patients With Acute Heart Failure (from the Heart Failure Network). 
  • Transcriptomic biomarkers for individual risk assessment in new-onset heart failure. 
  • Transfer times and outcomes in patients with ST-segment-elevation myocardial infarction undergoing interhospital transfer for primary percutaneous coronary intervention: APEX-AMI insights. 
  • Transient and persistent worsening renal function during hospitalization for acute heart failure. 
  • Transitional adherence and persistence in the use of aldosterone antagonist therapy in patients with heart failure. 
  • Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action. 
  • Transitions of care in heart failure: a scientific statement from the American Heart Association. 
  • Translating clinical trials into clinical practice: a survey assessing the potential impact of the Pediatric Heart Network Infant Single Ventricle Trial. 
  • Translating evidence into practice: use of statins in real-world patients with heart failure. 
  • Transthoracic impedance compared to magnetic resonance imaging in the assessment of cardiac output. 
  • Traveling the Interstices of Data Sharing. 
  • Treatment and risk in heart failure: gaps in evidence or quality? 
  • Treatment gaps in the pharmacologic management of heart failure. 
  • Treatment of functional mitral valve regurgitation with the permanent percutaneous transvenous mitral annuloplasty system: results of the multicenter international Percutaneous Transvenous Mitral Annuloplasty System to Reduce Mitral Valve Regurgitation in Patients with Heart Failure trial. 
  • Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP). 
  • Treatment of sleep-disordered breathing in heart failure impacts cardiac remodeling: Insights from the CAT-HF Trial. 
  • Trends and outcomes of patients with adult congenital heart disease and pulmonary hypertension listed for orthotopic heart transplantation in the United States. 
  • Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Registry. 
  • Trends in Heart Failure Clinical Trials From 2001-2012. 
  • Trends in Hospice Discharge and Relative Outcomes Among Medicare Patients in the Get With The Guidelines-Heart Failure Registry. 
  • Trends in Hospitalizations and Survival of Acute Decompensated Heart Failure in Four US Communities (2005-2014): ARIC Study Community Surveillance. 
  • Trends in Noncardiovascular Comorbidities Among Patients Hospitalized for Heart Failure: Insights From the Get With The Guidelines-Heart Failure Registry. 
  • Trends in Palliative Care Use in Veterans With Severe Heart Failure Using a Large National Cohort. 
  • Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. 
  • Trends in the use and outcomes of ventricular assist devices among medicare beneficiaries, 2006 through 2011. 
  • Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time? 
  • Triage after hospitalization with advanced heart failure: the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) risk model and discharge score. 
  • Tricuspid Valve Regurgitation Immediately After Heart Transplant and Long-Term Outcomes. 
  • Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation. 
  • Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. 
  • Troponin elevation in patients with heart failure: on behalf of the third Universal Definition of Myocardial Infarction Global Task Force: Heart Failure Section. 
  • Tumor necrosis factor, natural killer activity and other measures of immune function and inflammation in elderly men with heart failure. 
  • Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. 
  • Two-Year Outcomes with a Magnetically Levitated Cardiac Pump in Heart Failure. 
  • Two-stage total cardioaortic replacement for end-stage heart and aortic disease in Marfan syndrome: case report and review of the literature. 
  • UNUSUAL NEUROLOGICAL AND CARDIOVASCULAR COMPLICATIONS OF RESPIRATORY FAILURE. 
  • Ultrafiltration in decompensated heart failure with cardiorenal syndrome. 
  • Ultrafiltration in heart failure with cardiorenal syndrome. 
  • Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. 
  • Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. 
  • Understanding heart failure through the HF-ACTION baseline characteristics. 
  • Understanding right ventricular dysfunction and functional tricuspid regurgitation accompanying mitral valve disease. 
  • Unexpected deviation in circadian variation of ventricular arrhythmias: the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. 
  • Unmet expectations of medications and care providers among patients with heart failure assessed to be poorly adherent: results from the Chronic Heart Failure Intervention to Improve MEdication Adherence (CHIME) study. 
  • Unraveling the Mystery of Troponin Elevation in Heart Failure. 
  • Unraveling the pathophysiology of acute heart failure: an inflammatory proposal. 
  • Up-regulation of connexin45 in heart failure. 
  • Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee. 
  • Update on perioperative right heart assessment using transesophageal echocardiography. 
  • Urologic sepsis/shock. 
  • Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. 
  • Use and predictors of heart failure disease management referral in patients hospitalized with heart failure: insights from the Get With the Guidelines Program. 
  • Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation. 
  • Use of Heart Failure Medical Therapies Among Patients With Left Ventricular Assist Devices: Insights From INTERMACS. 
  • Use of HeartWare Ventricular Assist System for systemic ventricular support of a pediatric patient after Mustard procedure. 
  • Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes: An Exploratory Analysis From the RELAX-AHF Trial. 
  • Use of Mineralocorticoid Receptor Antagonists in Patients With Heart Failure and Comorbid Diabetes Mellitus or Chronic Kidney Disease. 
  • Use of Oral Anticoagulation in Eligible Patients Discharged With Heart Failure and Atrial Fibrillation. 
  • Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart. 
  • Use of a continuous-flow device in patients awaiting heart transplantation. 
  • Use of aldosterone antagonists in heart failure. 
  • Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. 
  • Use of biomarkers to "guide" care in chronic heart failure: what have we learned (so far)? 
  • Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. 
  • Use of biomarkers to guide outpatient therapy of heart failure. 
  • Use of cardiac resynchronization therapy in patients hospitalized with heart failure. 
  • Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. 
  • Use of guideline-recommended therapies for heart failure in the Medicare population. 
  • Use of hand carried ultrasound, B-type natriuretic peptide, and clinical assessment in identifying abnormal left ventricular filling pressures in patients referred for right heart catheterization. 
  • Use of hydralazine-isosorbide dinitrate combination in African American and other race/ethnic group patients with heart failure and reduced left ventricular ejection fraction. 
  • Use of nitroglycerin by bolus prevents intensive care unit admission in patients with acute hypertensive heart failure. 
  • Use of remifentanil in infants. 
  • Use of the 6-min walk distance to identify variations in treatment benefits from implantable cardioverter-defibrillator and amiodarone: results from the SCD-HeFT (Sudden Cardiac Death in Heart Failure Trial). 
  • Use of the Patient Health Questionnaire-9 and a detailed suicide evaluation in determining imminent suicidality in distressed patients with cardiac disease. 
  • Usefulness and Cost-Effectiveness of Universal Echocardiographic Contrast to Detect Left Ventricular Thrombus in Patients with Heart Failure and Reduced Ejection Fraction. 
  • Usefulness of 2 centrifugal ventricular assist devices in a total artificial heart configuration: A preliminary report. 
  • Usefulness of Coronary Artery Calcium to Predict Heart Failure With Preserved Ejection Fraction in Men Versus Women (from the Multi-Ethnic Study of Atherosclerosis). 
  • Usefulness of Palliative Care to Complement the Management of Patients on Left Ventricular Assist Devices. 
  • Usefulness of Pulse Amplitude Changes During the Valsalva Maneuver Measured Using Finger Photoplethysmography to Identify Elevated Pulmonary Capillary Wedge Pressure in Patients With Heart Failure. 
  • Usefulness of a Noninvasive Device to Identify Elevated Left Ventricular Filling Pressure Using Finger Photoplethysmography During a Valsalva Maneuver. 
  • Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study). 
  • Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial). 
  • Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. 
  • Usefulness of clinical and NT-proBNP monitoring for prognostic guidance in destabilized heart failure outpatients. 
  • Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure. 
  • Usefulness of combining necrosis and platelet markers in triaging patients presenting with chest pain to the emergency department. 
  • Usefulness of hand-carried ultrasound to predict elevated left ventricular filling pressure. 
  • Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. 
  • Usefulness of right ventricular fractional area change to predict death, heart failure, and stroke following myocardial infarction (from the VALIANT ECHO Study). 
  • Usefulness of soluble and surface-bound P-selectin in detecting heightened platelet activity in patients with congestive heart failure. 
  • Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. 
  • Usefulness of spironolactone in a specialized heart failure clinic. 
  • Using Biomarkers to Guide Heart Failure Therapy. 
  • Using Natriuretic Peptides for Selection of Patients in Acute Heart Failure Clinical Trials. 
  • Using biomarkers to "guide" heart failure management: current perspectives and future directions. 
  • Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study. 
  • Utility of Patient-Reported Outcome Instruments in Heart Failure. 
  • Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. 
  • Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. 
  • Utility of concomitant tricuspid valve procedures for patients undergoing implantation of a continuous-flow left ventricular device. 
  • Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure. 
  • Utility of socioeconomic status in predicting 30-day outcomes after heart failure hospitalization. 
  • Utilization of cardiac resynchronization therapy in eligible patients hospitalized for heart failure and its association with patient outcomes. 
  • Utilization of hospice and predicted mortality risk among older patients hospitalized with heart failure: findings from GWTG-HF. 
  • VALsartan In Acute myocardial iNfarcTion (VALIANT) trial: baseline characteristics in context. 
  • Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure. 
  • Validated, electronic health record deployable prediction models for assessing patient risk of 30-day rehospitalization and mortality in older heart failure patients. 
  • Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. 
  • Validation of an atrial fibrillation risk algorithm in whites and African Americans. 
  • Validation of the Barcelona Bio-Heart Failure Risk Calculator in a cohort from Boston. 
  • Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients. 
  • Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. 
  • Valsartan, captopril, or both in myocardial infarction. 
  • Value of Cardiovascular Magnetic Resonance Imaging-Derived Baseline Left Ventricular Ejection Fraction and Volumes for Precise Risk Stratification of Patients With Ischemic Cardiomyopathy: Insights From the Surgical Treatment for Ischemic Heart Failure (STICH) Trial. 
  • Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial. 
  • Variation in Warfarin Use at Hospital Discharge After Isolated Bioprosthetic Mitral Valve Replacement: An Analysis of the Society of Thoracic Surgeons Adult Cardiac Surgery Database. 
  • Variations in and correlates of length of stay in academic hospitals among patients with heart failure resulting from systolic dysfunction. 
  • Vascular and renal prostaglandins as counter-regulatory systems in heart failure. 
  • Vascular complications of cardiac catheterization. 
  • Vascular rarefaction in peripheral skeletal muscle after experimental heart failure. 
  • Vascular smooth muscle responsiveness to noradrenaline and phenylephrine following experimental heart failure in dogs. 
  • Vasodilators in the management of congestive heart failure. 
  • Vasodilators in the treatment of acute heart failure: what we know, what we don't. 
  • Vasopeptidase inhibitor reduces inhospital costs for patients with congestive heart failure: results from the IMPRESS trial. Inhibition of Metallo Protease by BMS-186716 in a Randomized Exercise and Symptoms Study in Subjects With Heart Failure. 
  • Vasopressin receptor antagonists. 
  • Vasopressin receptor antagonists. Therapeutic potential in the management of acute and chronic heart failure. 
  • Vasopressin: a new target for the treatment of heart failure. 
  • Ventricular Assist Device Utilization in Heart Transplant Candidates: Nationwide Variability and Impact on Waitlist Outcomes. 
  • Ventricular arrhythmia storms in postinfarction patients with implantable defibrillators for primary prevention indications: a MADIT-II substudy. 
  • Ventricular conduction and long-term heart failure outcomes and mortality in African Americans: insights from the Jackson Heart Study. 
  • Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. 
  • Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. 
  • Vessel dilator, long acting natriuretic peptide, and kaliuretic peptide increase circulating prostaglandin E2. 
  • Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study. 
  • Warfarin and Aspirin Versus Warfarin Alone for Prevention of Embolic Events in Patients with a HeartMate II Left Ventricular Assist Device. 
  • Watching the WATCH trial: the role of sponsors and data monitoring committees. 
  • Water and sodium in heart failure: a spotlight on congestion. 
  • Weekend hospital admission and discharge for heart failure: association with quality of care and clinical outcomes. 
  • Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. 
  • What Defines a Valuable Investment in Global Health Research? 
  • What Is a Life Worth?: A Tribute to Dr. William Little, a Pioneer in the Understanding of Heart Failure With Preserved Ejection Fraction. 
  • What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial. 
  • What is the role of serial high-sensitivity troponin measurements in chronic heart failure? 
  • What's Harder: Seeing a Doctor or Reducing Readmissions? 
  • What's Next for Acute Heart Failure Research? 
  • What's One More Day? 
  • When Business and Science Clash, How Can We Avoid Harming Patients?: The Case of AVOID-HF. 
  • When Complementary and Alternative Medicine Meets Heart Failure-a Modest Proposal. 
  • When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion? 
  • When VAD Things Happen to Good People. 
  • When cardiac failure, kidney dysfunction, and kidney injury intersect in acute conditions: the case of cardiorenal syndrome. 
  • When renal and cardiac insufficiencies intersect: is there a role for natriuretic peptide testing in the 'cardio-renal syndrome'? 
  • When the heart runs out of heartbeats: treatment options for refractory end-stage heart failure. 
  • Where patients with mild to moderate heart failure die: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Which beta-blocker for heart failure? 
  • Which heart failure patients profit from natriuretic peptide guided therapy? A meta-analysis from individual patient data of randomized trials. 
  • Which inhibitor of the renin-angiotensin system should be used in chronic heart failure and acute myocardial infarction? 
  • Who enrolls in the Medicare Part D prescription drug benefit program? Medication use among patients with heart failure. 
  • Who is a candidate for a left ventricular assist device? Everyone? 
  • Who wants a left ventricular assist device for ambulatory heart failure? Early insights from the MEDAMACS screening pilot. 
  • Whole blood impedance aggregometry for the assessment of platelet function in patients with congestive heart failure (EPCOT Trial). 
  • Whose heart will get broken? Troponin testing and future heart failure. 
  • Why JACC: heart failure? 
  • Why Negative Trials Are Positive for Heart Failure Patients. 
  • Why We Respect Randomized Controlled Clinical Trials in Heart Failure. 
  • Why is depression bad for the failing heart? A review of the mechanistic relationship between depression and heart failure. 
  • Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. 
  • Why the Authors Use Cardiac Resynchronization Therapy with Defibrillators. 
  • Will Biomarkers Succeed as a Surrogate Endpoint in Heart Failure Trials? 
  • Willingness to pay for telemedicine assessed by the double-bounded dichotomous choice method. 
  • Working Toward an Improved Understanding of Chronic Cardiorenal Syndrome Type 4. 
  • Worldwide Experience of a Durable Centrifugal Flow Pump in Pediatric Patients. 
  • Worsening Heart Failure Following Admission for Acute Heart Failure: A Pooled Analysis of the PROTECT and RELAX-AHF Studies. 
  • Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. 
  • Worsening Renal Function in Patients With Acute Heart Failure Undergoing Aggressive Diuresis Is Not Associated With Tubular Injury. 
  • Worsening depressive symptoms are associated with adverse clinical outcomes in patients with heart failure. 
  • Worsening heart failure during hospitalization for acute heart failure: Insights from the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF). 
  • Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study. 
  • Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. 
  • Worsening renal function during decongestion among patients hospitalized for heart failure: Findings from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) trial. 
  • X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector. 
  • Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. 
  • [Brazilian guidelines on platelet antiaggregants and anticoagulants in cardiology]. 
  • [Calcium antagonists in the treatment of heart failure. Re-evaluation of therapeutic strategies]. 
  • [Comparative prognostic value of plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute destabilized heart failure]. 
  • [III Brazilian Guidelines on Chronic Heart Failure]. 
  • patient and practice factors associated with improvement in use of guideline-recommended therapies for outpatients with heart failure (from the IMPROVE HF trial). 
  • sST2 Predicts Outcome in Chronic Heart Failure Beyond NT-proBNP and High-Sensitivity Troponin T. 
  • Β-arrestin: a signaling molecule and potential therapeutic target for heart failure. 
  • β blockers for heart failure: which works best? 
  • β-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Barker, Piers Christopher Andrew, Professor of Pediatrics, Pediatrics, Cardiology
  • Bowers, Margaret Therese, Associate Professor in the School of Nursing, School of Nursing
  • Bradford, William Dalton, Professor of Pathology, Pathology
  • Brennan, J. Matthew, Associate Professor of Medicine, Medicine, Cardiology
  • Carboni, Michael Paul, Assistant Professor of Pediatrics, Pediatrics, Cardiology
  • Curtis, Lesley H., Professor in Population Health Sciences, Medicine, General Internal Medicine
  • Ghadimi, Kamrouz, Associate Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Grambow, Steven C., Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Hirschey, Matthew, Associate Professor, Pharmacology & Cancer Biology
  • Karhausen, Jorn, Assistant Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Landstrom, Andrew Paul, Assistant Professor of Pediatrics, Cell Biology
  • Lekavich, Carolyn Louise, Assistant Professor in Medicine, School of Nursing
  • Limkakeng Jr., Alexander Tan, Associate Professor of Surgery, Surgery, Emergency Medicine
  • Mentz, Robert John, Associate Professor of Medicine, Medicine, Cardiology
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Distinguished Professor of Cardiology, Medicine, Clinical Pharmacology
  • Patel, Uptal Dinesh, Adjunct Professor in the Department of Medicine, Medicine, Nephrology
  • Pitt, Geoffrey Stuart, Adjunct Professor in the Department of Medicine, Medicine, Cardiology
  • Reed, Shelby Derene, Professor in Population Health Sciences, Duke Science & Society
  • Russell, Stuart Dean, Professor of Medicine, Medicine, Cardiology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Swaminathan, Madhav, Professor of Anesthesiology, Anesthesiology, Cardiothoracic
  • Turner, David Ashley, Associate Professor of Pediatrics, Pediatrics, Critical Care Medicine
  • White, Phillip James, Assistant Professor in Medicine, Pharmacology & Cancer Biology